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An In Silico Liver: Model of Gluconeogenesis 
Elie Chalhoub 
 
Abstract 
 
     An in silico liver was developed in attempt to represent the in vivo state of the fasted 
liver. It featured two conceptual models. The first one represented carbohydrate 
metabolism of the human liver, which included the heterogeneous nature of the liver by 
incorporating spatial variation of key enzyme activities. This model was able to predict 
the overall fluxes in tissue and the effect of high intensity exercise on the various hepatic 
fluxes. A second model of hepatic metabolism was developed to represent the complex 
interplay between gluconeogenesis, lipid metabolism, and alcohol metabolism in the 
fasted rat liver. Biochemical pathways are represented by key kinetic reactions that 
include allosteric and substrates effectors, and phosphorylation/dephosphorylation 
enzymes regulation. The model also incorporates the compartmentation and inter-
compartmental transports between the cytosol and the mitochondria, and transport of 
metabolites between blood compartment and the tissue. The model is based on the 
experimental set-up of fasted perfused rat livers. The model was used to simulate the 
effects of the two main gluconeogenic substrates available during the fasting state--
lactate and pyruvate--along with the addition of fatty acids and/or ethanol. The model 
predicts successfully the rates of glucose and ketone production, substrate uptake, and 
citric acid cycle. Parameter estimations were performed in order to obtain a set of 
physiological parameters capable of representing the liver under various combinations of 
nutrients. Parameter sensitivity analysis was generated to quantify the contribution of 
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each parameter to the model output. The model was validated with data available in the 
published literature from ex vivo studies.  
     The in silico liver constitutes a tool that can be used to predict the effect of 
physiological stimuli on flux and concentration distributions. This will provide an 
increase in the understanding of such effects and to determine what parameters, enzymes, 
and fluxes are responsible for a particular perturbation. These findings can prove critical 
in determining the causes of various liver-related diseases, therefore offering more 
possibilities for diagnosis and testing new therapeutic agents.  
 
  
 - viii - 
 
 
TABLE OF CONTENTS 
Page 
ABSTRACT....................................................................................................................... vi 
LIST OF TABLES............................................................................................................. xi 
LIST OF FIGURES .......................................................................................................... xii 
CHAPTER I INTRODUCTION……………….…………………….……………………1 
       1.1  Problem Statement and Specific Aims……………………….. ........................... 1 
  1.2 Background ........................................................................................................... 4  
   1.2.1 Liver Anatomy ............................................................................................... 4  
   1.2.2 Liver Metabolism........................................................................................... 6  
   1.2.3 Mathematical Models of the Liver................................................................. 9  
 1.3 Significance and Approach ................................................................................... 13   
   
CHAPTER II A DISTRIBUTED MODEL OF CARBOHYDRATE TRANSPORT AND 
METABOLISM IN THE LIVER DURING REST AND HIGH-INTENSITY 
EXERCISE………………………………………………………………………………17 
 
 2.1 Introduction........................................................................................................... 17  
 2.2 Model Development ............................................................................................. 21  
   2.2.1 Overall Liver Model .................................................................................... 21  
   2.2.2 Single Sinusoid Model................................................................................. 23  
   2.2.3 Governing Equations ................................................................................... 26  
   2.2.4 Metabolic Pathways ..................................................................................... 29  
  
 - ix - 
 
 2.3 Results .................................................................................................................. 36   
 2.4 Discussion ............................................................................................................. 49   
 
CHAPTER III  GLUCONEOGENESIS AND LIPID METABOLISM IN THE 
PERFUSED LIVER……………………………………………………………………...54 
 
 3.1 Introduction........................................................................................................... 54  
 3.2 Model Development ............................................................................................. 58  
   3.2.1 Metabolic Pathways ..................................................................................... 58  
   3.2.2 Model of the In Vivo Liver .......................................................................... 73  
   3.2.3 Model of the Perfused Liver ........................................................................ 74  
  3.3 Results ................................................................................................................ 76   
 3.4 Discussion ............................................................................................................. 84   
CHAPTER IV CYTOSOLIC-MITOCHONDRIAL COMPARTMENTATION IN THE 
PERFUSED LIVER……………………………………………………………………...90 
 
 4.1 Introduction........................................................................................................... 90  
 4.2 Model Development ............................................................................................. 95  
   4.2.1 Metabolic Pathways ..................................................................................... 95  
   4.2.2 Model of the Perfused Liver ...................................................................... 121  
   4.2.3 Parameter Estimation and Simulation Strategy ......................................... 122  
 4.3 Results   ............................................................................................................   125   
 4.4 Discussion ........................................................................................................... 137   
 
CHAPTER V ETHANOL OXIDATION IN THE PERFUSED LIVER………………141 
 
 5.1 Introduction......................................................................................................... 141  
 5.2 Model Development ........................................................................................... 146  
  
 - x - 
 5.3 Results ................................................................................................................ 153  
   5.3.1 Lactate Perfusions...................................................................................... 153  
   5.3.2 Pyruvate Perfusions ................................................................................... 158  
 5.4 Discussion ........................................................................................................... 165   
 
CHAPTER VI  CONCLUSIONS AND FUTURE DIRECTIONS……………………….. 
 
 6.1 Summary of Results............................................................................................ 169  
   6.1.1 Distributed Model ...................................................................................... 169  
   6.1.2 Gluconeogenesis and Lipid Metabolism in the Perfused Liver ................. 170  
   6.1.3 Cytosolic-Mitochondrial Compartmentation in the Perfused Liver .......... 171  
   6.1.4 Ethanol Metabolism in the Perfused Liver ................................................ 172  
 6.2 Recommendations for Future Directions ............................................................ 172   
   6.2.1 Oxidative Phosphorylation ........................................................................ 172  
   6.2.2 Alanine Metabolism................................................................................... 173  
   6.2.3 Insulin and Glucagon Control.................................................................... 176  
BIBLIOGRAPHY………………………………………………………………………177 
 
APPENDIX…………………………………………………….……………………….203 
 
 
 
 
 
 
 
  
 - xi - 
LIST OF TABLES 
 
CHAPTER II 
 
 2.1 Model parameters ................................................................................................. 24  
 2.2 Fluxes, kinetic expressions, and parameter values ............................................... 32  
 2.3 Species concentrations in liver tissue ................................................................... 33  
 2.4  Literature sources for enzyme activities in periportal and perivenous regions ... 34  
 2.5 Sensitivity coefficients to Km’s............................................................................ 44  
 2.6 Sensitivity coefficients to Vmax’s ........................................................................ 45  
CHAPTER III 
 
 3.1 Reaction rate stoichiometry, kinetic expressions, and parameter values.............. 59  
 3.2 Steady state restuls at the overnight fasted state................................................... 70  
 3.3 Input functions used in simulations ...................................................................... 77  
CHAPTER IV 
 
 4.1 Reaction rates and kinetic expressions ................................................................. 99  
 4.2 Kinetic parameters .............................................................................................. 113  
 4.3 Initial cytosolic, mitochondrial, and blood concentrations................................. 120  
 4.4  Parameters with the largest magnitude of sensitivity to NADHc and NADHm 123  
 4.5 Input functions used in simulations .................................................................... 125  
CHAPTER V 
 
 5.1 Kinetic reactions for the ethanol model .............................................................. 148  
 5.2 Kinetic parameters used in the ethanol model .................................................... 150  
 5.3 Input functions used in simulation of the perfused liver .................................... 151  
 5.4 Input functions used in simulation of the perfused liver, with fatty acids.......... 152  
  
 - xii - 
   
LIST OF FIGURES 
 
CHAPTER I 
 
 1.1 Lobule structure of a liver....................................................................................... 4  
 1.2 Schematic representation of an acinus ................................................................... 4  
CHAPTER II 
 2.1 Schematic of the lobule structure within the liver ................................................ 22  
 2.2 Schematic of a single sinusoid.............................................................................. 25  
 2.3 Schematic of a single idealized sinusoid as basis for the model .......................... 26  
 2.4 Reaction network considered in tissue model....................................................... 30  
 2.5 Linear and exponential functions of Vmax........................................................... 35  
 2.6 Net glucose and lactate production by the liver.................................................... 37  
 2.7 Net rates of glucose production and lactate uptake along the length of sinusoid . 39  
 2.8 Reaction fluxes as a functin of sinuoid length ...................................................... 40  
 2.9 Sensitivities of net overall glucose production and lactate uptake ...................... 41  
 2.10 Net glucose production and lactate uptake by the liver ..................................... 47  
CHAPTER III 
 
 3.1 Reaction network considered in tissue model....................................................... 72  
 3.2 Schematic of perfusion system ............................................................................. 75  
 3.3 Fluxes calculated from perfusion model with lactate as substrate........................ 79  
 3.4 Simulations using the perfusion model with variations in a single parameter ..... 81  
 3.5 Fluxes calculated from perfusion model with pyruvate as substrate .................... 82  
 3.6 Fluxes calculated frm perfusion model with lactate as substrate.......................... 83  
  
 - xiii - 
 3.7 Glucose production dynamics............................................................................... 84  
CHAPTER IV 
 4.1 Reaction network considered in tissue model....................................................... 96  
 4.2 Normalized sensitivities of the most sensitive parameters ................................. 124  
 4.3 Redox ratio calculated from perfusion model..................................................... 127  
 4.4  Fluxes calculated from perfusion model............................................................ 129 
 4.5 Fluxes  calculated from perfusion model............................................................ 131 
 4.6  Fluxes and ATP/ADP ratios calculated from perfusion model ......................... 133  
 4.7 Adenine nucleotide concentrations calculated from perfusion model................ 135  
 4.8 Glucose production and ketogenesis................................................................... 136  
CHAPTER V 
 
 5.1 Metabolic pathway of the liver including ethanol metabolism........................... 147  
      5.2 Redox ratio and fluxes calculated from perfusion model with lactate and 
lactate+ethanol as substrates ............................................................................. 154  
 5.3 Metabolic fluxes calculated from perfusion model with lactate and lactate+ethanol 
as substrates ....................................................................................................... 156  
5.4 Redox ratio and fluxes calculated from perfusion model with lactate, 
lactate+oleate, and lactate+oleate+ethanol as substrates................................... 157  
      5.5 Fluxes calculated from perfusion model with lactate, lactate+oleate, and 
lactate+oleate+ethanol as substrates.................................................................. 158  
      5.6 Redox ratio and fluxes calculated from perfusion model with pyruvate and 
pyruvate+ethanol as substrates .......................................................................... 159  
  
 - xiv - 
     5.7 Metabolic fluxes calculated from perfusion model with pyruvate and 
pyruvate+ethanol as substrates .......................................................................... 160  
      5.8 Redox ratio and fluxes calculated from perfusion model with pyruvate, 
pyruvate+oleate, and pyruvate+oleate+ethanol as substrates ........................... 161  
      5.9 Fluxes calculated from perfusion model with pyruvate, pyruvate+oleate, and 
pyruvate+oleate+ethanol as substrates .............................................................. 162  
5.10 Fluxes calculated from perfusion model with physiological levels of pyruvate, 
pyruvate+oleate, and pyruvate+oleate+ethanol as substrates ........................... 163  
     5.11  Dynamics of glucose, pyruvate, and ketone production calculated from perfusion 
model with lactate and lactate+ethanol as substrates ........................................ 164  
 
 
 
  
    
 1
 
 
 
 
 
 
 
 
 
CHAPTER I 
 
INTRODUCTION 
 
 
 
1.1 Problem Statement and Specific Aims 
 
     The liver is a complex organ, with disparate functions of maintaining glucose homeostasis, 
toxin clearance, and bile secretion.  To accomplish these objectives, the liver makes use of 
comprehensive metabolic network, further complicated by a non-uniform distribution of enzyme 
activities along the billion sinusoids within the tissue. An in silico liver can be a tool to better 
advance the understanding of  normal metabolic processes and their abnormalities, as 
well as to test the efficacy of new drugs used in the treatment of life threatening diseases 
such as type II diabetes and fatty liver disease. The overall goal of this study is to develop 
a model of an in silico liver that can accurately represent the in vivo state of a fasted rat 
liver by accurately predicting the reaction and transport flux distributions and species 
concentrations under various nutritional and hormonal changes. This process can be 
achieved by implementing biochemical reactions that represent the key metabolic 
pathways in the liver. These reactions reflect short term enzyme regulation such as 
allosteric effectors, specific substrate interactions, and effects of 
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phosphorylation/dephosphorylation by using in vitro kinetic data and specific 
mechanisms.   This work is divided into four specific aims, as described below. 
 
Aim 1. Develop a distributed model of carbohydrate transport and metabolism in 
the in vivo human liver during rest and high-intensity exercise.   A model of reaction 
and transport in the liver that describes the metabolite concentration and reaction flux 
dynamics separately within the tissue and blood domains was developed. The blood 
domain contains equations for convection, axial dispersion, and transport to the 
surrounding tissue; and the tissue domain consists of reactions representing key 
carbohydrate metabolic pathways. The tissue is modeled as a tubular reactor with axial 
concentration distributions.  The model includes the metabolic heterogeneity of the liver 
by incorporating spatial variation of key enzymatic maximal activities.  This model 
provides a framework for evaluating the relative importance to hepatic function of 
various phenomenological changes that occur during exercise.  The model can also be 
used to assess the potential effect of metabolic heterogeneity on metabolism.  
 
Aim 2. Develop a computer model of gluconeogenesis and lipid metabolism in the 
perfused rat liver A  model of the perfused rat liver to predict intermediate metabolite 
concentrations and fluxes in response to changes in various substrate concentrations in 
the perfusion medium was developed.  The blood and tissue compartments are each 
considered to be well-mixed.  The model simulates gluconeogenesis in the liver perfused 
separately with lactate and pyruvate, and the combination of these substrates with fatty 
acids (specifically, oleate).  The model consists of the key reactions representing 
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gluconeogenesis, glycolysis, fatty acid metabolism, the citric acid cycle, oxidative 
phosphorylation, and ketogenesis.   Michaelis-Menten type kinetic expressions, with 
control by ATP/ADP, are used for most of the reactions.  For key regulated reactions—
FBPase, PFK, PC, PDC, and PK—rate expressions that incorporate allosteric effectors, 
specific substrate relationships (e.g. cooperative binding), and/or 
phosphorylation/dephosphorylation using in vitro enzyme activity data and knowledge of 
the specific mechanisms were developed.  The model was validated by comparing model 
predictions to ten sets of experimental data from seven different published works, with no 
parameter adjustments. This model is a useful tool to analyze the complex relationships 
between carbohydrate and fat metabolism, with potential applications to many metabolic 
disorders.  
 
Aim 3. Incorporation of cytsolic/mitochondrial compartmentation into the 
gluconeogenesis model for fasted perfused rat livers. The gluconeogenesis model  
developed in Aim 2 simulates the effects of fatty acid uptake on glucose production, 
ketogenesis, TCA cycle, and substrate uptake (lactate and pyruvate) in the perfused liver. 
Results obtained with gluconeogenesis from lactate showed  good agreement with 
experimental data, specifically with respect to rates of glucose production and lactate 
uptake. Results from pyruvate were lower by 50% compared to experimental data. 
Moreover ketogenesis rates were overestimated in both cases. Therefore species 
compartmentation, inter-compartmental transport between mitochondria and cytosol and 
aspartate-malate shuttle were added to the model to ensure the right balance of 
NADH/NAD+ between the cytosol and mitochondria. Detailed TCA cycle and anionic 
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transport mechanism across the mitochondrial membrane reactions were added to ensure  
better physiological representations of the redox ratio in the cytosolic and mitochondrial 
compartment, gluconeoenesis, TCA cycle and ketogenesis rates. 
 
Aim 4. Development of a model for ethanol oxidation in fasted perfused rat liver.   
The effects of ethanol on the redox ratio and various metabolic rates such as 
gluconeogenesis and ketogenesis was simulated through the addition of ethanol to liver 
perfused with lactate and pyruvate. Reactions involved in ethanol metabolism were added 
to the model developed in Aim 3. 
 
1.2 Background  
1.2.1  Liver Anatomy 
     The gross anatomy of the liver reveals the existence of two main lobes, the right and 
the left, shaped in the form of wedges. Each lobe is a cluster of thousands of uniform 
smaller functional units called lobules. The lobule measures about one millimeter in 
Fig 1.2. Schematic representation of an acinus representing the 
zonation areas of a lobule. Zone1:perivenous region ; zone2: 
transient zone ; zone3:  pericentral region. 
http://arbl.cvmbs.colostate.edu/hbooks/pathphys/digestion/liver/hi
sto_acinus.html 
Fig. 1.1 Lobule structure of a liver 
http://bh.knu.ac.kr/~sdsong/images/HB16-liver.gif 
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diameter and consists of many cells called hepatocytes. It has a hexagonal shape with 
approximately six portal triads at the vertices and a central vein in the middle. The portal 
triad consists of a bile duct, a branch of the portal vein, and a branch of the hepatic artery. 
The liver receives its blood supply through two sources: the hepatic artery and the portal 
vein. The portal vein carries blood supplied with nutrients and digested substances 
absorbed from the small intestine. The portal vein provides 75% of the liver’s blood 
supply while the remaining 25 % comes through the hepatic artery which carries blood 
rich in oxygen from the aorta as shown in Fig. 1.1.  
     The terminal branches of the hepatic artery and the portal vein of the portal triad 
empty its blood content into small channels called sinusoids  Sinusoids are low-pressure 
vascular tunnels that carry blood from the portal triads toward the central vein. The 
lobule contains millions of sinusoids that are lined in parallel to groups of highly 
fenestrated endothelial cells and are surrounded circumferentially by plates of 
parenchymal cells-hepatocytes allowing the exchange of nutrients and oxygen between 
the blood and the hepatocytes. The space between the endothelial cells and the 
hepatocytes is known as the space of Disse which serves as a plasma filter collecting and 
providing the body’s lymph. The lobule in Fig. 1.1 is considered to be the structural unit 
of the liver while the hepatic acinus (Rappaport 1960; Rappaport 1976)  (Fig. 1.2), which 
is hard to visualize, is considered as the functional unit of the liver. The acinus is roughly 
divided into three zones depending on the distance of the hepatocytes from the portal 
tract. These zones are: the periportal region, the transitory zone, and the perivenous 
region. As blood flows through the liver it carries oxygen, substrates, and different 
hormones to the periportal region, whereas the perivenous region receives deoxygenated 
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blood enriched in CO2, substrates, and hormones. Hepatocytes located along the length of 
the sinusoid process the blood flowing along it differently in different zones. The 
upstream hepatocytes (periportal) possess different enzyme activities and subcellular 
structures from the downstream cells (perivenous). These different functional 
characteristics of the hepatocytes are responsible for the phenomenon of “zonation”. 
Gluconeogenesis, β-oxidation, and oxidative phosphorylation are predominant in the 
periportal zone since these cells are exposed to oxygenated blood; on the other hand 
glycolysis and lipogenesis are mostly located in the perivenous region.  
     The hepatocytes form the main functional unit of the liver by performing various 
metabolic, endocrine and secretory functions. They are capable of synthesizing different 
type of metabolites used by different organs to maintain the homeostasis of the whole 
organism. The liver is responsible for metabolic processes of carbohydrate, fat, and 
protein metabolism. The liver also plays a major role in bile secretion that is necessary in 
lipid digestion and in the clearance of toxins such as ammonia and drugs. 
 
1.2.2 Liver Metabolism      
     The liver plays a central role in maintaining homeostasis by controlling the rate of 
uptake and release of glucose. During the absorptive phase the liver removes excess 
blood glucose by transforming it into a large glycogen--via the glycogenesis pathway, 
and then by transforming it into triglycerides through glycolysis and liponeogenesis. 
During the postabsorptive phase, the liver initially restores the normal blood glucose 
level by breaking down the glycogen stored in the liver via glycogenolysis. When the 
stored glycogen becomes scarce the hepatocytes respond by activating an alternate 
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metabolic pathway-gluconeogenesis. Gluconeogenesis is mainly concerned with 
synthesizing glucose from non-hexose precursors such as lactate, amino acids, and 
glycerol. The hepatocytes achieve these different metabolic functions by switching 
through a network with regulation by hormones and other effectors. 
     Gluconeogenesis.  Gluconeogenesis is the major source of glucose during fasting. 
This pathway is achieved through a set of enzyme-catalyzed steps that are unique to 
gluconeogenesis and in part through steps common to both gluconeogenesis and 
glycolysis. The common steps are fully reversible whereas the unique steps are 
considered to bypass the irreversible steps of the glycolytic pathway, hence conserving 
energy. Two important futile cycles are active during gluconeogenesis and are involved 
in the regulation of the glucose production: the phosphoenolpyruvate/pyruvate cycle, and 
the fructose1,6 bisphosphate/fructose-6-phosphate cycle. These substrate cycles are 
important in determining the direction and the rate of the flux. Regulation of these rates 
can occur at the site of the enzyme reactions catalyzing these substrate cycle steps. 
Different types of regulation are involved in this process such as substrate effectors, 
covalent modification, and through phosphphorylation/dephosphorylation (by means of 
hormonal control) of the enzymes. 
     The bifunctional enzyme 6 phosphofructo-2-kinase/fructose-2,6bisphosphatase exerts 
a regulatory role on fructose 1,6 bisphosphatase (FBPase), and phosphofructokinase 
(PFK). Fructose 2,6 bisphosphate, a product of this bifunctional enzyme, is an allosteric 
activator for PFK and an inhibitor for fFBPase. PFK is also regulated by ATP, playing 
the role of an inhibitor while AMP acts as an activator. AMP ia also acts an 
uncompetitive inhibitor for the FBPase enzyme. Glucagon regulates  FBPase by means of 
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phosphorylation and dephosphorylation through cyclic-AMP (cAMP) which activates 
Protein Kinase A. Pyruvate kinase (PK) is regulated by glucagon during fasting. 
Glucagon acts on the pyruvate kinase by phosphorylation through the protein kinase A 
(PKA) which is mediated by means of cAMP. ATP and alanine (Ala) act as an allosteric 
inhibitor of PK, whereas the F1,6BP product of PFK acts as an activator. Pyruvate 
carboxylase (PC) is another key enzyme in gluconeogenesis and is activated by acetyl-
CoA (AcCoa), while ADP acts as an uncompetitive inhibitor to pyruvate and acts as a 
competitive inhibitor to ATP. 
     Protein Metabolism.   The major aspects of protein metabolism in the liver consist of 
transamination of amino acids, urea synthesis, synthesis of plasma protein, and formation 
of heparin. During the early stages of starvation, protein degradation in muscle is high, 
providing the liver with the necessary supply of amino acids in order to support 
gluconeogenesis. These amino acids are transaminated in the liver through specific 
aminotransferases, the most dominant one being alanine aminotransferase and aspartate 
aminotransfease. Alanine is converted to pyruvate via alanine aminotransferase, 
providing an important precursor for gluconeogenesis during fasting.  
     The second important role of liver with respect to protein metabolism is the synthesis 
of urea. Ammonia accumulation is toxic since it can affect the central nervous system 
leading to encephalopathy. The liver acts rapidly and efficiently to remove the ammonia 
that is formed from amino acid catabolism by the urea cycle. In addition, the liver is 
responsible for synthesizing albumin, a major constituent of plasma protein. 
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     Fatty acid metabolism and ketogenesis.   Fatty acids taken up by the liver can either 
be esterified to produce phospholipid and triacyglycerol, or oxidized to produce acetyl-
CoA. The break down of fatty acids starts with the activation of the fatty acids in the 
cytosol by addition of an acyl-CoA derivative before it gets transported into the 
mitochondria by specific transport sysytems. Once the fatty acids are inside the 
mitochondria they are oxidized via the β-oxidation to acetyl-CoA which can either enter 
the tri-carboxylic-acid (TCA) cycle for oxidation to CO2, providing the necessary energy 
for the cell, or can be transformed into the ketone bodies, acetoacetate and 
hydroxybutyrate. Ketone bodies are released into the blood, where other tissues such as 
the brain and the muscle use them during the fasting state.  
     The rate of ketogenesis in the liver is mainly regulated by the level of fatty acids in the 
blood and by the availability of acetyl-CoA. The processing of the acetyl-CoA in the 
TCA cycle depends essentially on the availability of oxaloacetate for the citrate synthesis 
reaction and the rate of TCA cycle flux. 
     D-3- hydroxybutyrate dehydrogenase(BHBdh), a key enzyme of ketogenesis, reduces 
NADH and it is considered to reflect the ratio of free  NAD/NADH in the mitochondria 
which is proportional to the ratio of acetoacetate (AcAc)/β-hydroxybutyrate (BHB). The 
ratio of NAD+/NADH is an indicator for the direction of this reaction; a low ratio will 
favor the formation of BHB while a higher rate will increase the AcAc concentration.  
 
1.2.3 Mathematical Models of the Liver 
     Given the complexity of liver metabolism, it is important to understand the 
mechanisms and regulation behind these complex pathways not only in qualitative terms 
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but also in quantitative terms. Mathematical modeling represents a useful tool to test 
physiological hypotheses and can be a source for immeasurable parameters, 
intermediates, and fluxes. These estimations can be of great importance to understand 
metabolic and nutritional regulation. Various researchers and investigators have 
attempted to develop a mathematical model of the liver. These models were classified in 
two main categories: the lumped model and the distributed-in-space model.  
     The lumped model is based on the assumption that the liver is a well-mixed organ. 
Garfinkel and colleagues (Achs et al. 1971; Anderson et al. 1971) developed the first 
comprehensive model of liver metabolism by using the lumped model theory. In their 
work, they model the gluconeogenic pathway by setting a series of algebraic rate 
equations representing part of  gluconeogenesis between phosphoenoyl-pyruvate (PEP) 
and glucose. The main purpose of their study was to obtain a set of enzymatic parameters 
which can be used to simulate  the level of intermediates during gluconeogenesis. They 
used experimental measurements of gluconeogenic intermediates determined from 
previous studies by Williamson and colleagues who used perfused rat liver (Williamson 
et al. 1969). Each individual enzyme was optimized separately to match the expected 
steady state flux before all the kinetic reactions were combined. This model has some 
major simplifications. It focused more on the rate of conversion from PEP to glucose 
ignoring key dehydrogenase reactions such as lactate dehydrogenase and β-
hydroxybutyrate dehydrogenase (responsible for the ketone body production). The author 
included the effects of the redox ratio of NADH/NAD+ and the ATP, ADP, AMP on 
some of the reactions by setting them as fixed concentrations, however the model lacks 
the necessary mass balances for the redox and the ATP and ADP. The PK reaction was 
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not introduced in this model, therefore ignoring another important potential futile cycle 
that is responsible for regulating the PEP supply. Other key reactions such as PC and 
phosphoenol-pyruvate carboxykinase (PEPCK) were omitted for simplicity, hence failing 
to represent the importance of acetyl CoA on activating these reactions during increased 
fatty acid supply.  Garfinkel (1971a; 1971b) used a similar strategy in order to construct a 
model of the TCA cycle, by using experimental data from Williamson (Williamson et al. 
1969). These models did not integrate all the major pathways (gluconeogenesis, TCA 
cycle, β-oxidation, and ketone metabolism) in the liver, which relate the effect of lipid 
metabolism on gluconeogenesis. 
     El-Refai and Bergman (1976) developed a mathematical model for glycogen 
metabolism. They simulated the dynamic interactions between hormones; specifically 
glucagon and insulin, on overall hepatic glucose production. Their rate expressions were 
represented by simple Michaelis-Menten kinetics, and the kinetics parameters were 
determined from in vitro published data. No kinetic expressions were used for the 
gluconeogenic pathway and it was lumped into a constant flux.  The effect of insulin and 
glucagon were mediated through the level of cAMP, which was assumed to be directly 
proportional to the maximal velocity (Vmax) of the glycogen degradadtion. The model 
did not include the effect of cofactors such as ATP and UTP into their kinetics. A similar 
approach was used by Kurland and D’Argenio (1988) with the addition of dynamics of 
some gluconeogenic intermediates.  
     Bohnensack and Fritz (1991) developed a mathematical model for liver metabolism 
based on experimental data from a fasted rat liver perfused with a combination of 
ammonia, alanine and fatty acids. The model consisted of 13 kinetic reactions 
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representing the essential pathways through gluconeogenesis, alanine catabolism, and 
energy metabolism. The kinetic parameters of the model equations were estimated by 
fitting the model to the experimental data. The model is simple and many pathways were 
lumped. It lacks many adequate kinetic expressions.  Five of the kinetic reactions were 
expressed by Michaelis-Menten equations, whereas the others were not represented by 
their own kinetics parameters, but as a function of other fluxes (e.g: glucose rate= ½(rate 
(PEPCK)–rate (PK))). The model equations did not include the ATP and ADP 
concentrations. 
     Calik and Akbay (2007) used a different approach to model human liver metabolism. 
Their study implemented the mass flux balance analysis by maximizing a selected 
objective function (palmitate synthesis), instead of relying on the reaction kinetics. The 
model assumed the intermediates to be in quasi-steady state. This model is very extensive 
and included all the major pathways in the liver (gluconeogenesis, glycolysis, pentose 
pathway, TCA cycle, catabolism and biosynthesis of the amino acids). The model 
consisted of 125 reaction fluxes and 83 metabolites. Glucose and amino acids uptake 
rates were used as inputs to calculate the flux distributions in the human liver. As a flux 
balance analysis model, it did not determine the intermediate concentrations found at 
steady state. 
     Recently, Nolan et al. (2006) developed a model by combining the metabolic flux 
analysis, Gibbs free energy balances and  nested optimization. The only inputs to this 
model were in the form of experimental flux measurements and thermodynamic 
constraints, which were in the form of negative Gibbs free energy. Beard and Qian (2005) 
have also used the combination of flux balance (FBA) and the energy balance analyses 
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(EBA) and applied it to hepaticc glycogenesis and glycogenolysis. This work differs from 
the earlier cited ones in its ability to predict the intermediates or reactant concentrations 
at steady state. The introduction of EBA to the FBA enables these models to make 
physiological predictions. However, these models still suffer from their inability to 
provide accurate fluxes distributions.  
     The assumption of the liver as a well-mixed organ does not represent its true nature. 
Several researchers (Ahmad et al. 1983; Saville et al. 1992) have attempted to model the 
liver as a spatially distributed model due to the heterogeneous nature of the liver. The 
application of such models was limited mostly to pharmacokinetic representations, such 
as the clearance of hepatic drugs. 
     Bassingthwaite et al. (1970) developed a model that described the transport of oxygen 
between the capillary and the tissue. This model represents the capillary and the tissue in 
the form of a cylinder surrounded by a concentric tissue domain. The advantage of this 
model was that it represented the concentration of metabolites in both the blood 
compartment and the tissue. It also features the concentration in the blood along axial and 
radial directions. 
     These models lack the details and the complexity of the liver pathways thought to be a 
critical factor in modeling the in silico liver. In addition these models did not account for 
the zonation of hepatocytes.  
 
1.3 Significance and Approach 
     The ultimate aim of any in silico model of a liver is to be able to represent the 
complex nature of the liver, including its structural heterogeneity, and its diverse 
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metabolic functions. The creation of such a model would reduce the need for physical 
testing and probably reduce the use of invasive treatments. Researchers as well as 
medical professionals would be able to have a tool at hand that can enable them to obtain 
a wide variety of steady state and dynamic data and perform different in silico 
experiments related to liver diseases such as type II diabetes, liver cancer, and fatty liver 
disease.  
     An in silico model would also offer an opportunity to scientists to develop and test 
various drugs in order to understand their effect on the liver metabolism.  It is difficult to 
gain data from organs such as the liver in vivo, and therefore data acquisition in humans 
is limited to sampling from venous and arterial plasma  and urine. Animals represent a 
slight advantage, since specific vessels such as hepatic vein and portal vein are 
accessible. This limitation to measurements in plasma  can not give enough information 
regarding fluxes,  such as  endogenous production, storage and intermediate catabolism 
rates. The in silico liver plays an important role by estimating parameters and metabolic 
fluxes not available from direct measurement. 
     The in silico liver will help in understanding the effect of liver heterogeneity, and 
metabolic zonation on its metabolic function. The characteristics of an ultimate in silico 
liver mentioned above are a long term goal which requires an intense collaboration 
between computer modeling and physiology/biology. The model should be able, in the 
early stages, to accurately reflect the behavior of the normal liver and to predict its 
metabolic outcome under various in vivo nutritional states, and different hormonal 
stimulation, such as: glucagon, insulin, and catecholamine. The model should accurately  
predict the metabolic flux distributions (glucose production, fatty acid oxidation, 
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ketogenesis rate, TCA cycle, rate of uptake or release of different metabolites such as 
lactate, amino acids, glycerol) as well as intermediates (glucose, lactate, glycerol, alanine, 
pyruvate, acetylCoA, ATP, ketone bodies).  
     This primary goal can be achieved by building a model around a healthy liver. 
Experimental data from human subjects are not  sufficient to examine the detailed 
process of liver function. Perfused rat liver offer a wealth of experimental data that are 
obtained under well-controlled experiments. These experiments also offer a possibility to 
validate the model predictions. While previous models were constructed for some 
specific pathways, they lack the integration of different pathways and the testing at 
various nutritional states. 
     The goal of this study is to achieve a more predictive and robust model. This can be 
achieved by incorporating a set of realistic and physiological kinetic expressions 
representing the different metabolic pathways and combining it with the physiological 
and anatomical heterogeneity of the organ.  
     This study aims at providing a tool to predict and evaluate the metabolic flux 
distributions during gluconeogenesis in the liver and to evaluate the complex interplay of 
gluconeogenesis and lipid metabolism, and the various factors controlling the interactions 
of these pathways in the liver. The liver is modeled essentially on the basis of two 
separate compartments: blood and tissue domain. The blood domain is represented 
mathematically by metabolite mass balance equations and transport reactions, while the 
tissue domain is also compartmentalized into the cytosol and mitochondria,  consisting of 
mass balances and kinetic expressions representing principal reactions in glycolysis, 
gluconeogenesis, glycogenolysis, fatty acid metabolism, The TCA cycle, ketogenesis, 
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and the oxidative phosphorylation pathways. Simulations of the perfused rat livers were 
generated under conditions of infusion of various substrates. The model was validated 
using physiological data gathered from literature from perfused rat livers subjected to 
various substrate combinations and dietary conditions.  The model was tested with 
combinations of gluconeogenic substrates, lactate and pyruvate, along with fatty acids 
and ethanol, in order to investigate the interrelationship between gluconeogenesis and 
lipid metabolism. Parameters were estimated based on sets of experimental data gathered 
from published literature. The model was also independently validated using different 
sets of experimental data from fasted rat liver perfused with combinations of substrates.  
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CHAPTER II 
 A DISTRIBUTED MODEL OF CARBOHYDRATE TRANSPORT 
AND METABOLISM IN THE LIVER DURING REST AND HIGH-
INTENSITY EXERCISE 
 
2.1 Introduction 
     Mathematical models of the liver can be divided into two broad categories: lumped 
models that consider the organ as well-mixed, and single-drug elimination models that 
consider the heterogeneous nature of the organ.  Garfinkel (1971a,b) developed the first 
comprehensive model of liver metabolism using the lumped approach and detailed in 
vitro-based kinetic expressions.  Other hepatic carbohydrate metabolism models based on 
the lumped model approach include that developed by El-Refai and Bergman (1976), 
who simulated glycogen metabolism, and  Beard and Qian (2005), who developed a 
thermodynamic constraint-based model, among others.   Numerous others have 
developed metabolic models that consider specific functions or pathways within the liver, 
again using the well-mixed approach.  Rowland et al. (1983) used this approach to predict 
the elimination of drugs such as lignocaine and mepridine.   In addition to liver models, 
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there is a very large body of work on models of complex metabolic systems (including 
other organ systems, cell lines, and single-celled organisms) that are based on the well-
mixed approach. 
     While the well-mixed approach may be appropriate for single-celled organisms and 
cell lines, it is less appropriate for organs, such as the liver, that have a distributed-in-
space organization.  The human liver is constructed of about 1000 lobules, with each 
lobule consisting of about a million channels through which blood flows (the sinusoids), 
with each sinusoid surrounded by  a layer of  hepatocytes.  The sinusoids are arranged 
roughly in parallel, and drain into a central vein.  Models that consider this distributed-in-
space nature have represented the liver by a system of parallel tubes in which blood flows 
through each tube with the same velocity.  The elimination of drugs such as ethanol, 
galactose, and diazepam has been modeled using this approach (e.g. Saville et al., 1992). 
These models are mathematically simple—they do not include dispersion and usually 
consist of a single species mass balance and single reaction.  
     Roberts and Rowland (1985) proposed a dispersion model of the liver.  As in the 
parallel tube approach, the dispersion model assumes that the liver is a tubular reactor.  In 
addition, the model includes axial dispersion which is based on cumulative effects of 
radial variations in velocity, variations in length of the sinusoid, convective mixing in the 
flow direction of blood in the sinusoid, and diffusion. The model was applied to the drugs 
antipyrine, carbamazepine, and lignocaine. The model consists of a partial differential 
equation for the drug in one compartment (sinusoid) and a first order elimination rate  
     Gray and Tam (1986) have suggested a model that considers the liver as a series of 
compartments connected together. The model is based on the tanks-in-series model used 
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by chemical engineers. Each compartment is considered to be well mixed.  The model 
does not differentiate the blood from the tissue compartments.  Tsuji et al. (1983) 
developed a liver model consisting of mass balances for a single species (i.e. β-lactam 
antibiotics) in three compartments, representing the sinusoids, space of Disse and tissue.  
     Bassingthwaite et al. (1970) developed a model for capillary - tissue exchange that 
combined the Krogh’s cylinder model from 1919 for the transport of oxygen from the 
capillary into tissue with the dispersion model. The model is of a single straight capillary 
surrounded by a concentric tissue compartment. The model had two sets of equations, 
one representing concentration in the capillary and the other in the tissue. This model was 
used to predict the concentration of a metabolite along the axial direction in a capillary,  
and along axial and radial directions in the tissue.  This work was extended to represent 
parallel multi-capillary systems in King et al. (1996) and Deussen and Bassingthwaighte 
(1996).   
     None of these distributed-in-space models considered the complex network of 
metabolic pathways found in the liver, nor the unique feature of the liver, that is, the 
metabolic heterogeneity or zonation shown by the hepatocytes.  Hepatocytes from the 
periportal zone of the liver have different enzyme activities from the perivenous zone 
(Jungermann et al. 1982). It has been shown that the periportal zone has a relatively high 
gluconeogenesis rate since the zone is rich in enzyme activities  such as glucose-6-
phosphatase, fructose 1,6 bisphosphatase and phosphoenol pyruvate carboxykinase, while 
the perivenous zone is rich in glycolytic enzyme activities such as pyruvate kinase and 
glucokinase.   During the absorptive phase, the perivenous cells take up glucose from the 
blood and convert it into glycogen and lactate. The lactate is released into the blood 
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stream, and in combination with lactate released by the gut, is then absorbed by the 
periportal cells and converted to glycogen through gluconeogenesis. During the fasting 
phase, the periportal cells release glucose from the breakdown of glycogen and through 
gluconeogenesis, while the perivenous cells form lactate through glycogen breakdown.  
     We have combined the features of the detailed carbohydrate metabolism found in the 
lumped models with features of the dispersion, Krogh cylinder, and multi-capillary 
system approaches in order to represent carbohydrate metabolism as well as tissue 
heterogeneity and axial concentration gradients.  The model of the single sinusoid 
considers two compartments: the blood compartment, with convection, axial dispersion, 
and transport to the surrounding tissue; and the tissue compartment, where reactions 
representing key processes of glycolysis, gluconeogenesis, glycogenolysis, tricarboxylic 
acid cycle, oxidative phosphorylation, and fatty acid degradation and synthesis take 
place.   Each reaction is represented by Michaelis-Menten expressions with modulation 
by ADP/ATP and/or NADH/NAD+, as appropriate, using an approach similar to that by 
Salem et al. (2002). The model includes the metabolic heterogeneity of the liver by 
incorporating spatial variation of key enzymatic activities.  By means of this model one 
can predict gradients in reaction rates in the tissue, and determine whether these gradients 
result primarily from concentration gradients in the sinusoid or from zonation of enzyme 
activities.   The results from the single sinusoid model are then scaled-up to provide 
values for total organ output fluxes and concentrations which are compared to 
experimental data.  
     This liver model was intended to be included in a whole-body model being developed 
by other members of the research team.  One of the goals of the whole-body model 
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development was the integration of physiological data related to high-intensity exercise 
and an improved understanding of controlling factors underlying the physiological 
response to exercise.  To this end, hepatic concentrations and fluxes during the fasted, 
high-intensity exercise state were calculated using the model presented here.  These 
simulations allow one to determine the relative importance of various physiological 
changes that occur during exercise on hepatic glucose/lactate output, such as the 
increased arterial lactate concentration and the changes in enzymatic activities induced by 
glucagon secretion.  
 
2.2 Model Development 
2.2.1 Overall Liver Model 
     The human liver is known to have 1 million lobules, with each lobule containing about 
1000 sinusoids.  Each lobule is drained by a central vein, and the output from all lobules 
is collected in the hepatic vein.  Blood flows roughly in parallel through all of the 
approximately 1 billion sinusoids.  A schematic of the liver, which is the basis of the 
model presented here, is shown in Figure 2.1.   
     The net production rate of species i in sinusoid j (pij) is given by a mass balance over 
the entire sinusoid:  
 )1.2()( ,,,,,, bloodijLxjbloodijxsjji CCAvp
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where vj   is the blood velocity in sinusoid j, Axs,j is the cross-sectional area of each 
sinusoid calculated from the sinusoid diameter (ds), bloodiC ,∞  is the concentration of 
species i in the blood upstream of  the sinusoid (i.e. mixture of the hepatic artery and 
portal vein), and jLxbloodiC ,, =  is the concentration of species i at the outlet of each 
sinusoid j (i.e. the central vein).  The net production from the entire liver is given by: 
 
 
  
     All sinusoids are assumed to have the same length (L), blood velocity (v), and cross-
sectional area.  The sinusoid length has been reported to be 0.25 – 1 mm (Rappaport 
1980; MacPhee et al. 1995; LeCouteur 2004).   Blood velocity distributions have been 
reported to range from 0-400 μm/s (MacPhee et al. 1995), with means of 69 μm/s in 
mouse and 180 μm/s in rat, while Koo and Liang (1979) reported velocities of 150 – 250 
μm/s in rat.  The sinusoid diameter (ds) is reported at values from 4 to 15 um, with the 
Figure 2.1.  Schematic of the lobule structure within the liver.   
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diameter slightly increasing from periportal to perivenous ends (LeCouteur 2004; 
MacPhee et al. 1995; Rappaport 1980). The actual values used in the model (Table 2.1) 
were selected from within the reported ranges, with the criteria that they result in liver 
geometry that is consistent with macroscopic measurements of human liver.  Using the 
equation for total liver blood flow rate, Q, and assuming that all the sinusoids have the 
same length and velocity (i.e., vj=v): 
∑= usoidsn
j
jxsj AvQ
sin
,  
results in Q=1.47 L/min blood flow (compared to 1.5 L/min as commonly reported), 83% 
liver mass equal to hepatocytes (compared to 80% as commonly reported), and residence 
time within a single sinusoid of 5 sec (compared to mean residence time of  4 sec, 
Goresky, 1980).   
     The concentration of each species at the outlet of each sinusoid ( jLxbloodiC ,, = ) is 
obtained from the mass balances comprising the model of the individual sinusoid, given 
in the following section.  
 
2.2.2 Single Sinusoid Model 
     Each sinusoid is lined with endothelial cells, which are separated from the single row 
of surrounding hepatocytes by the space of Disse (Figure 2.2).   The endothelial cells 
contain fenestrae, or pores, that permit dissolved substances in the blood to enter the 
space of Disse, but prevent transport of large particles such as red blood cells.  
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Table 2.1 Model parameters. 
Variable Description Value used in 
model 
Additional information/reference
 ds  
 
 
Diameter of sinusoid 5.7 μm 
             
 
4 um (PP) and 5 um (PP) 
(LeCouteur 2004);  
5.9 um (PP) and 7.3 um (PV) in 
mice (MacPhee et al. 1995); 7-15 
um (Rappaport 1980) 
 dt 
 
½ of hepatocyte sheet 
thickness 
 
5.5 μm  
 
3.6 μm (calculated from Goresky 
et al. 1973);  6-12 um human 
hepatocyte radius,  2.5-8 um in 
other tissue 
(http://www.bartleby.com/107/pag
es/page1196.html)  
ded Endothelial cell 
thickness + space of 
Disse 
1.8 μm 
 
Calculated from Goresky et 
al.1973 
 
L 
 
Sinusoid length 1 mm 
 
 
 
1 mm (LeCouteur 2004); .25 mm 
(Rappaport 1980);  0.3 mm, 
estimated from images (MacPhee 
et al. 1995) . 
Vtissue  Volume of tissue 
surrounding a single 
sinusoid 
9.5x10-8 cm3 Calculated. 
Vblood Volume of blood 
within a single 
sinusoid plus the space 
of Disse. 
4.42x10-8 cm3 Calculated. 
 v 
 
Velocity of blood in 
sinusoid 
183 um/s ; 
 yields τ=5.4 sec 
Mean values: 69 um/s (mouse) and 
180 um/s (rat), range: 0-400 um/s 
(MacPhee et al. 1995); 150, 250 
um/s, rat (Koo and Liang 1979)  
nsinusoids Number of sinusoids in 
the liver 
5.23 x 109  
Q Blood flow rate 
through liver 
1.47 L/min  
 DG Diffusivity of glucose 
in blood  
5.46 x 10 -4 
cm2/min 
 
Renkin 1977 
 DL 
 
Diffusivity of lactate 
in blood 
7.71 x 10 -4 
cm2/min  
Calculated using Renkin’s model 
(Fournier et al. 1998).  
1.013 x 10-4  x (MW)-0.46   
 Da,G Dispersion coefficient 
of glucose 
5.50 x 10 -4 
cm2/min 
Calculated using Equation 2.4 
Da, L Dispersion coefficient 
of lactate 
7.74 x 10 -4 
cm2/min 
Calculated using Equation 2.4 
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Figure 2.2.  Schematic of a single sinusoid. 
 
    An idealized view of the sinusoid is used as the basis for the model (Fig. 2.3). The liver 
tissue is represented as a cylindrical region surrounding the sinusoid with a constant cross 
sectional area.   The model can be considered to consist of three domains: the sinusoid, 
the space of Disse, and the tissue.  Goresky et al. (1973) have shown through their tracer 
studies that species concentrations in the space of Disse equilibrate rapidly and are nearly 
equal to the species concentrations within the sinusoids.  Moreover, convective transport 
within this region can be considered negligible.  Therefore, mass balances are only 
written for the sinusoid and tissue domains, while the concentrations within the space of 
Disse are assumed to be equal to the concentrations at the corresponding axial position in 
the sinusoid.   
Portal venule
Blood (sinusoid)
Space of Disse
Periportal Perivenous
x 
Hepatic arteriole 
Hepatocytes
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Figure 2.3.  Schematic of a single idealized sinusoid as basis for the model. Large arrows represent the flow 
of blood within the sinusoid.  ds is the diameter of the sinusoid; dt is the half-thickness of the hepatocyte 
layer; ded is the width of the endothelial cell layer plus the space of Disse; Ci,blood is the concentration of 
species i within the sinusoid, as function of distance and time; Ci,tissue is the concentration of species i within 
the tissue, as function of distance and time; L is the length of an average sinusoid; C∞i,blood is the 
concentration of species i entering the sinusoid from the portal artery and hepatic vein.  Values of variables 
are given in Table 2.1.  
 
 
2.2.3 Governing Equations 
     The mass balance for each species in the blood within a single sinusoid is based on the 
convective flow of blood through the sinusoid, the dispersion occurring due to the flow, 
and the transport of the metabolite from blood into the hepatocytes. The mass balance 
equation is given by Taylor’s axial dispersion model (Fogler 2001), which describes an 
axial-dispersion model  of a compound through a tubular reactor, with slight modification 
by including the transport of the species from blood into the tissue: 
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where Ci is the concentration of species i, t is time, x is axial distance along the sinusoid, 
Da,i is the dispersion coefficient,  and tbiJ −,  is the transport flux from the blood into 
tissue.  The kinetics for bi-directional carrier-mediated transport is given by the 
simplified expression:  
           
 
 
 
The dispersion coefficients were calculated using the Aris–Taylor’s relation (Fogler, 
2001):                                       
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where Di is the diffusion coefficient of species i in blood.   
     The mass balance of each species in the tissue includes transport between the blood 
and tissue and reaction kinetics. Due to the relatively small tissue thickness, 
concentration gradients in the radial direction are neglected.  Axial diffusion is also 
neglected.  The tissue here is treated as a set of sub-compartments connected in parallel to 
the sinusoid domain, via the space of Disse domain.   Since the concentrations in the 
space of Disse equilibrate rapidly with the concentrations in the corresponding position 
within the sinusoid, the radial flux can be considered to result from the concentration 
difference between each tissue sub-compartment and the corresponding region of the 
sinusoid. Reactions occur inside each tissue sub-compartment, and each sub-
compartment is considered to be well-mixed. The concentration gradient in the tissue is 
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thus driven by different rates of transport into/out of each tissue sub-compartment, as 
well as different reaction rates in each sub-compartment.  The general mass balance 
equation for each metabolite i in tissue is then: 
           
 
 
where iR  = rate of reaction of each metabolite within each tissue sub-compartment. 
     The transport flux for the tissue equation is divided by the volume ratio (Vratio) of 
tissue to blood to make the units consistent for the two compartments.  By doing this, the 
units of the transport flux will be with respect to each compartmental volume: 
 
     
where 
blood
tissue
ratio V
VV = ,  Vtissue is the volume of tissue surrounding a single sinusoid, and 
Vblood  is the total volume of blood within both a single sinusoid and the space of Disse. 
     Equations 2.3 and 2.5 are made dimensionless in the axial direction by defining the 
following variables: 
Using the above variables, Equation 2.3 can be written as follows: 
          
 
where Pe is the Peclet number which is defined as  
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Using the parameter values given in Table 2.1, PeGLC and PeLAC are calculated to be 200 
and 142 respectively.  
     The boundary conditions are obtained by assuming that the flow of blood is plug flow 
(i.e. no dispersion) before entering and after leaving the sinusoids. These are called 
Danckwert’s boundary conditions and represent an open system.  The corresponding 
boundary conditions are given by (Fogler 2001): 
 
 At x = 0:  
  
At x = L: 
   
The initial concentrations depend upon the physiological state and will be discussed in 
the Results section. 
 
2.2.4 Metabolic Pathways 
     Simplified pathways representing glycolysis, gluconeogenesis, glycogenolysis, 
glycogen synthesis,  citric acid cycle, oxidative phosphorylation, triglyceride breakdown, 
and fatty acid synthesis and degradation were included (Figure 2.4).  Each of these 
pathways is represented by 1-3 key reactions.  The name of the reaction either 
corresponds to the enzyme name (when representing a single reaction) or to the names of 
the substrate and product (when representing a series of reactions lumped together).   
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Kinetic expressions are given in Table 2.2.  Reversible, near-equilibrium reactions 
(RGAP?PEP, RLAC?PYR) are represented by a simplified form of a reversible, ping-pong 
mechanism.  All other reactions are assumed to be essentially irreversible and are 
represented by Michaelis-Menten kinetic expressions with modulation by CADP/CATP and 
CNADH/CNAD+ as relevant.  The flux through the citric acid cycle was assumed to exist in 
an additive “ping-pong” relationship (Salem et al. 2002).  
 
 
 
 
 
      
 
 
 
 
 
 
 
 
Figure 2.4.  Reaction network considered in tissue model.  Arrows without enzyme names indicate a series 
of reactions that have been lumped together.  The ATPase reaction represents the total of all ATP-utilizing 
reactions that are not considered explicitly in the model.  GK: glucokinase; G6Pase: glucose-6-
phosphatase; Glyphos: glycogen phosphorylase; OxPhos: oxidative phosphorylation, PK: pyruvate kinase; 
PC: pyruvate carboxylase; PEPCK: phosphoenyl pyruvate carboxykinase; PDH: pyruvate dehydrogenase; 
LDH: lactate dehydrogenase; G6P: glucose-6-phosphate; GAP: glyceraldehyde-3-phosphate; GR3P: 
glycerol-3-phosphate; PEP: phosphoenyl pyruvate; AcCoA: acetyl CoA. 
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     Kinetic parameters were estimated from concentration and flux data measured at the 
overnight fasted, resting state.  The input and output fluxes at steady state were estimated 
from a combination of  in vivo experiments on humans and dogs and internal fluxes were 
then calculated using flux balance analysis (FBA).   Species concentrations were 
compiled mostly from experiments with overnight fasted rats. The set of experimental 
and calculated fluxes and concentrations are shown in Tables 2.2 and 2.3, respectively.  
In the case of irreversible reactions, the Km in each reaction was set equal to the 
experimental substrate concentration at steady state, the Km for  CADP/CATP, represented 
by PSi, was set equal to the steady state experimental CADP/CATP  ratio, and the Km for 
CNADH/CNAD+, represented by RSi, was set equal to the experimental CNADH/CNAD+ ratio, 
all measured in animals following an overnight fast.   From these parameter values and 
concentration and flux values, the Vmax’s  were calculated uniquely using the kinetic 
expressions.  Reversible reactions were handled differently.  In general, the Vmax’s and 
Keq’s were determined from in vitro measurements, and then the Km’s were calculated 
such that the net flux through the reaction matched the experimental (or FBA-calculated) 
flux.  The Haldane equation (relating kinetic parameter values at near-equilibrium) was 
used to reduce the number of unknown parameters and to ensure consistency with 
thermodynamic constraints.  If no kinetic expression is given, then that flux was assigned 
a constant value in the model, given by either the measured or calculated flux.   
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Table 2.2.  Fluxes, kinetic expressions and parameter values (PS=CATP/CADP; RS=CNAD+/CNADH).  The 
fluxes used for parameter estimation are derived from either experimental data (with reference given), or 
calculated from flux balance analysis.  Fluxes are in μmol substrate/gww hep/min, unless otherwise 
specified.  ‡Some of the input/output fluxes used deviate somewhat from experimental reports.  Since this 
model is to be used in a model of the whole body, the input and output fluxes were required to be consistent 
with the overall balances in the body for species such as FA, TGL, Glc, ALA, GLR, and LAC.  GLR: 
glycerol; Glc: glucose; Gly: glycogen; LAC: lactate; OXA: oxaloacetate.  *Value calculated via Flux 
Balance Analysis (FBA).   
Rate Flux used 
for 
parameter 
estimation  
 
Flux 
calc. 
from 
simula
tion 
Kinetic Expression Parameter 
Values (Vmax in 
μmol/gww/min; 
Km in μmol/gww) 
RGK 0.136 
(Miyoshi et 
al. 1988; 
Shulmanet 
al. 1985) 
0.14 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PS/1PS/1
PS/1
CK
CV
it_GLCGK,m
t_GLCGKmax,  Vmax,GK= 0.54 KM,GK=3.61 
PSi=0.45 
RG6Pase 0.721* 
 
0.717 
PGPaseGm
PGPaseG
CK
CV
66,
66max,
+  
Vmax,G6Pase=1.41 
Km,G6Pase=0.06 
RGlyPhos  
 
0.304 µmole 
C6/gww/mi
n 
(Petersen et 
al., 1996) 
   
RG6P->GAP   0.136 µmole 
C6/gww/mi
n 
(Miyoshi et 
al. 1988; 
Shulman et 
al. 1985) 
0.134 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
CK
CV
iPGGAPPGm
PGGAPPG
/1/1
/1
6_6,
6_6max,  
Vmax,G6P_GAP=0.54 
Km,G6P_GAP =0.06 
RGAP->G6P    0.83 µmole 
C3/gww/mi
n * 
0.815 
GAPPGGAPm
GAPPGGAP
CK
CV
+6_,
6_max,  
Vmax,GAP_G6P=1.60 
Km,GAP_G6P=0.0031 
RPEP-
>GAP,net 
0.472* 0.458 
PEPGAPm
ADPNADPiGAP
GAPPEPm
ATPNADHPEP
GAPPEPeq
ADPNADPiGAP
ATPNADHPEP
GAPPEPm
GAPPEP
K
CCCC
K
CCC
K
CCCCCCC
K
V
_,_,
_,_,
_max,
1 +
+
++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
 
Vmax,PEP_GAP=94 
(Diem and Lentner 
1970) 
Km,PEP_GAP= 
2.7x10-4 
Km,GAP_PEP= 
1.75x10-4 
Keq,PEP_GAP=4167 
(Reich and Selkov 
1981) 
RGR3P-
>GAP 
0.0888*; 
(0.112 in 
Brundin and 
Wahren 
1993) 
   
RPK 0.94 * 0.931 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
CK
CV
iPEPPK,m
PEPpkmax,  
Vmax,PK=3.78 
Km,PK=0.046 
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RPC 1.416* 1.39 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
CK
CV
iPYRPCm
PYRPC
/1/1
/1
,
max,  Vmax,PC=5.66 
Km,PC=0.059 
RPEPCK 1.416 (Jones 
et al. 1991)* 
1.39 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PS/1PS/1
PS/1
CK
CV
iOXAPEPCK,m
OXAPEPCKmax,  Vmax,PEPCK=5.66 
Km,PEPCK=0.0003 
RPDH 0.0 (Magnusson et al. 1991)  
 
 
 
Table 2.3. Species concentrations in liver tissue, at the overnight fasted state, used to estimate kinetic 
parameters.  
Species Concentration used to 
estimate parameters 
(μmol gww-1 hep) 
Reference 
Glc,tissue 3.61 
 
Bergmeyer 1974 
Glc,blood 3.5 Bergman and El-Refai 1975 
G6P 0.06 Bergmeyer 1974 
glycogen 391 Petersen et al. 1996 
GAP 0.0031 Stubs et al. 1972 
GR3P 0.281 Bergmeyer 1974 
PEP .046 Bergmeyer 1974 
PYR 0.059 Stubbs et al. 1972 
OXA 0.0003 Bergmeyer 1974 
LAC,blood 1.2 Bergmeyer 1974 
LAC,tissue 0.98 Krebs 1967 
AcCoA 0.1 Bergmeyer 1974 
Oxygen 7.33 Brundin and Wahren 1991 
ATP 3.43 
 
Gyorgy et al. 1995; Morikawa et al. 1998; 
Gannon et al. 2002; Hultman et al. 1975; 
Boesiger et al. 1994 
NADH+NAD+ 1.22 Bergmeyer 1974 
NADH/NAD+ .0014 Stubbs et al. 1972 
Pi 5.74 Morikawa et al. 1998; Bode et al. 1973 
 
     The zonation phenomenon is incorporated into the model by assuming either linear 
(Vmax= Vo,l+ a·x/L) or exponential (Vmax=Vo,e·exp(b·x/L) variations in maximal activities 
for the reactions for which the phenomenon has been observed.   The parameter values in 
these functions were determined by assuming that the relative changes in maximal 
enzyme activities between the periportal and perivenous regions are similar to those 
reported in the literature  (Table 2.4), and that the maximal activities at x/L=0.5 are given 
by the values in Table 2.2.  The parameters used in the functions for Vmax are given in 
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Table 2.4 and the functions are graphed in Figure 2.5.  The use of exponential functions 
is based on the hypothesis that substrate concentration gradients along the sinusoid are 
most likely exponential (e.g. as measured for pO2), which may influence the distribution 
of enzyme activity. There is clear literature support for the zonation of glucokinase (GK),  
glucose-6-phosphatase (G6Pase), fructose-1,6-bis-phosphatase (represented by 
Vmax,GAP?G6P ), phosphoenolpyruvate carboxykinase (PEPCK), and pyruvate kinase (PK).  
Although zonation of pyruvate carboxylase (PC) has not been specifically reported, 
because of this enzyme’s key role in gluconeogenesis, the zonation of Vmax,PC was 
included using a function similar to that used for Vmax,PEPCK.  Similarly, the results were 
calculated with zonation of phosphofructokinase (represented by Vmax,G6P?GAP ) using a 
similar function to that of GK.  The incorporation of zonation of Vmax,G6P?GAP  did not 
change any of the flux profiles, except for that of VG6P?GAP itself (data not shown), and 
thus does not seem to be essential.  Although zonation is also known to occur in lipid 
metabolism, this was not addressed in this work since detailed lipid metabolism kinetics 
are not included in the model.  
Table 2.4.  Literature sources for maximal enzyme activities in periportal and perivenous regions, and the 
parameters values used in the linear (Vmax= Vo,l+ a·x/L) or exponential (Vmax=Vo,e·exp(b·x/L) zonation 
functions.  
Reaction Reference Vo,l 
(μmol/g/min)
a 
(μmol/g/min)
Vo,e 
(μmol/g/min) 
b 
(μmol/g/min)
Vmax,GK Jungermann et al. 
1982 
0.17 0.74 0.27 1.39 
Vmax,G6Pase Katz et al. 1977 1.87 -0.87 2.46 -1.07 
Vmax,GAP?G6P Matsumura et al. 
1984 
2.70 2.16 2.83 0.58 
Vmax,PK Guder and Schmidt 
1976; Jungermann 
1988 
2.33 -1.33 2.50 -0.81 
Vmax,PEPCK Guder and Schmidt 
1976; Matsumura 
et al. 1984 
8.54 -5.76 9.52 -1.04 
Vmax,PC  8.54 -5.76 9.52 -1.04 
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Figure 2.5.  Linear and exponential functions of Vmax as a function of distance along the sinusoid length.  
Functions are fitted by assuming that  the Vmax (given in Table 2.2) occurs at x/L=0.5,  and using the ratio 
of maximal activities from periportal to perivenous, derived from data found in the references in Table 2.4.  
Function parameters are given in Table 2.4.  The dashed line is a linear fit to the data, solid line is 
exponential fit. 
 
     The model consists of 13 mass balances: glucose in blood and tissue(GLCb, GLCt), 
lactate in blood and tissue (LACb, LACt), and in tissue only: glucose-6-phosphate(G6P), 
phosphoenolpyruvate (PEP), pyruvate (PYR), AcCoA, oxaloacetate (OXA), ATP, 
NADH, glycogen (GLY),  glyceraldehyde-3-phosphate (GAP).  The quantities  
CNADH+CNAD+, CATP+CADP, and CPi are assumed to be constant, with values given in 
Table 2.3.  
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The governing equations in the blood, which is a partial differential equation for each 
species in the blood, were converted to ordinary differential equations by means of the 
finite difference method using 200 grid points.  The governing equations in the tissue  
were written for each species for each of the 200 grid points.  All  ODE’s were then 
solved simultaneously using the FORTRAN routine LSODE.   
     The sensitivity coefficients of concentration of species i (Ci) and flux i (Ri) to 
parameter Kj are defined as: 
)10.2(; ,,
jj
ii
jRi
jj
ii
jCi KK
RRS
KK
CCS ∂
∂=∂
∂=  
Partial derivatives were estimated by central finite differences.  
 
2.3 Results 
     Simulations were first performed at the resting, overnight fasted state, without 
zonation, and with boundary conditions given by: 
mMC
mMC
bloodLAC
bloodGLC
2.1
5.3
,
,
=
=
∞
∞  
     The resulting fluxes are nearly identical to the experimental (Table 2.2) and the 
calculated concentrations agree closely with the experimental concentrations (not shown).  
Since these fluxes and concentrations were used to estimate the kinetic parameters, these 
results indicate that the program and model are consistent and do not constitute 
independent verification of the model.  
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     The total glucose output and lactate uptake by the liver in the fasted, resting state, 
calculated from Equation 2.2 and assuming constant Vmax’s,  are shown in Figure 2.6.  
The simulated values for both glucose output and lactate uptake are nearly identical to 
experimental values.  The incorporation of zonation, whether linear or exponential, has 
no effect on the overall liver output, mainly because the functions used in zonation were 
based on setting the Vmax (at x/L=0.5) equal to the constant Vmax used in the “no 
zonation” simulation.   
 
 
 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6.  (a) Net glucose production by the liver and (b) net lactate uptake by the liver at the fasted, 
resting state, using blood flow = 1.47 L/min and parameters given in Tables 2.1 and 2.2.  Results are shown 
for both exponential and linear zonation functions.  Results were calculated using a single enzyme with a 
zonation function, then with zonation in all six enzymes simultaneously, and also with no zonation (i.e. 
constant Vmax’s).  Experimental data from the literature are shown for comparison.  
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      The net glucose production and lactate uptake rates along the sinusoid length are 
shown in Figure 2.7.  As shown in Figure 2.7a (with no zonation), the net glucose and 
lactate fluxes are essentially constant along the length of the sinusoid, indicating that at 
the relatively high blood velocities (and therefore Pe), the species concentration gradients 
in the axial direction are minimal, causing little variations in fluxes.  Figures 2.7(b-g) 
show the results from simulations where a single enzyme has its Vmax as a function of 
distance.  These results indicate that PK, F1,6BPase (represented by GAP?G6P), and PC 
have the greatest influence on spatial variation in glucose and lactate fluxes.  With 
zonation of all six reactions (Figure 2.7h), synergistic effects are observed with a 35% 
decrease in glucose production between periportal and perivenous regions, and with 
lactate flux changing from uptake (in periportal) to production in the perivenous region.   
Experimental values (Jungermann 1983) of net glucose production from microdissected 
liver tissue and from cultured hepatocytes stimulated to represent either periportal or 
perivenous cells are shown in Figure 2.7h.  While the magnitude of change between 
periportal and perivenous was greater in the experiments than the simulations, the 
simulations do show the expected trend.  Furthermore, there is significant uncertainty in 
the experimental data.  For instance, the data from the liver tissue are actually calculated 
from measurements of maximal enzyme activities and substrate concentrations from the 
tissue extracts, and assuming Michaelis-Menten kinetics, so there is significant room for 
error there.  Secondly, the cultured hepatocyte system is, at best, an approximation of the 
two regions of the liver parenchyma in vivo.   
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Figure 2.7.  Net rates of  glucose production, JGLC,t?b,net and lactate uptake JLAC,b?t,net by the tissue along the length of the sinusoid, in fasted, 
resting condition. (a) no zonation; (b) – (g) with zonation only for the enzyme indicated in the graph title, with all other enzymes having 
constant activity; solid line: linear zonation; dotted line: exponential zonation;  (h) zonation of all six enzymes simultaneously, compared 
with experimental data from Jungermann, 1983;  solid line: linear zonation function; dotted line: exponential zonation function; ⁫: tissue 
extracts from periportal (shown at x/L=0) and perivenous (shown at x/L=1) zones of microdissected rat liver parenchyma, with fluxes 
calculated from measured local enzyme activities and substrate concentrations and assuming Michaelis-Menten kinetics; Ο: measured in 
cultured hepatocytes that have been stimulated to resemble either periportal (shown at x/L=0) or perivenous (shown at x/L=1) cells, and 
placed in media representing the fasted state,. 
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Figure 2.8.  Reaction fluxes as a function of sinusoid length, during the fasted, resting state, with zonation of all six reactions, and without zonation.  Fluxes are 
normalized to the flux value at x/L=0.  Lines represent simulations, open circles represent experimental data from cultured hepatocytes, stimulated to resemble 
either periportal (shown at x/L=0) or perivenous (shown at x/L=1) cells, and placed in media representing the fasted state, from Jungerman 1983.  
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Figure 2.9.  Absolute values of the sensitivities of net overall glucose production (SPGLC,,j) and lactate uptake (SPLAC,,j) to kinetic parameters j, given in the x-axis.   
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     The fluxes through each of these six reactions (calculated with zonation in all six 
reactions, compared to no zonation) are shown in Figure 2.8, after normalization to the 
flux at x/L=0.   Again, fluxes in each reaction are nearly constant along the length when 
there is no zonation, indicating that there is little effect of potential concentration 
gradients on flux distributions.   The axial variations become much more significant with 
the incorporation of enzyme zonation, with the glycolytic fluxes (GK, PK) increasing 
with distance and the gluconeogenic fluxes (G6Pase, F1,6BPase, PEPCK, PC) 
decreasing.   For example, the calculated glucokinase flux, with zonation,  increases six-
fold between periportal (x/L=0) and perivenous (x/L=1).  This result is identical to the 
six-fold increase in glycolytic flux measured in periportal-like vs. perivenous-like 
hepatocytes (Jungermann 1983).   On the other hand, the calculated G6Pase flux 
decreases between periportal and perivenous,  but to a much lesser extent than  that 
reported by Jungerman (5% decrease in calculated value, compared to 48% decrease in 
measured gluconeogenic flux).  The G6Pase reaction flux does not change as 
significantly as the maximal activity for G6Pase (Figure 2.5),  since the flux is tempered 
by the substrate concentration and the relatively large blood flow rate in the liver. 
     The parametric sensitivity coefficients were calculated using the model without 
zonation representing the fasted, resting state.  The sensitivities of overall glucose 
production (PGLC) and lactate uptake (PLAC) relative to the kinetic parameters are shown 
in Figure 2.9. The lactate uptake is much more sensitive to parameters than the glucose 
output, since the glucose output is a function of both glycogen degradation (which is set 
to a constant)  as well as the lactate uptake and intermediary reactions.  Not surprisingly, 
the fluxes are most sensitive to parameters in some of the key regulatory reactions, such 
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as PK, PC, and F1,6BPase (represented by GAP?G6P).  Also note that the sensitivity to 
the parameters related to nonspecific ATP demand is also relatively high.  But for all 
parameters, the sensitivities of overall glucose output and lactate uptake are less than one, 
indicating that the results are stable and that no single parameter has an amplification 
effect on the overall fluxes.   
      The sensitivities for all internal fluxes and species concentrations are shown in Tables 
2.5 and 2.6.   In general, concentrations and fluxes were more sensitive to Vmax’s than to 
Km’s, indicating the importance of having good estimates especially for the Vmax’s.  The 
Vmax’s corresponding to gluconeogenic reactions were most influential, i.e. G6Pase, PC, 
GAP?G6P, and PK (which affects the amount of cycling during gluconeogenesis).  The 
most influential Km is Km,ATP_ADP, which appears in the nonspecific ATP usage kinetic 
expression.  This parameter does not have direct physiological significance, and thus an 
experimental value is unavailable.  The transport parameters had relatively little effect on 
the results, indicating that the system is more metabolically driven rather than transport 
driven.  
     The sensitivities of all the fluxes to all the parameters are all less than one, indicating 
that there were no cases of disproportionate effects of parameters on flux distributions.  
On the other hand, the OXA concentration was hypersensitive to Vmax,PEPCK, Vmax,PC, 
Vmax,ATP_ADP, and to a less extent, Vmax,OxPhos.   This results from the low in vivo 
concentration of OXA (0.0003 μmol/g/ww).   
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Table 2.5  Sensitivity coefficients to Km’s, defined by Eq. 2.10. Values in boldface have magnitude greater than 0.50. 
,
 Km,GK Km,G6pase Km,G6P_GAP Km,GAP_PEP Km,PK Km,LAC_PYR Km,PYR_LAC Km,OxPhos Km,PC Km,PEPCK Km, PEP_GAP Km,GAP_G6P Km,ATP_ADP Km,Glc,b_t Km,LAC,b_t e5
Glcblood 4.9E-04 -1.7E-03 1.7E-03 4.5E-03 4.7E-03 2.3E-03 -2.3E-03 -2.0E-03 -4.9E-03 0.0E+00 -4.5E-03 -4.7E-03 8.4E-03 -5.3E-06 -4.1E-04 0.0E+00
Glctissue 6.9E-04 -2.3E-03 2.3E-03 6.3E-03 6.5E-03 3.2E-03 -3.2E-03 -2.8E-03 -6.9E-03 0.0E+00 -6.3E-03 -6.5E-03 1.2E-02 9.5E-03 -5.8E-04 0.0E+00
LACblood -3.4E-03 1.1E-02 -1.1E-02 -3.1E-02 -3.2E-02 -1.6E-02 1.6E-02 1.4E-02 3.3E-02 0.0E+00 3.1E-02 3.2E-02 -5.7E-02 3.6E-05 2.8E-03 0.0E+00
LACtissue -1.2E-02 3.9E-02 -3.9E-02 -1.1E-01 -1.1E-01 -5.5E-02 5.5E-02 5.0E-02 1.2E-01 -7.4E-07 1.1E-01 1.1E-01 -2.0E-01 1.3E-04 -6.7E-02 0.0E+00
G6P -1.5E-01 9.5E-01 4.0E-02 1.0E-01 1.1E-01 3.9E-02 -3.9E-02 -1.0E-02 -8.3E-02 -1.1E-06 -1.0E-01 -1.1E-01 3.4E-01 1.6E-03 -7.1E-03 0.0E+00
GLY 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00
ATP 5.4E-03 -5.4E-03 5.4E-03 3.0E-03 3.1E-03 -2.0E-02 2.0E-02 5.7E-02 4.2E-02 0.0E+00 -3.0E-03 -3.1E-03 2.8E-01 -5.9E-05 3.6E-03 0.0E+00
NADH 1.7E-02 -1.7E-02 1.7E-02 9.4E-03 9.8E-03 -6.4E-02 6.4E-02 2.9E+00 1.4E-01 0.0E+00 -9.5E-03 -9.7E-03 2.5E+00 -1.8E-04 1.2E-02 0.0E+00
PYR -4.7E-02 1.2E-01 -1.2E-01 -2.9E-01 -3.0E-01 3.4E-01 -3.4E-01 -1.0E+00 1.7E-01 -1.2E-06 2.9E-01 3.0E-01 -2.0E+00 5.0E-04 -6.3E-02 0.0E+00
AcCoA 8.6E-03 -8.6E-03 8.6E-03 4.7E-03 4.9E-03 -3.2E-02 3.2E-02 8.4E-01 6.8E-02 0.0E+00 -4.7E-03 -4.9E-03 1.0E+00 -9.1E-05 5.8E-03 -1.7E-04
PEP -4.3E-02 1.9E-01 -1.9E-01 -5.7E-01 3.6E-01 2.8E-01 -2.8E-01 -1.1E+00 -6.1E-01 -1.5E-06 5.7E-01 5.9E-01 -5.4E-01 4.6E-04 -5.1E-02 0.0E+00
OXA -4.7E-02 1.2E-01 -1.2E-01 -2.9E-01 -3.0E-01 3.4E-01 -3.4E-01 -1.0E+00 -8.1E-01 1.0E+00 2.9E-01 3.0E-01 -2.0E+00 5.0E-04 -6.3E-02 0.0E+00
GAP -2.5E-02 2.1E-01 -2.1E-01 2.1E-01 2.2E-01 7.9E-02 -7.9E-02 -2.2E-02 -1.7E-01 0.0E+00 -2.1E-01 7.5E-01 6.8E-01 2.7E-04 -1.4E-02 0.0E+00
GK -4.2E-01 -9.9E-03 9.9E-03 7.9E-03 8.2E-03 -3.1E-02 3.1E-02 9.3E-02 6.5E-02 -4.8E-06 -7.9E-03 -8.1E-03 4.7E-01 4.5E-03 5.6E-03 0.0E+00
PK -3.1E-02 1.0E-01 -1.0E-01 -2.8E-01 -2.9E-01 1.8E-01 -1.8E-01 -7.6E-01 -3.7E-01 7.2E-06 2.8E-01 2.9E-01 -7.4E-01 3.3E-04 -3.2E-02 2.9E-06
G6Pase -7.6E-02 -2.0E-02 2.0E-02 5.1E-02 5.3E-02 2.0E-02 -2.0E-02 -5.2E-03 -4.2E-02 9.3E-07 -5.1E-02 -5.3E-02 1.8E-01 8.2E-04 -3.6E-03 0.0E+00
TCA 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 -6.0E-06 0.0E+00 0.0E+00 0.0E+00 0.0E+00 -6.2E-05 0.0E+00 0.0E+00 0.0E+00
OxPhos 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 -3.2E-06 0.0E+00 0.0E+00 0.0E+00 0.0E+00 -4.4E-05 0.0E+00 0.0E+00 0.0E+00
LDH 3.9E-02 -1.3E-01 1.3E-01 3.5E-01 3.7E-01 1.8E-01 -1.8E-01 -1.7E-01 -3.9E-01 3.3E-06 -3.6E-01 -3.7E-01 6.4E-01 -4.1E-04 -3.3E-02 0.0E+00
PC -1.5E-02 5.1E-02 -5.1E-02 -1.4E-01 -1.4E-01 1.4E-01 -1.4E-01 -5.3E-01 -3.1E-01 4.8E-06 1.4E-01 1.4E-01 -4.0E-01 1.6E-04 -2.6E-02 0.0E+00
PEPCK -1.5E-02 5.1E-02 -5.1E-02 -1.4E-01 -1.4E-01 1.4E-01 -1.4E-01 -5.3E-01 -3.1E-01 4.8E-06 1.4E-01 1.4E-01 -4.0E-01 1.6E-04 -2.6E-02 0.0E+00
G6P_GAP -6.8E-02 4.2E-01 -4.2E-01 5.6E-02 5.8E-02 -1.3E-02 1.3E-02 8.8E-02 2.6E-02 0.0E+00 -5.6E-02 -5.8E-02 6.4E-01 7.2E-04 2.3E-03 0.0E+00
GAP_G6P -1.3E-02 1.1E-01 -1.1E-01 1.1E-01 1.1E-01 4.1E-02 -4.1E-02 -1.2E-02 -8.7E-02 1.6E-06 -1.1E-01 -1.1E-01 3.7E-01 1.4E-04 -7.4E-03 8.2E-07
PEP_GAP 1.7E-02 -5.7E-02 5.7E-02 1.6E-01 1.6E-01 8.0E-02 -8.0E-02 -7.3E-02 -1.7E-01 2.9E-06 -1.6E-01 -1.6E-01 2.8E-01 -1.8E-04 -1.5E-02 1.5E-06
ATPase 8.8E-03 -8.8E-03 8.8E-03 4.8E-03 5.0E-03 -3.2E-02 3.2E-02 9.4E-02 6.8E-02 -8.0E-07 -4.9E-03 -5.0E-03 1.9E-02 -9.6E-05 5.9E-03 0.0E+00
Glc,b_t_net 6.7E-03 -2.3E-02 2.3E-02 6.2E-02 6.4E-02 3.2E-02 -3.2E-02 -2.9E-02 -6.8E-02 -2.0E-05 -6.2E-02 -6.4E-02 1.1E-01 -5.8E-05 -5.8E-03 -2.3E-06
LAC,b_t,net 3.8E-02 -1.3E-01 1.3E-01 3.5E-01 3.7E-01 1.8E-01 -1.8E-01 -1.7E-01 -3.9E-01 -5.0E-05 -3.6E-01 -3.7E-01 6.4E-01 -4.4E-04 -3.3E-02 -1.3E-05
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Table 2.6. Sensitivity coefficients to Vmax’s, defined by Eq. 2.10. Values in boldface have magnitude greater than 0.50.
          
Vmax,GK
          
Vmax,G6pase
      
Vmax,G6P_GAP
         
Vmax,PK
         
Vmax,LDH
         
Vmax,TCA
       
Vmax,OxPhos
         
Vmax,PC
          
Vmax,PEPCK
    
Vmax,PEP_GAP
    
Vmax,GAP_G6P
    
Vmax,ATP_ADP
     
Vmax,Glc,b_t
     
Vmax,LAC,b_t
Glcblood -4.9E-04 4.6E-03 -3.6E-03 -9.1E-03 2.3E-03 0.0E+00 -3.3E-04 1.0E-02 5.8E-05 4.6E-03 9.4E-03 -4.1E-03 1.6E-05 1.7E-03
Glctissue -6.9E-04 6.4E-03 -5.0E-03 -1.3E-02 3.2E-03 0.0E+00 -4.5E-04 1.4E-02 6.0E-05 6.4E-03 1.3E-02 -5.8E-03 -3.0E-02 2.4E-03
LACblood 3.4E-03 -2.4E-02 2.4E-02 6.2E-02 -1.6E-02 0.0E+00 2.2E-03 -7.0E-02 6.9E-04 -3.1E-02 -6.4E-02 2.8E-02 -1.1E-04 -1.1E-02
LACtissue 1.2E-02 -8.3E-02 8.6E-02 2.1E-01 -5.5E-02 -7.4E-07 7.4E-03 -2.4E-01 6.9E-04 -1.1E-01 -2.3E-01 1.2E-01 -3.9E-04 2.9E-01
G6P 2.0E-01 -9.5E+00 -8.5E-02 -2.0E-01 3.9E-02 0.0E+00 -1.5E-02 1.7E-01 8.3E-05 1.0E-01 2.1E-01 -9.0E-02 -5.1E-03 2.8E-02
GLY 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00
ATP -5.5E-03 1.1E-02 -1.2E-02 -6.1E-03 -2.0E-02 0.0E+00 -1.4E-02 -8.6E-02 -4.3E-05 3.0E-03 6.7E-03 -8.8E-02 1.8E-04 -1.5E-02
NADH -1.6E-02 3.6E-02 -3.7E-02 -1.9E-02 -6.4E-02 0.0E+00 -1.7E-01 -2.6E-01 -1.5E-04 9.5E-03 2.1E-02 -6.8E-02 5.7E-04 -4.6E-02
PYR 5.1E-02 -2.7E-01 2.7E-01 6.2E-01 3.5E-01 0.0E+00 1.1E+00 -3.5E-01 7.2E-04 -2.9E-01 -7.0E-01 2.4E+00 -1.6E-03 2.7E-01
AcCoA -8.2E-03 1.8E-02 -1.8E-02 -9.5E-03 -3.2E-02 -1.0E+00 -7.7E-02 -1.3E-01 -7.3E-05 4.8E-03 1.0E-02 -3.9E-02 2.9E-04 -2.3E-02
PEP 4.4E-02 -4.3E-01 4.5E-01 -6.8E-01 2.8E-01 0.0E+00 1.0E+00 1.5E+00 6.0E-04 -5.7E-01 -1.7E+00 -1.7E-01 -1.4E-03 2.1E-01
OXA 5.1E-02 -2.7E-01 2.7E-01 6.2E-01 3.5E-01 0.0E+00 1.1E+00 3.6E+00 -5.3E+01 -2.9E-01 -7.0E-01 2.4E+00 -1.6E-03 2.7E-01
GAP 2.5E-02 -4.9E-01 5.1E-01 -4.2E-01 7.9E-02 0.0E+00 -2.8E-02 3.6E-01 1.5E-04 2.1E-01 -2.4E+00 -1.2E-01 -8.3E-04 5.9E-02
GK 4.3E-01 2.2E-02 -2.1E-02 -1.6E-02 -3.1E-02 0.0E+00 -2.2E-02 -1.3E-01 -4.3E-05 8.0E-03 1.7E-02 -1.0E-01 -1.4E-02 -2.3E-02
PK 3.0E-02 -2.2E-01 2.2E-01 5.6E-01 1.8E-01 7.2E-07 2.1E-01 7.3E-01 3.7E-04 -2.8E-01 -5.9E-01 -4.2E-02 -1.0E-03 1.3E-01
G6Pase 7.8E-02 5.5E-02 -4.4E-02 -1.0E-01 2.0E-02 0.0E+00 -7.6E-03 8.6E-02 4.3E-05 5.2E-02 1.1E-01 -6.7E-02 -2.5E-03 1.4E-02
TCA 0.0E+00 -3.4E-06 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 8.5E-07 0.0E+00 0.0E+00
OxPhos 0.0E+00 -1.9E-05 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 0.0E+00 -6.3E-06 0.0E+00 0.0E+00 2.2E-05 0.0E+00 0.0E+00
LDH -3.9E-02 2.7E-01 -2.8E-01 -7.0E-01 1.8E-01 0.0E+00 -2.4E-02 7.9E-01 2.8E-04 3.6E-01 7.4E-01 -3.3E-01 1.3E-03 1.3E-01
PC 1.5E-02 -1.1E-01 1.1E-01 2.8E-01 1.4E-01 0.0E+00 1.4E-01 6.1E-01 2.9E-04 -1.4E-01 -2.9E-01 -7.6E-02 -4.9E-04 1.1E-01
PEPCK 1.5E-02 -1.1E-01 1.1E-01 2.8E-01 1.4E-01 0.0E+00 1.4E-01 6.1E-01 3.0E-04 -1.4E-01 -2.9E-01 -7.6E-02 -4.9E-04 1.1E-01
G6P_GAP 6.7E-02 -8.9E-01 9.1E-01 -1.1E-01 -1.3E-02 0.0E+00 -2.8E-02 -5.3E-02 -3.0E-05 5.7E-02 1.2E-01 -1.2E-01 -2.3E-03 -9.5E-03
GAP_G6P 1.2E-02 -2.2E-01 2.3E-01 -2.1E-01 4.1E-02 0.0E+00 -1.5E-02 1.8E-01 7.9E-05 1.1E-01 2.2E-01 -1.2E-01 -4.2E-04 3.0E-02
PEP_GAP -1.7E-02 1.2E-01 -1.2E-01 -3.1E-01 8.0E-02 0.0E+00 -1.1E-02 3.5E-01 1.6E-04 1.6E-01 3.2E-01 -1.5E-01 5.7E-04 5.9E-02
ATPase -8.9E-03 1.9E-02 -1.9E-02 -9.8E-03 -3.2E-02 0.0E+00 -2.1E-02 -1.4E-01 -6.9E-05 4.9E-03 1.1E-02 3.3E-02 2.9E-04 -2.4E-02
Glc,b_t_net -6.9E-03 6.4E-02 -4.9E-02 -1.2E-01 3.2E-02 0.0E+00 -4.2E-03 1.4E-01 6.2E-05 6.2E-02 1.3E-01 -5.8E-02 1.9E-04 2.3E-02
LAC,b_t,net -3.9E-02 2.7E-01 -2.8E-01 -7.0E-01 1.8E-01 0.0E+00 -2.4E-02 7.9E-01 2.5E-04 3.6E-01 7.4E-01 -3.3E-01 1.3E-03 1.3E-01
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     The model, without zonation, was modified to account for physiological changes 
during high-intensity exercise (0.195 kW), and the overall calculated glucose output and 
lactate uptake rates were compared to experimental values.  Figure 2.10 contains 
simulation results representing the resting state and quasi-steady state at 20 minutes of 
exercise.  During longer periods of exercise many other physiological changes occur 
which are not represented in the model.  It is known that blood flow through the liver 
decreases by about 50% (Wahren et al. 1971) during high intensity exercise as nutrients 
and oxygen are diverted to the heart and muscle tissue.  The results in Figure 2.10(ii) 
indicate that a 50% decrease in blood flow rate alone has negligible effect on glucose 
production and lactate uptake, and thus is not sufficient modification of the model to 
represent exercise.  According to Wahren et al. (1971), arterial lactate concentration 
increases 5-fold in humans during exercise, and assuming negligible lactate uptake in the 
gut, the value for C∞LAC,blood was increased  5-fold to 6.0 mM.  Figure 2.10(iii) shows that 
this increase in lactate concentration also has negligible effect on glucose output, 
although lactate uptake does increase by 30%.  Glycerol uptake rate was then increased 
3-fold and the glycogen degradation rate was increased to 2.2 umol/g/min, based on 
measurements in humans by (Wahren et al. 1971), and amino acid uptake (represented by 
alanine uptake) was increased 3-fold (Wasserman et al. 1991).  These fluxes are assumed 
to be constant over the 20-minute simulation period.  The incorporation of these changes 
into the model causes a doubling of hepatic glucose production (Figure 2.10iv), but the 
changes are still not enough to account for the 5-fold increase in observed glucose output 
during exercise (Wahren et al. 1971).  Lactate uptake actually becomes negative, which is 
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an unrealistic resulting indicating that there is a bottleneck in the gluconeogenic reactions 
that keeps the extra substrate from exiting the tissue as glucose.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10.  Net glucose production and lactate uptake by the liver, calculated at quasi-steady state at 20 
minutes following transition from resting to high-intensity exercise. i) Resting, overnight fasted state (i.e. 
initial condition); ii) liver blood flow rate decreased by ½; iii) same parameters as in (ii), plus: 5-fold 
increase in lactate concentration in the combined hepatic artery/portal vein input to the liver (C∞LAC,blood ) to 
6.0 mM; iv) same parameters as in (iii), plus: 3-fold increase in glycerol uptake, to 0.51 umol/g/min, 
increase in glycogen breakdown to 2.2 umol/g/min, and 3-fold increase in alanine uptake;  v) same changes 
as in (iv), plus: changes in Vmax of GK, G6Pase, PFK, PC, and PEPCK resulting from the decrease in 
insulin concentration and increase in glucagon during exercise; vi) measured value at high intensity 
exercise (Wahren, 1971).  
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It is known that exercise causes a 28% decrease in arterial insulin concentration (Wahren 
et al. 1971; Wahren et al.1974), which is already low because of the fasting state; more 
specifically, a 37% decrease occurs at high intensity exercise (Wharen  et al. 1971).  
Exercise also causes an increase in glucagon concentration (Wahren et al.1974;  Howlett 
et al. 1998).  Additionally, the increased adrenergic activity during exercise causes an 
increase in adrenaline, noradrenaline (Enevoldsen et al. 2004), and epinephrine (Howlett 
et al. 1998).  The insulin decrease and glucagon increase, together, cause the maximal 
enzyme activity of PK to decrease (Ito et al. 1998), and of G6Pase (Barzilai and Rossetti 
1993), PEPCK and F1,6 bisphosphatase to increase (Ito et al. 1998).  Glucagon induces 
the inhibition of PFK and PK via short-term allosteric action (Ito et al. 1998), while 
insulin acts conversely.  Glucagon also induces  PEPCK and F1,6 bisphosphatase activity 
over the long-term via gene expression, with inverse action by insulin.  Simulations by 
El-Refai and Bergman (1976) have also suggested that the maximal activity of GK 
increases 100% upon insulin stimulation. 
     The hormonal changes during exercise described in the previous paragraph were 
incorporated into the model by decreasing Vmax,GK and  Vmax,G6P?GAP by 50%,  increasing 
Vmax,G6Pase  2-fold, and increasing Vmax,PC and  Vmax,PEPCK  2½ -fold immediately upon 
switching to the high-exercise state.  As shown in Figure 2.10(v), these changes cause a 
4-fold increase in hepatic glucose production, which compares favorably with 
experimental values (Figure 2.10vi).  Calculated lactate uptake also increases, matching 
the experimental value.  
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2.4 Discussion 
     A model of reaction and transport in the liver that can describe the metabolite 
concentration and reaction flux dynamics separately within the tissue and blood domains 
was developed. The blood domain contains equations for convection, axial dispersion, 
and transport to the surrounding tissue; and the tissue domain consists of reactions 
representing key processes of glycolysis, gluconeogenesis, glycogenolysis, tricarboxylic 
acid cycle, oxidative phosphorylation, and fatty acid degradation and synthesis. The 
model includes the metabolic heterogeneity of the liver by incorporating spatial variation 
of key enzymatic maximal activities. 
     This model builds upon and integrates information from previous models of liver 
metabolism that have focused on either subsets of reactions, have included 
comprehensive set of metabolic pathways assuming well-mixed tissue, or have described 
the heterogenous nature of the liver in terms of a single species or reaction.   
Furthermore, the kinetic parameters and the data used for validation were based for the 
most part on human data, and to a lesser extent, on in vivo experiments with dogs or in 
vitro experiments with rats.   We believe that this emphasis on use of in vivo data to 
obtain kinetic parameters circumvents the common criticism of complex models that use 
kinetic parameters that have been measured in environments that are very different from 
the intact system.   Given that, there is still considerable uncertainty in parameter values, 
and assumptions made about  Km values then affected the values of Vmax’s needed to be 
consistent with the in vivo data.  Fortunately, our sensitivity analysis showed that the 
results were much less sensitive to the selection of Km’s than to Vmax’s, and the Vmax’s 
that were most influential belong to the regulatory reactions in glycolysis and 
 50
gluconeogenesis, for which there is substantial availability of in vitro experimental data.  
The kinetic parameters of the ATPase reaction also were among the most influential.  
Since this reaction represents many ATP-using reactions and the parameters have no 
direct physiological meaning, it may be better to consider this reaction flux as an 
adjustable parameter that has upper and lower limits derived from in vivo flux balance 
analysis.   
     Simulation results at the overnight fasted, resting state agree closely with experimental 
values of fluxes and concentrations, and overall glucose uptake and lactate output are 
confirmed with independent data.  The incorporation of zonation of glycolytic and 
gluconeogenic enzyme activities causes the expected increase in glycolysis and decrease 
in gluconeogenesis along the sinusoid length.   The results from simulations with and 
without zonation indicate that transport gradients are not sufficient to account for 
observed axial variations in gluconeogenesis and glycolysis, and that a distributed-in-
space arrangement of enzyme activities is necessary to achieve this result.  By 
incorporating the zonation of each enzyme separately in the model, we could ascertain 
the importance of each enzyme to the axial variation in glucose and lactate fluxes.  While 
several enzymes were more influential, e.g. PK, F1,6BPase (represented by RGAP?G6P),  
and PC,  no single enzyme alone with zonation caused a significant axial variation in 
fluxes.  The zonation of all reactions combined served to increase the axial variations of 
glucose and lactate fluxes.    
     The physical causes of zonation, whether resulting from hormonal or oxygen gradients 
or differential innervation, as have been hypothesized (Jungermann 1983) have not been 
addressed in this work.  While substantial evidence exists that enzymes of the fatty acid 
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metabolic pathways also exhibit distributed activities (Jungermann1988; Bederman et al. 
2004),  the analysis of enzymatic zonation presented here is strictly limited to the central 
carbohydrate pathways.    
     The model results are based on the assumption that the sinusoids are structured in 
parallel, and have uniform size and velocity.  In reality, there is significant variation in 
both length and blood velocity, with a fraction of the sinusoids switching between having 
flow and no flow at any one time (MacPhee et al. 1995).  Moreover, there is branching in 
some of the sinusoids, and some of the hepatic arterioles and portal venules may connect 
with the sinusoid at up to a third of the distance down the sinusoid.  The effects of this 
complicated flow pattern and structure on the simulated metabolic results presented here 
are non-obvious, and will be subject of a future study.  
     During high-intensity exercise, the hepatic glucose production in humans increases 
nearly 5-fold, with a smaller increase in lactate uptake.  The simulations shown here 
indicate that observed changes in arterial substrate concentrations and hepatic blood flow 
rate are not sufficient to shift the liver metabolism enough to account for this increased 
glucose output.  Changes in gluconeogenic and glycolytic enzyme activities, whether 
caused by exercise-induced changes in insulin, glucagon, adrenaline, noradrenaline, or 
epinephrine, or even by direct adrenergic stimulation of the liver are needed to achieve 
the overall metabolic changes observed.    The amounts of induction or inhibition of 
enzymatic activities that were incorporated into the model were based on extrapolation 
from information from the literature.  The simulations have shown that hormonal effects 
on all the reactions analyzed are crucial for the physiologically realistic response of the 
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liver to exercise, and changes in individual enzyme activities (data not shown) were not 
sufficient to achieve this. 
     The changes in hormone concentrations, and the subsequent changes in enzyme 
activities, do not occur immediately at the onset of exercise.  Since these changes in 
enzyme activities were incorporated in the model at the onset of exercise, the simulated 
transients are unrealistically fast (not shown), and thus only the steady state simulation 
results representing the physiological conditions expected at about 20 minutes of exercise 
were presented here.  Several modifications to the model are needed to generate more 
realistic dynamics.  Mass balance equations of hormones, especially insulin and 
glucagon, with upstream arterial concentrations that vary with time according to available 
experimental data, need to be added to the system.  The influence of hormones will be 
especially visible in the distributed model, since hormone degradation occurs within the 
liver and significant gradients in hormone concentrations occur along the sinusoid length 
(Jungermann 1987).  The allosteric effects on enzyme activity by the relevant local 
hormone concentrations (most likely the glucagon/insulin ratio), mediated by cAMP and 
phosphorylation or dephosphorylation reactions, need to be accounted for in the 
appropriate kinetic expressions.   These changes can be expected to result in a more 
gradual response to the onset of exercise as well as to changes in dietary conditions.    
     Simulations were performed based on the fasted state, which is the condition under 
which many of the human exercise studies are performed.  Since relatively simple kinetic 
expressions were used in the model, the response to exercise in the fed state will not 
closely match experimental data.  Incorporation of allosteric regulatory mechanisms into 
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the key reactions in glycolysis and gluconeogenesis will result in a more robust model 
that is valid under a variety of nutritional states.  
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CHAPTER III 
 
GLUCONEOGENESIS AND LIPID METABOLISM IN THE 
PERFUSED LIVER 
  
 
3.1 Introduction 
 
     The maintenance of glucose homeostasis is one of the main functions of the liver in all 
mammals.  It is accomplished through elegant regulation of the gluconeogenesis, 
glycolysis, glycogenolysis, fatty acid oxidation, and other pathways of intermediary 
metabolism.  Gluconeogenesis in the liver has been studied extensively over the past four 
decades, resulting in a better understanding of the factors that regulate the rates of 
glucose synthesis from various substrates, and the effects of substances such as fatty 
acids and ethanol on this process.   
     Despite this wealth of experimental data, the challenge remains to be able to predict 
how alterations in specific physiological stimuli will affect gluconeogenic flux in the 
liver.  This type of prediction will have potential benefit for designing therapeutic agents, 
both biochemical and genetic-based, for a variety of pathologies affecting the liver.  An 
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in silico liver that is physiologically accurate can be a cost-effective method for screening 
potential therapeutic agents.     
     Metabolic models of the liver can be divided into two broad categories: lumped 
models that consider the organ as well-mixed, and distributed-in-space models that 
consider the heterogeneous nature of the organ.  Garfinkel and colleagues (Achs et al. 
1971; Anderson et al. 1971) developed the first well-recognized model of liver 
metabolism using detailed in vitro-based kinetic expressions.  Their model of 
gluconeogenesis consisted of kinetic expressions for reactions taking place between 
phosphoenoylpyruvate (PEP) and glucose, with the net flux through enolase (interpreted 
from experimental data under a variety of substrates) taken as the input to the model.  
Since the reactions kinetics of pyruvate carboxylase (PC) and liver-type pyruvate kinase 
(PK-L) were not considered, the futile cycling that occurs through these reactions was 
neglected.  Moreover, the model lacked ATP and redox balances, the ketogenic reactions 
and some of the dehydrogenase reactions that are critical to controlling the relationships 
between lipid metabolism and gluconeogenesis.  Furthermore, this work was done prior 
to knowledge about important regulator effects, such as cAMP-mediated phosphorylation 
of key regulatory enzymes such as PK-L and  fructose-1,6-bisphosphatase (FBPase) and 
the allosteric effects of fructose-2,6-bisphosphate (F2,6BP).  Using a similar approach, 
Bergman and El Refai (1975) simulated glycogen (Glyc) synthesis and degradation and 
glucose output at fixed rates of gluconeogenesis.  A subset of glycolytic and 
glycogenolytic reactions around glucose-1-phospahte (G1P), glucose-6-phosphate (G6P), 
and fructose-6-phosphate (F6P) was the subject of a power law formalism model applied 
to an in vitro experimental system, using tissue extracts (Torres 1994).   Hepatic citric 
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acid cycle flux was modeled as an isolated subsystem, using parameter values that were 
time-dependent and adjusted for each substrate (Garfinkel 1971a, 1971b).    
     More recent modeling approaches have eschewed dynamic models for ones based on 
steady state, without the need for reaction kinetics. These include, the steady state flux 
balance analysis (FBA) approach with optimization of a presumed objective function 
(Nolan et al. 2006; Calik and Akbay 2000) (including energy constraints), FBA with 
Fischer discriminant analysis (Chan et al. 2003) and the FBA and thermodynamic 
constraint-based model (Beard and Qian 2004).   All of these approaches consist of a 
comprehensive system of reactions describing hepatic metabolism and they provide 
insight into the distribution of fluxes at various steady states.  The approach by Beard and 
Qian (2004) is particularly interesting, since it utilizes both FBA and thermodynamic 
constraints; even without kinetic parameters it can predict species concentrations at 
steady state and analyze the control structure.  However, these FBA-based methods 
require the use of experimental measurements of fluxes as inputs to the model, and since 
they lack reaction kinetics, have limited predictive value.  
     The liver, in reality, has a very heterogeneous organization, and several published 
works have considered its distributed-in-space nature by representing the liver as a 
system of parallel tubular reactors (Saville et al. 1992; Roberts and Rowland 1985) for 
prediction of the elimination rates of specific drugs.  In Chapter II of this dissertation,  a 
distributed-in-space model, which employs a simplified reaction system representing 
gluconeogenesis and associated pathways and takes into account heterogeneity in enzyme 
distribution, i.e. “zonation”, (Jungermann et al. 1982) has been used to investigate the 
role of zonation in the relative rates of glycolysis and gluconeogenesis along the sinusoid 
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in the fasted, resting state, as well as to study the effect of high-intensity exercise on 
glucose production.  While this distributed model uses available information concerning 
liver structure and enzyme distributions, there are few data available to validate the 
model’s predictions at this level of detail.  Most of the available data are derived from the 
entire organ, such as measurements of the concentrations of intermediates from tissue 
homogenates, metabolic flux determinations from arterial-venous differences (for in 
vivo), or input-perfusate concentrations (for perfused liver), with or without tracers. This 
makes it nearly impossible to thoroughly validate a distributed model.  Furthermore, most 
measurements of enzymatic kinetic parameters in liver also represent the average value 
for the tissue.   
     In this chapter, we have developed a lumped model of hepatic metabolism, with an 
emphasis on gluconeogenesis and fatty acid metabolism.  While the model was kept as 
simple as possible to achieve tractability, reactions are included as necessary to account 
for the relationship between gluconeogenesis and lipid metabolism.  Additional reactions, 
such as those occurring mainly in glycolysis, are included to increase the flexibility of the 
model for future applications.  Michaelis-Menten type kinetic expressions were used for 
many of the reactions.  However, the exclusive use of these expressions was inadequate 
for achieving the expected physiological results.  For key regulated reactions—FBPase, 
PFK, PC, PDC, and PK—rate expressions were used that incorporate allosteric effectors, 
specific substrate relationships (e.g. cooperative binding), and/or 
phosphorylation/dephosphorylation, and were developed using in vitro enzyme activity 
data and knowledge of the specific mechanisms.  
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The model is first used to represent the 24 hr fasted rat liver in vivo.  Since many 
of the most well-controlled, data-rich experiments available in the literature have been 
performed with the perfused liver, we then modified the model to account for the 
conditions of the ex vivo liver in a recirculated perfusion system.   With the same set of 
kinetic parameters, this model is used to predict the effect of fatty acid uptake on 
gluconeogenesis rates during separate lactate and pyruvate perfusions.  Our simulations 
are then compared with experimental data available from the literature.   
 
3.2 Model Development 
3.2.1 Metabolic Pathways 
     The metabolic pathways considered in the model development are glycolysis, 
gluconeogenesis, the tricarboxylic acid cycle (TCA), fatty acid oxidation, fatty acid 
synthesis, ketogenesis, oxidative phosphorylation, and glycogen degradation (Fig. 3.1).  
Each pathway is represented by a few key reactions, mainly those essential for defining 
the relationships between lipid metabolism and gluconeogenesis.   
     The rate expressions are given in Table 3.1.  The rate mechanism for transport 
between the blood and tissue domains is described by facilitated diffusion.  The kinetic 
expressions for some of the relatively irreversible reactions are expressed by simple 
Michaelis-Menten kinetics, with modulation by ADP/ATP (PS) and NADH/NAD+ (RS), 
as relevant.  Reversible, near-equilibrium reactions (e.g. RGAP?PEP, RLDH) are represented 
by a simplified form of a reversible, ping-pong mechanism, with the Haldane equation 
used to relate kinetic parameter values at near-equilibrium and to ensure consistency with 
thermodynamic constraints.   
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Table 3.1. Reaction rate stoichiometry, kinetic expressions, and parameter values used in the model. Definitions: PS=CADP/CATP; RSm=CNADH(m)/CNAD(m)+;  
(m):mitochondrial; (c): cytosolic;  FBA: flux balance analysis, used to calculate some of the reaction rate fluxes from  flux measurements of species entering and 
exiting the tissue at steady state.  Steady state flux measurements are given in Table 3.2.  Concentrations that are considered constant have been assigned the 
following values:   CAMP=0.125 μmol gww-1 hep (Garfinkel et al. 1979) ; CcAMP=0.0094 μmol gww-1 hep (Pilkis et al. 1975);     CPi=5.74 μmol gww-1 hep (Chan et 
al. 2003; Christian and Christain 1983); CF2,6BP=0.00013 μmol gww-1 hep (Diem and Lentner 1970; Garfinkel et al. 1979); CNH4+=0.7 μmol gww-1 hep (Achs et 
al. 1971; Calik and Akbay 2000); CCoA=0.25 μmol gww-1 hep (Bracht et al. 1993);    (CATP+CADP+CAMP)total= 5.08 μmol gww-1 hep (Bergmeyer 1974; Hems et al. 
1966);   (CNADH + CNAD+)total= 1.50 μmol gww-1 hep (Bergmeyer 1994; Stubs et al. 1972;Williamson et al. 1969a; Williamson et al. 1970).    
 
Steady state concentrations, used to estimate parameters values, are: aCNAD+ (c),SS from reference Williamson et al. 1969a, assuming 80-90% unbound; bCNADH (c),SS 
calculated from CNAD+ (c),SS  and (CNADH + CNAD+)total.  Keq,RS = 112, calculated from reference Achs et al. 1971.    
 
*Reactions corrected from manuscript published from this chapter.  
 
To reduce table space, superscripts in tables refer to the following references: 
1    Agius and Alberti 1985 
2    Bantenburg and Olson 1976 
3    Bergmeyer 1994 
4    Chien et al.  2000 
5    Christian and Christian 1983 
6    Diem and Lentner 1970 
7    Ekdahl and Ekman 1983 
8    Engela dn Dalziel 1967 
9    Gross et al. 1967 
10  Hems et al. 1966 
11  Krebs 1967 
12  Magnusson et al. 1991 
13  McClure et al. 1971 
14  Pusca and Belovich 2012 
15  Reich and Selkov 1981 
16  Scrutton and White 1972 
17  Stubs et al. 1972 
18  Van Schaftingen et al. 1980 
19  Williamson et al. 1970 
 
20  Exton and Park 1967 
21  Huang 1997 
22  Jin et al. 2004 
23  Neese et al. 1995 
24  Petersen et al. 1996 
25  Rossetti et al. 1993 
26  Salem et al. 2002 
27  Torres 1994 
28  Tucker and Dawson 1979 
29  Williamson et al 1969b 
30 Bode et al. 1973 
31 Chp. II of this thesis 
32 Pison et al. 1998 
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Rate Kinetic Expression Parameter Values Method of determining 
parameters 
 
 Set equal to steady state 
CADP/CATP 10 
   Parameters common to several 
reactions: 
PSi=0.44 
 
RSi=0.2 
 
Set equal to steady state 
CNADH(m)/CNAD+(m) 19 
A. Reaction Rates 
Calculated from RGK 
flux (from FBA, assuming 30% 
cycling) and steady state GLC 
concentration3 
RGK 
 
GLC + ATP → G6P+ ADP 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
CK
CV
itGLCGKm
tGLCGK
/1/1
/1
_,
_max,  
Vmax,GK = 
2.19 µmol gww hep-1min-1 
 
 
 
KM,GK =6.25 µmol/gww hep 
Set equal to steady state GLC 
concentration3  
Calculated from RG6Pase flux 
from FBA and steady state 
G6P concentration3 
RG6Pase 
 
G6P→GLC 
PGPaseGm
PGPaseG
CK
CV
66,
66max,
+  
Vmax,G6Pase= 
3.65 µmol gww hep-1min-1 
 
 
Km,G6Pase=0.102 µmol/gww hep 
Set equal to steady state G6P 
concentration3 
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Calculated from RGI flux 
from FBA and steady state 
F6P and G6P 
concentrations3 
Set equal to steady state 
F6P concentration3 
Set equal to steady state 
G6P concentration3 
 
RGI 
G6P ↔ F6P 
GIPGm
PG
GIPFm
PF
GIeq
PG
PF
GIPFm
GIPG
K
C
K
C
K
C
C
K
V
,6,
6
,6,
6
,
6
6
,6,
,6max,
1 ++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
 
Vmax,G6P,GI = 
32.8 µmol gww hep-1min-1 
 
 
Km,F6P,GI =0.046 µmol/gww hep 
 
 
Km,G6P,GI =0.10 µmol/gww hep 
 
Keq,GI=2.5 Calculated from  in vivo 
concentrations3 
 
 
RFBPase 
 
F1,6BP → F6P 
( )
( ) ( ) ( )( )
( ) ( )
FBPaseiAMP
AMP
FBPaseicAMP
cAMP
FBPaseBPiF
BPF
FBPaseBPF
BPF
n
n
FBP
n
FBP
n
nn
n
FBPase
K
C
K
C
K
C
K
C
c
L
V
FBP
fbp
fbp
fbp
fbpfbp
fgbp
,,
,6,2
6,2
,6,1
6,1
max,
;
;;
1
1
1
1
11
1
==
==
+++
+
++++
+
δγ
βμ
μγ
β
δγβγσβ
μμ
 
Vmax,FBPase=20 µmol gww hep-1min-1 
KF1,6BP,FBPase= 
4.84E-04 µmol/gww hep* 
KicAMP,FBPase= 
9.23E-03 µmol/gww hep* 
KiF2,6BP,FBPase = 
1.56E-02µmol/gww hep 
KiAMP,FBPase=0.106 µmol/gww hep 
nFBP=5.52 
LFBP=2.76E+06 
CFBP=0.56 
Calculated from in vitro 
kinetic data12,7 
*modified 10- 20% from 
the original source. 
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RPFK 
 
F6P + ATP  → F1,6BP + 
ADP ( )
                                             
                                       
         1
,
,
                                         
max,
2,
,
2
6,21,6,2
6,2,6,2
1
1
1
2
2
2
2
1
1,6
2
6
2
6
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+
+=
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+
+⋅=
++⎟⎟
⎟
⎠
⎞
⎜⎜
⎜
⎝
⎛
++=
⋅+
⋅=
AMPPFKiAMP
AMPPFKiAMP
BPFPFKBPiF
BPFPFKBPiF
nnATPn
ATP
APP
PFKPFPFK
PFATPPFK
PFATP
CQK
CK
T
CQK
CK
T
TT
PFKiATPK
CTPFKATPKCKK
CCK
CC
PFKV
V
σ
α
 
Vmax,PFK=3.75 µmol gww hep-1min-1 
KATP,PFK=2.91E-02 µmol/gww hep  
KiATP,PFK=0.058 µmol/gww hep  
KiAMP,PFK=1.16 µmol/gww hep  
KAPPF6P,PFK=4.0E-04 µmol/gww hep 
KiF2,6BP,PFK=1.7E-02 µmol/gww hep 
α =2.0              σ=3.5 
n1=3.0             n2=3.0 
Q1=100           Q2=50 
 
Calculated from in vitro 
kinetic data7,18 
. 
 
 
 
RPK 
 
PEP + ADP → PYR + ATP 
 
( )
( ) ( )
( ) ( ) ( )
PKFBP
FBP
PKiALA
ALA
PKATP
ATP
PKPEP
PEP
n
nn
PKALA
n
PKATP
n
p
n
PK
K
C
K
C
K
C
K
C
L
V
PK
PKPK
PKpk
PK
,,
,,
,
,
1
max,
;
;;
1
11
11
1
==
==
+++++
++
++ −
φβ
γπ
γπφβκ
γκβ
γππ
 
Vmax,PK=62.5µmol gww hep-1min-1 
KPEP,PK=3.2E-02 µmol/gww hep  
KATP,PK=0.435 µmol/gww hep 
KiALA,PK=1.16E-01µmol/gww hep  
KFBP,PK=5.80E-04 µmol/gww hep* 
Lp=1.60E+04 
nPK=3.10 
κΑΤP,PK=2.0  
κALA,PK=0.2   
Calculated from in vitro 
kinetic data14; modified 
from the original source. 
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in vitro6 
Set equal to product of  
steady state LAC 3,11,19 and 
NAD+(c) a concentrations 
Calculated from in vivo 
LDH flux5 and steady state 
LAC3,11,19, PYR3,11,17,  
NAD+(c)a, and NADH(c)b 
concentrations 
 
RLDH 
 
LAC + NAD+ ↔PYR + 
NADH 
( )
( )
( ) ( )
LDHPYRm
cNADHPYR
LDHLACm
cNADLAC
LDHeq
cNADHPYR
cNADLAC
LDHLACm
LDH
K
CC
K
CC
K
CC
CC
K
V
,,,,
,,,
max,
1 ++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
+
+
 
Vmax,LDH=195 µmol gww hep-1min-1 
 
Km,LAC,LDH=1.43 µmol/gww hep  
 
 
Km,PYR,LDH=4.77E-05 µmol/gww 
hep  
 
 
 
Keq,LDH=1.1E-04 in vitro
19 
in vitro6 
Set equal to product of  
steady state ALA3  and 
NAD+(c)a concentrations 
Calculated from in vivo 
flux5 and steady state 
ALA3, NAD+(c)a  , 
PYR3,11,17, and NADH(c)b 
concentrations 
 
RALA→ PYR 
 
ALA + NAD+ → PYR+ 
NADH 
( )
( )
( ) ( )
ALAPYRm
cNADHPYR
PYRALAm
cNADALA
PYRALAeq
cNADHPYR
cNADALA
PYRALAm
PYRALA
K
CC
K
CC
K
CC
CC
K
V
,,,,
,,,,
,max,
1 ++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
+
+
 
Vmax,ALA,PYR= 
300 µmol gww hep-1min-1 
KmALA,PYR=0.71 µmol/gww hep  
 
 
Km,PYR,ALA=2.4E-07 µmol/ 
gww hep  
 
 
Keq,ALA,PYR=2.5E-03 In vitro8 
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RPYR?PEP 
 
PYR + ATP + GTP  → 
 PEP + ADP + GDP + Pi + 
CO2 
 
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
+
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
=
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
PCPC
PC
PC
n
ATP
ADP
PCATPADPi
ATP
PCAcCoAa
n
AcCoA
PCPYRADPi
ADPn
PYR
PCPYR
n
ATP
PCATP
PCPYRADPi
ADP
PC
C
C
K
K
K
C
K
CC
K
C
K
K
C
V
13
2
1
,,,
,,
,,,
,,
,,,
max,
1
1
1
1
1
1
ϖ
ϖ
 
Vmax,PC=12.4 µmol gww hep-1min-1 
KATP,PC=0.034 (µmol/gww hep)^1.03  
KPYR,PC=7.1 (µmol/gww hep)^0.8  
KiADP,PYR,PC=1.74 µmol/gww hep  
KiADP,ATP,PC=0.521 µmol/gww hep  
Ka,AcCoA,PC=2.28E-05 
(µmol/gwwhep)^1.65 
n1,PC =1.03 
n2,PC =0.80 
n3,PC  =1.65 
 
Calculated from in vitro 
kinetic data for pyruvate 
carboxylase13,16 
In vitro6 
Set equal to  product of  
PEP3, NADH(c)b, and 
ATP3,10 concentrations,; 
modified during parameter 
estimation 
Calculated from RPEP ↔ GAP 
flux from FBA and steady 
state PEP3, ATP3,10, 
NAD+(c)a,    NADH(c)b, 
GAP17,19, and ADP3 
 
RPEP ↔ GAP 
 
PEP + ATP + NADH↔ 
GAP + ADP + NAD+ 
( )
( )
( ) ( )
PEPGAPm
ADPcNADPiGAP
GAPPEPm
ATPcNADHPEP
GAPPEPeq
ADPcNADPiGAP
ATPcNADHPEP
GAPPEPm
GAPPEP
K
CCCC
K
CCC
K
CCCC
CCC
K
V
,,,,
,,,,
,max,
1
+
+
++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
 
Vmax,PEP,GAP = 
94.0 µmol gwwhep-1min-1 
 
Km,PEP,GAP =4.3E-05 µmol/gww hep  
 
 
Km,GAP,PEP=9.13E-03 µmol/ 
gww hep  
 
Keq,PEP,GAP=4166 
In vitro15  
Calculated from 
RGAP↔F1,6BP 
flux from FBA and steady 
state GAP concentration17,19 
*RGAP→F1,6BP 
 
2GAP→F1,6BP GAPBPFGAPm
GAPBPFGAP
CK
CV
+6,1,,
6,1,max,  
Vmax,GAP,F1,6BP = 
4.97 µmol gwwhep-1min-1 
 
Km,GAP,F1,6BP = 
0.0194 µmol/gww hep  
 
Set equal to steady state 
GAP concentration17,19 
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RPDC 
 
PYR + NAD+ → AcCoA + 
NADH 
( ) ( )PYRPDCmPDC
CoA
AcCoA
PDC
PDC
PYRPDC
CKRS
C
C
PS
CV
+⎟⎟⎠
⎞
⎜⎜⎝
⎛ ++⎟⎠
⎞⎜⎝
⎛ + 2
max,
11 δβα
 
Vmax,PDC = 
1.88 µmol gww hep-1min-1 
KPDC=0.20 µmol/gww hep  
α,PDC = 0.9 
β,PDC = 25;  δ,PDC = 0.50 
Calculated from in vitro 
kinetic data1,2  
Calculated from in vivo 
flux5, steady state FFA4, 
PS10, and 
RSm19concentrations 
RFFA → AcCoA 
 
FFA + 2ATP + 7NAD+ + 
7FAD→ 
8AcCoA + 7NADH + 
7FADH + 
2ADP 
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
RSRS
RS
CK
CV
imi
m
FFAAcCoAFFAm
FFAAcCoAFFA
/1/1
/1
/1/1
/1
,,,,
,max,  
Vmax,FFA,AcCoA= 
6.76 µmol gww hep-1min-1 
 
Km,FFA,AcCoA =0.36 µmol/gww hep  
 Set equal to steady state  
FFA concentration4 
Calculated from RTG→FFA 
flux from FBA and steady 
state TG,t9 concentration 
RTG→FFA 
 
 tTGFFATGm
tTGFFATG
CK
CV
,,,
,,max,
+  
FFATGV ,max,  = 
3.67 µmol gww hep-1min-1 
FFATGmK ,,  = 
0.0071 µmol/gww hep  
Set equal to steady state   
TG,t9 concentration 
Calculated from in vivo 
flux5 and steady state PS10 
and assumed GLR,t 
concentrations.  
RGLR_t→GR3P 
 
GLR+ATP→GR3P+ADP ⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
CK
CV
itGLRPGRGLRm
tGLRPGRGLR
/1/1
/1
,3,,
,3,max,
 
PGRGLRV 3,max, = 
0.79 µmol gww hep-1min-1 
 
PGRGLRmK 3,, = 
 0.125 µmol/gww hep  
Set equal to the assumed 
steady state GLR,t 
concentration 
in vitro6  
Set equal to product of  
steady state GR3P3  and 
NAD+(c)a concentrations 
 
RGR3P↔GAP 
 
GR3P+NAD+↔GAP+NADH 
( )
( )
( ) ( )
PGRGAPm
cNADHGAP
GAPPGRm
cNADPGR
GAPPGReq
cNADHGAP
cNADPGR
GAPPGRm
GAPPGR
K
CC
K
CC
K
CC
CC
K
V
3,,,3,
3
,3,
3
,3,
,3max,
1 ++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
+
++
 
Vmax,GR3P,GAP= 
115 µmol gww hep-1min-1 
Km,GR3P,GAP=0.47 µmol/gww hep  
 
 
Km,GAP,GR3P= 
7.06E-07 µmol/gww hep  
 
Keq,GR3P,GAP=1.3E-04 
 
Calculated from RGR3P↔GAP 
flux from FBA and steady 
state GR3P3, NAD+(c)a,    
NADH(c)b, and GAP17.19 
concentrations in vitro15 
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Calculated from RFA_syn 
flux from FBA and steady state 
AcCoA concentration3 
RFA_syn 
 
8AcCoA + 7ATP →  
FFAc16 + 7ADP 
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
CK
CV
iAcCoAsynFAm
AcCoAsynFA
/1/1
/1
_,
_max,
 
synFAV _max, = 
2.7 µmol gww hep-1min-1 
 
synFAmK _, =0.13 µmol/gww hep  
Set equal to the steady state 
AcCoA3 concentration. 
Calculated from RTG_f 
flux from FBA and steady state 
FFA concentration4 
RTG_f 
 
3FFAc16 + 2ATP + GR3P →  
TG + 2ADP 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
++−
−
PSPS
PS
CCK
CCV
iFFAPGRfTGm
FFAPGRfTG
/1/1
/1
3,
3max,  fTGV −max, =  
0.43 µmol gww hep-1min-1 
 
fTGmK −, =0.11 µmol/gww hep  
Set equal to the product of 
steady state FFA4 and GR3P3 
concentrations. 
Calculated from in vivo flux22 
and steady state AcCoA3 
concentration. 
RTCA 
8AcCoA+ADP +3NAD+ + 
FAD→ 
  16CO2 + ATP + 3NADH 
+FADH 
⎜⎜⎝
⎛
+−++ PSPS
PS
RSRS
RSCV
imi
m
AcCoATCAmzx /1/1
/1)1(
/1/1
/1
,,
, εε
 
 
Vmax,TCA= 
22.33 µmol gww hep-1min-1 
 
ε =0.75 Derived previously.26 
Calculated from RAcCoA→AcAc 
flux from FBA and steady state 
AcCoA concentration3 
RAcCoA→AcAc 
2AcCoA→AcAc+2C
oA AcCoAAcAcAcCoAm
AcCoAAcAcAcCoA
CK
CV
+_,
_max,  
AcAcAcCoAV _max, = 
9.28 µmol gww hep-1min-1 
AcAcAcCoAmK _, = 
0.124 µmol/gwwhep  
Set equal to steady state AcCoA 
concentration3 
In vitro28 
 
Set equal to product of  steady 
state concentrations of 
AcAc3,11,19 and NADHm 
(assumed = 0.01  μmol gww-1 
hep)27,29 
Calculated from RBHBdh 
flux from FBA and steady state 
substrate concentrations 
 
 
 
RBHBdh 
 
AcAc + NADH↔BHB + 
NAD 
 
      
( )
( )
( ) ( )
AcAcBHBm
mNADBHB
BHBAcAcm
mNADHAcAc
BHBdheq
mNADBHB
mNADHAcAc
BHBAcAcm
BHBAcAc
K
CC
K
CC
K
CC
CC
K
V
_,_,
,_,
_max,
1
+
+
++
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
 
BHBAcAcV _max,  = 
60 µmol gww hep-1min-1 
BHBAcAcmK _, = 
0.0071µmol/gww hep  
 
 
AcAcBHBmK _, = 
0.0059µmol/gww hep  
BHBdheq
K
,
=20 in vitro19 
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Calculated from ROxPhos flux 
from FBA and steady state  
O220 concentration 
ROxPhos 
 
O2 + 5ADP + 2NADH → 
2H20 + 5ATP +2NAD+ 
 
⎜⎜⎝
⎛
+⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ mi
m
iOOxPhosm
OOxPhos
RSRS
RS
PSPS
PS
CK
CV
2
2
,
max,
 
Vmax,OxPhos= 
37.8 µmol gww hep-1min-1 
 
Km,OxPhos=7.3 µmol/gww hep  
 
Set equal to the steady state  
O220 concentration 
Calculated from Rurea flux from 
FBA and steady state NH4+  
3concentration 
Rurea 
2NH4+HCO3+3ATP→ 
urea+2ADP+2Pi+AMP+PPi 
 
4,
4max,
NHuream
NHurea
CK
CV
+ ⎟⎟⎠
⎞
⎜⎜⎝
⎛
+ PSPS
PS
i /1/1
/1  
Vmax,urea=2.57 µmol gww hep-1min-
1 
 
 
Km,urea=0.70 µmol/gww hep  
Set equal to steady state NH4+ 3 
concentration 
RGlyc?G6P 
(Glyc)n ? (Glyc)n-1 + 
G6P              
RGlyc?G6P=  0.0358 µmol gww hep
-1min-1    Set equal to in vivo flux24 
B. Transport Rates 
Calculated from in vivo 
flux22,23,25 and steady state 
GLC,b5 concentration 
JGLC,b-t,net 
 )(
)(
,,,,
,,,max,
tGlcbGlctbGlcm
tGlcbGlctbGlc
CCK
CCV
++
−
−
−  
Vmax,Glc,b_t= 
17.8 µmol gww hep-1min-1 
 
Km,Glc,b_t=5.07 µmol/gww hep Set equal to steady state 
GLC,b5 concentration 
Calculated from in vivo flux 
5and  steady state 
LAC,b5concentration 
JLAC,b-t,net 
)(
)(
,,,,
,,,max,
tLacbLactbLacm
tLacbLactbLac
CCK
CCV
++
−
−
−  
Vmax,LAC,b_t= 
22.5 µmol gww hep-1min-1 
 
Km, LAC,b_t=1.2 µmol/gww hep Set equal to steady state 
LAC,b5 concentration 
Calculated from in vivo flux 
5and steady state  
FFA,b5concentration 
JFFA,b-t,net 
)(
)(
,,,,
,,,max,
tFFAbFFAtbFFAm
tFFAbFFAtbFFA
CCK
CCV
++
−
−
−  
Vmax,FFA,b_t= 
4.7 µmol gww hep-1min-1 
 
Km,FFA,b_t=0.67µmol/gww hep Set equal to steady state  
FFA,b5concentration 
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Calculated from in vivo flux 5 
and steady state GLR,b5 
concentration 
JGLR,b-t,net 
)(
)(
,,,,
,,,max,
tGLRbGLRtbGLRm
tGLRbGLRtbGLR
CCK
CCV
++
−
−
−  
Vmax,GLR,b_t= 
2.53 µmol gww hep-1min-1 
 
Km,GLR,b_t=0.16 µmol/gww hep Set equal to steady state 
GLR,b5 concentration 
Calculated from flux from FBA 
and steady state TG,b 
concentration 
JTG,b-t,net 
)(
)(
,,,,
,,,max,
tTGbTGtbTGm
tTGbTGtbTG
CCK
CCV
++
−
−
−  
Vmax,TG,b_t= 
0.044 µmol gww hep-1min-1 
 
Km,TG,b_t=0.4 µmol/gww hep  Set equal to steady state TG,b 
concentration (assumed) 
Calculated from in vivo flux 5 
and steady state ALA,b5 
concentration 
JALA,b-t,net 
)(
)(
,,,,
,,,max,
tALAbALAtbALAm
tALAbALAtbALA
CCK
CCV
++
−
−
−  
Vmax,ALA,b_t= 
12 µmol gww hep-1min-1 
 
Km,ALA,b_t=0.56 µmol/gww hep Set equal to steady state 
ALA,b5 concentration 
Calculated from in vivo flux5  
and steady state BHB,b5,21  
concentration 
JBHB,b-t,net 
)(
)(
,,,,
,,,max,
tBHBbBHBtbBHBm
tBHBbBHBtbBHB
CCK
CCV
++
−
−
−  
Vmax,BHB,b_t= 
2.64 µmol gww hep-1min-1 
 
Km,BHB,b_t=0.85 µmol/gww hep  Set equal to steady state 
BHB,b5,21  concentration 
Calculated from in vivo flux 5 
and steady state PYR,b5 
concentration 
Jpyr,b-t,net 
)(
)(
,,,,
,,,max,
tPYRbPYRtbPYRm
tPYRbPYRtbPYR
CCK
CCV
++
−
−
−  
Vmax,PYR,b_t= 
8 µmol gww hep-1min-1 
 
Km,PYR,b_t=0.062 µmol/gww hep  Set equal to steady state 
PYR,b5 concentration 
Calculated from in vivo flux 5  
and steady state AcAc,b5  
concentration 
JAcAc,b-t,net 
)(
)(
,,,,
,,,max,
tAcAcbAcActbAcAcm
tAcAcbAcActbAcAc
CCK
CCV
++
−
−
−  
Vmax,AcAc,b_t= 
34.8125 µmol gww hep-1min-1 
 
Km,AcAc,b_t=0.7 µmol/gww hep  Set equal to steady state 
AcAc,b5  concentration 
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     The kinetic parameters were generally obtained either by from in vitro kinetic studies 
with purified enzymes, by calculation from in vivo data and the assumed rate expression, 
or a combination of these methods.  For reversible reactions, the equilibrium constants 
and Vmax’s were obtained from the literature; the forward Km was set equal to the 
product of the substrate concentrations and the reverse Km was calculated based on the in 
vivo flux and concentrations. Michaelis-Menten kinetics were often used as 
simplifications for a series of reactions and do not necessarily represent a specific 
enzyme.  Most often, parameters were calculated from in vivo data rather than from in 
vitro kinetic studies of purified enzymes.   The Km was set equal to the approximate 
steady state concentration of the corresponding substrate, while the Vmax was calculated 
by setting the reaction expression equal to the corresponding in vivo flux expected during 
the 24-hour fasted state (given in Table 3.2).  The specific approach used for each 
reaction is indicated in Table 3.1.  
     In some cases, Michaelis-Menten and reversible kinetics, as described above, were 
found to be inadequate for achieving the expected physiological responses during 
gluconeogenesis and lipid metabolism.  Thus, the rate expressions were modified to take 
into account allosteric effectors, specific substrate relationships (e.g. cooperative 
binding), and phosphorylation/dephosphorylation.  Detailed kinetic expressions were 
developed for five regulated reactions—FBPase, PFK, PC, PDC, and PK—using in vitro 
enzyme activity data and knowledge of the specific mechanisms gleaned from the 
literature (Table 3.1).  The rate expression of FBPase includes the effect of 
phosphorylation and dephosphorylation by means of cAMP-dependent protein kinase, 
along with AMP as an uncompetitive inhibitor and F2,6BP as a competitive inhibitor.        
  70
Table 3.2.  Steady state results, at the overnight fasted state, experimental and calculated using Eqns. 1 and 
4, with upstream blood concentrations given here: C*Glc= 4.6 mM3;    C*LAC=1.7 mM3 ;      C*PYR=0.12mM3;    
C*FFA=1.5 mM3,30;          C*AcAc=0.43 mM3,30;       C*BHB= 1.2 mM30;      Physical parameters used in Eqn. 3.2 
are: ;  Fblood =6.57 ml/min ; Vtissue=5.25 cm3,  12 ; Vblood =1.03 cm3, 31 .  Reaction rates (Ri) and transport rates 
(Ji,b-t) are given in Table 3.1 (+: production rate, -: uptake rate).  Superscripts refer to citations  given in 
Table 3.1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolite Concentrations μmol gww hep-1 Fluxes μmol gww hep-1min-1 
 Calculated Experimental  Calculated Experimental 
Glc,tissue 6.3 4.5-63  JGLC,b-t,net 1.11 1.2-1.922,23,25 
Glc,blood 5.55 5.07-5.485 JLAC,b-t,net -1.38 -1.545 
F6P 0.039 0.0463  JBHB,b-t,net 1.09 0.935 
F1,6BP 0.0023 0.0163 JALA,b-t,net -0.59 -0.645 
G6P 0.087 0.1023  JPYR,b-t,net -0.12 -0.145 
glycogen 109 109-1753 JFFA,b-t,net -0.87 -0.85 
GAP 0.015 0.02117,19 JGLR,b-t,net -0.96 -0.145 
GR3P 0.25 0.313 GK 0.57  
PEP 0.0061 0.053 G6Pase 1.68  
PYR,blood 0.024 0.0625 GI 1.07  
PYR,tissue 0.023 0.059 3,11,17 GAP?F1,6BP 2.15  
LAC,blood 0.59 0.85-1.25 FBPase 1.08  
LAC,tissue 0.46 0.35-0.953,11,19 PFK 0.007  
AcAc,blood 1.47 0.68-0.995,21 PEP?GAP 2.08  
AcAc,tissue 1.61 0.5-0.783,11,19 PK 0.0003  5.56 22 
BHB,blood 2.07 0.85-1.75,21 PYR?PEP 2.09 3-3.632, 7.922 
BHB,tissue 5.6 2.233,11,19 LDH 1.26  
ALA,blood 0.23 0.565 GLR?GR3P 0.099  
ALA,tissue 0.18 0.4753 GR3P?GAP 0.06  
AcCoA 0.13 0.133 FAT_syn 0.71  
ATP 3.46 3.433,10 FFA?AcCoA 0.86  
ATP+ADP+AMP 5.07 3.68-5.23,10 TG_f 0.11  
NADH(m)/NAD(m)+ 0.25 0.1819 AcCoa?AcAc 4.83  
NADH(c)/NAD(c)+ 0.0021 0 .001717,19 OxPhos 8.20  
   TCA 1.37 1.7522 
   JTG,b-t,net 0.03  
   PDC 0.0023  
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The PFK expression is based on the bi-bi mechanism, where ATP acts as substrate 
inhibitor while AMP and F2,6BP are activators.  The kinetics of the lumped reaction 
RPYR?PEP is represented by the kinetics of the PC reaction, with activation by acetyl CoA 
and inhibition by ADP, where ADP plays the role of uncompetitive inhibition with 
respect to pyruvate and competitive inhibition with respect to ATP.  The PK expression 
reflects phosphorylation as an allosteric effect mediated by  cAMP-dependent protein 
kinase,  inhibition by both ATP and alanine and activation by F1,6BP.  One of the PK 
model parameters (KF1,6BP,PK) was modified significantly from the original kinetic 
model23 to provide the expected fluxes at physiological concentrations of allosteric 
regulators not considered in the previous in vitro studies.  The rate kinetics of PDC were 
developed to account for inhibition by acetyl CoA, ATP/ADP ratio, and NADH/NAD+ 
ratio and the effect of inhibition by phosphorylation of the enzyme by pyruvate 
dehydrogenase kinase that is mediated through ATP.  Kinetic parameters were obtained 
by fitting the reaction expressions to in vitro kinetic data using least squares regression.    
     Although cytosolic-mitochondrial compartmentation is not considered specifically, the 
mitochondrial redox state is significantly different from the cytoplasmic redox state, and 
this difference between the two compartmental concentrations was found to significantly 
affect reaction rates involving NADH coupled enzymes.  A pseudo-mitochondrial 
compartment was established only for NADH/NAD+, with the assumption that the 
mitochondrial redox ratio, RSm (defined as CNADH(m)/CNAD(m)+), is in equilibrium with the 
cytosolic ratio RS (CNADH(c)/CNAD(c)+); this assumption is expressed as  RSm =  Keq,RS · RS.  
The equilibrium constant Keq,RS is calculated from the ratios of free cytosolic and 
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mitochondrial CNADH/CNAD+  at the fasted steady state,  obtained from measurements of 
CLAC/CPYR and CBHB/CAcAc, respectively, at equilibrium.   
 
Figure 3.1.  Reaction network considered in tissue model.  Dashed lines indicate a series of reactions that 
have been lumped together.  Detailed stoichiometry for each reaction shown here is given in Table 3.1.  
The ATPase reaction represents the total of all ATP-utilizing reactions that are not considered explicitly in 
the model.  GK: glucokinase; G6Pase: glucose-6-phosphatase; Glyphos: glycogen phosphorylase; OxPhos: 
oxidative phosphorylation, PK: pyruvate kinase; PC: pyruvate carboxylase; PDC: pyruvate dehydrogenase 
complex; LDH: lactate dehydrogenase; BHBdh: :β -hydroxybutyrate dehydrogenase; GAP: 
glyceraldehyde-3-phosphate; GR3P: glycerol-3-phosphate; PEP: phosphoenyl pyruvate; AcAc: 
acetoacetate; BHB:β-hydroxybutyrate; AcCoA: acetyl CoA; ALA: alanine. 
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3.2.2 Model of the In Vivo Liver 
     The liver is represented by two well-mixed domains representing the tissue and blood 
compartments, with mass balances for each metabolite i given by:  
                                                                                                          
 
 
 
 
where Ci*  is the concentration of each species in the blood upstream of the liver 
(calculated from a weighted average of portal vein and hepatic artery concentrations; 
Table 3.2); Ci,tissue and Ci,blood  are concentrations of species i in the tissue and blood 
domains, respectively;  J i,b-t  is the transport rate between the blood and tissue domains, 
in units of μmol g tissue-1 min-1;  Ri,j  is the reaction rate of each reaction j with species i 
as substrate or product; Fblood  is the blood flow rate through the liver.  The ratio of tissue 
volume to blood volume (Vtissue/Vblood ) is used for conversion of units of J i,b-t  from tissue 
volume units to blood volume units.     
     The mass balance equation of the tissue (Eq. 3.1) is written for each intermediate 
within the cell shown in the metabolic pathway in Fig. 3.1 (Glc, LAC, ALA, AcAc, BHB, 
Glyc, glycerol (GLR), TG, FA, PYR, ATP, NADH, G6P, F6P, F1,6BP, GAP, PEP, 
AcCoA, GR3P), using the stoichiometry given in Table 3.1.  The mass balance for GTP 
is included within the balance for ATP by assuming a fast equilibration of neucleoside 
diphosphokinase.  Eq. 3.2 is written for every intermediate that occurs in the blood, as 
shown in Figure 3.1 (i.e. Glc, LAC, ALA, AcAc, BHB, GLR, TG, FA, and PYR).  Eqns. 
)1.3(,,
, ∑+= −
j
jitbi
tissuei RJ
dt
dC
)2.3()( ,,
*, ⎟⎟⎠
⎞
⎜⎜⎝
⎛−= −−
blood
tissue
tbi
blood
blood
bloodii
bloodi
V
VJ
V
FCC
dt
dC
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3.1 and 3.2 were solved simultaneously at steady state.  Since enzyme kinetic parameters 
were in general obtained from liver extracted from fasted rats, and the upstream blood 
concentrations (Ci*) were obtained from blood samples from fasted rats, this simulation 
represents the conditions in vivo for a liver from a 24-hour fasted rat.    
 
3.2.3 Model of the Perfused Liver 
 The model was then modified to represent the liver perfused ex vivo in a recycle 
system, as used by Williamson et al. (1969a) and others (see Figure 3.2).  The tissue mass 
balance is given by Eqn. 3.1.  The mass balance in the blood domain is given by:   
 
 
where Ci,perfusate is the concentration of  species i in the perfusion medium and Fperfusate  is 
the perfusate flow rate.  Since the content of the blood domain is actually the saline 
perfusion medium rather than blood, Eqn. 3.3 is only written for those metabolic 
intermediates expected to occur in the perfusate (i.e. GLC, LAC, ALA, AcAc, BHB, 
PYR).  The perfusion medium vessel, which we also assumed to be well-mixed, is 
represented by the following mass balance for each metabolic intermediate that exists in 
the blood domain:  
 
                                                                                                                            
where Vperfuate is the volume of the perfusion medium.  The quantities Fperfusate and 
Vperfusate in Eqn. 3.4 are assigned values that match the specific experimental conditions 
from the literature that are being simulated.  
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Figure 3.2.  Schematic of perfusion system. 
 
    It is generally recognized that the in vivo environment of an enzyme may be different 
from the in vitro experimental conditions from which the parameters are determined.   
Thus, parameter values were fine-tuned to within  ±10% of their original values using the 
parameter estimation method of generalized reduced gradient, nonlinear optimization 
(GRG2) to fit the dynamic solution of Eqns. 3.1, 3.3, and 3.4  to the experimental lactate 
perfusion data of Williamson, et al. (1969a) shown in Figure 3.3.  These parameter values 
are given in Table 3.1.  Three exceptions to this ±10% constraint were found to be 
necessary to achieve the expected physiological results:  KF1,6BP,FBPase was decreased 
16%,  KcAMP,FBPase was decreased  20%, and Km,PEP,GAP was decreased 90%.  This last 
parameter appears in the kinetic expression for the lumped reversible reaction RPEP ↔ GAP.  
The large change in this parameter value indicates that the method of setting the Km 
equal to the substrate concentration does not yield the expected results at physiological 
conditions for this reaction.    
 
 
Vblood
Ci,blood
Vtissue
Ci,tissue
Ji,b-t
Vperfusate
Ci,perfusate
F
F
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3.3 Results 
     The model was first solved at conditions representing the in vivo 24-hr fasted stated, 
using the kinetic parameters in Table 3.1  and the physical parameters and upstream 
blood concentrations  given in the caption of Table 3.2.  The steady state results are 
shown in Table 3.2 in comparison with experimental values available from the literature.  
In general there is excellent agreement between calculated and experimental values, with 
the exceptions of F-1,6-BP and PEP, which are significantly lower than the in vivo 
measurements (which are already very low), and the flux through PK, which becomes 
completely inhibited in the model at this state.  
 
  
  77
 Table 3.3.  Initial conditions and input functions used in simulation of the perfused liver. (RFA-endo=rate of 
endogenous fatty acid oxidation, normalized to µmol C16 (palmitate); J*FA-b-t = the sum of the uptake rate of 
FFA and rate of endogenous fatty acid oxidation).   
*Williamson et al. 1969b. 
Lactate Perfusion 
Initial 
conditions 
used in Eqn. 
3.4 
Saline pre-
perfusion; 
 0 < t ≤ 30 
Lactate infusion;  
30 < t ≤ 60  
Lactate + FA;  
60 < t ≤ 90 
Ci,perfusate (t=0) 
=0;  
i=Glc, LAC, 
BHB, AcAc 
(saline pre-
perfusion 
contains no 
substrate) 
RFA-endo = 0.105 
µmol gww hep-1min-1, 
assumed to be equal to  
experimental 
measurements of 
ketone production 
during this period*.   
 
RFA-endo = 0.0573  
µmol gww hep-1min-1, 
as estimated* from 
ketone production.   
 
 
CLAC,,perfusate = 
10(1-exp(-(t-30)/τ) mM 
(constant LAC 
concentration of 10 mM 
in perfusate); τ is time 
constant for achieving 
change in susbstrate 
concentration, set to 4 
min. 
J*FA-b-t=  
0.0573+0.27(1-exp(-(t-60) /τ), 
τ=2.5 min; total rate of 0.33 
µmol gww hep-1min-1 
determined  from experimental 
measurements of oleate 
infusion*.  
 
CLAC,,perfusate =10 mM 
 
Pyruvate Perfusion 
Initial 
conditions 
used in Eqn. 
3.4 
Saline pre-
perfusion; 
 0 < t ≤ 30 
Pyruvate infusion;  
30 < t ≤ 90 
Pyruvate + FA;  
90 < t ≤ 120 
Ci,perfusate (t=0) 
=0;  
i=Glc, LAC, 
BHB, AcAc, 
PYR 
(saline pre-
perfusion 
contains no 
substrate) 
RFA-endo = 0.105 
µmol gww hep-1min-1 
RFA-endo =0.0573  
µmol gww hep-1min-1 
 
CPYR,,perfusate = 
2(1-exp(-(t-30)/ τ) mM 
(constant PYR 
concentration of 2 mM 
in perfusate); τ=3 min. 
CLAC,,perfusate calculated 
from Eqn. 3.3.  
J*FA-b-t = 
0.0573+0.27(1-exp(-(t-60) / τ), 
τ=2.5 min; experimental FA 
uptake not reported; assumed 
equal to data from lactate 
perfusion.  
 
CPYR,,perfusate =2 mM 
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     The model was then used to simulate the lactate perfusion protocol of Williamson, et 
al. (1969a),  using the same set of kinetic parameters used in the in vivo model (Table 3.1, 
as described above), with input functions and initial conditions given in Table 3.3.  The 
simulation results compared to their experimental data are shown in Figure 3.3.  The first 
30 min represents the liver, just removed from the animal, and perfused with saline.  The 
replacement of the blood with saline, which contains no substrate, results in large 
concentration gradients of metabolites such as glucose, BHB, and AcAc; this leads to the 
very brief spikes in release of these substances from the tissue.  Some of the glucose 
production also results from gluconeogenesis from endogenous substrates and a small 
amount from glycogenolysis.    Lactate uptake drops quickly to zero because of the 
absence of substrate in the saline.  
     The simulated transition from saline perfusion to lactate perfusion begins at t>30 min.  
As expected, lactate uptake increases quickly and overshoots before settling to a steady 
state value.  This overshoot results from stimulation of lactate transport by the large 
concentration gradient between the perfusate and tissue.  At steady state, about 50% of 
the lactate (by mass) is converted to glucose, according to both the simulation and 
experimental data.  According to the reported experimental data, the remaining carbon 
goes into the TCA cycle for oxidation.  Our model underestimates TCA flux by about 
50%, and instead overestimates total ketone body (BHB and AcAc) production.  Futile 
cycling through the PFK-FBPase system accounts for 10% of the net gluconeogenic flux.  
While the exact amount of this futile cycling in vivo is difficult to quantify, it has been 
reported that in the fasted state, there is essentially no futile cycling (Hers and Shaftingen 
1989).    
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Figure 3.3.  Fluxes calculated from perfusion model with lactate as substrate.  Initial conditions represent 
the in vivo 24-hour fasted state; 0 < t ≤ 30 min: saline pre-perfusion (no substrate); 30 < t ≤ 60 min: lactate 
perfusion; 60 < t ≤ 90 min: lactate plus FA perfusion.  Details given in Table 3.3.  Symbols are 
experimental data from perfused fasted livers, from Williamson et al. 1969a, using a perfusion medium of  
Krebs-Henseleit bicarbonate buffer, with 4% bovine serum albumin, in a recirculated system;  solid lines 
are simulations, using Eqns. 1,3 and 4, with Fperfusate=50 ml/min and Vperfusate=100 ml (corresponding to the 
experimental protocol), and all other parameters as given in Table 3.1. In order to view the details of the 
lactate and fatty acid perfusion, the y-axis scale was expanded, which cut off the initial peak values (in 
μmol gwwhep-1min-1), given here: glucose production: 7.4; BHB production: 2.1; AcAc production: 6.0.  
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      Infusion with fatty acids is simulated beginning at t>60 min (Fig. 3.3).  The additional 
energy generated by hepatic fatty acid oxidation increases the gluconeogenic flux, so that 
both glucose production and lactate uptake increase, with close correspondence to the 
experimental data.  The increased AcCoA concentration, derived from the oxidation of 
exogenous fatty acids, inhibits flux through PDC and PK, while increasing flux through 
ketogenesis, as expected.  The oxidative phosphorylation flux also increases, similar to 
reported values.  
     The sensitivity of the major outputs (glucose production and lactate uptake) was 
investigated for the four parameters (Km,PEP,GAP,  KF1,6BP,PK,  KF1,6,BP,FBPase,  and 
KcAMP,FBPase) that needed to be modified significantly from the original values obtained 
from in vitro or in vivo data.  Figure 3.4 shows the dynamic flux profiles during lactate 
perfusion, where each parameter is varied individually, while all other parameters are 
held constant at the values given in Table 3.1.   The results are most sensitive to 
KF1,6,BP,FBPase, KcAMP,FBPase and KF1,6BP,PK, but sensitivity is still relatively low at these 
conditions, since a doubling of the parameter leads to, at most, a 10% change in glucose 
and lactate fluxes.   
    The model, with the same set of parameters as given in Table 3.1, was then used to 
simulate a variety of pyruvate, lactate, and fatty acid perfusion conditions, with the 
results compared to independent experimental data sets from the literature.  Figure 3.5 
shows the results of pyruvate perfusions.  While the model underestimates both the 
pyruvate uptake and glucose production compared to the experiments, the yields of 
glucose from pyruvate  calculated from the model are nearly the same as those measured, 
i.e. in Figure 3.5(a), 48% by mass of pyruvate is converted to glucose experimentally,  
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while the model predicts 45% conversion; in Figure 3.5(b), the experimental conversion 
is 50%, while the calculated conversion is 41%.  The addition of fatty acids at t=90 min 
(Figure 3.5(b)) increases pyruvate uptake, glucose production, and lactate production, 
with trends similar to the published experimental data.      
Figure 3.4.  Simulations using the perfusion model, using parameters as given in Table 3.1, with the 
variations in a single parameter, as specified.  Solid line: 2x Table 3.1 value; dashed line: Table 3.1 value; 
dotted line: 0.5x Table 3.1 value.  (a) Km,PEP,GAP; (b) KFBPase; (c)  KF6P,PFK; (d) KF1,6BP,PK.   
 
 
Glucose production
0.0
0.5
1.0
1.5
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1 m
in
-1
(a) Lactate uptake
0.0
1.0
2.0
3.0
4.0
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1  m
in
-1
Glucose production
0.0
0.5
1.0
1.5
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1  m
in
-1
(b) Lactate uptake
0.0
1.0
2.0
3.0
4.0
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1  m
in
-1
Glucose production
0.0
0.5
1.0
1.5
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1 m
in
-1
(c) Lactate uptake
0.0
1.0
2.0
3.0
4.0
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1 m
in
-1
Glucose production
0.0
0.5
1.0
1.5
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1 m
in
-1
(d) Lactate uptake
0.0
1.0
2.0
3.0
4.0
0 30 60 90
time (min) 
μm
ol
 g
he
p-
1 m
in
-1
  82
 
Glucose production
0.00
0.20
0.40
0.60
0.80
1.00
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
Pyruvate uptake
0.0
1.0
2.0
3.0
4.0
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
BHB release
-0.20
-0.15
-0.10
-0.05
0.00
0.05
0.10
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
AcAc release
0.00
0.10
0.20
0.30
0.40
0.50
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
A.
 
 
Glucose production
0.0
0.4
0.8
1.2
1.6
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
Lactate production
-0.4
0.0
0.4
0.8
1.2
1.6
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
Pyruvate uptake
0.0
1.0
2.0
3.0
4.0
5.0
6.0
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
Total ketones production
-1.0
0.0
1.0
2.0
3.0
0 30 60 90 120
time in min 
μm
ol
 g
he
p-
1  m
in
-1
B.
 
Figure 3.5.  Fluxes calculated from perfusion model with pyruvate as substrate.  Initial conditions represent 
the in vivo 24-hour fasted state.  Symbols are experimental data from perfused fasted livers, using a 
perfusion medium of  Krebs-Henseleit bicarbonate buffer, with 4% bovine serum albumin, in a recirculated 
system, with substrate added continuously to the medium.  Solid lines are simulations, using Eqns. 3.1,3 
and 4, with Fperfusate=50 ml/min,  Vperfusate=100 ml; simulation details given in Table 3.3 and all other 
parameters given in Tables 3.1. (a) 0 < t ≤ 30 min: saline pre-perfusion (no substrate); 30 < t ≤ 120 min : 
PYR perfusion.  Experimental data: ■  from Williamson et al. 1970b ; ▲ from Williamson et al. 1970a. (b)  
0 < t ≤ 30 min: saline pre-perfusion (no substrate); 30 < t ≤ 90 min: PYR perfusion; 90 < t ≤ 120 min: PYR 
plus FA perfusion. Experimental data: ♦ from Williamson et al. 1969a; ■ from Williamson et al. 1970b.  
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     Figure 3.6 shows the calculated glucose production compared to experimental data as 
reported in three separate published works using lactate as substrate.  The simulations are 
again using the same parameters given in Table 3.1.  While the model underestimates 
glucose production by about 40%  in Figs. 3.6a and 3.6c, the prediction is nearly identical 
to experimental in Fig. 3.6b.  
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Figure 3.6.  Fluxes calculated from perfusion model with lactate as substrate.  Initial conditions represent 
the in vivo 24-hour fasted state. Symbols are experimental data from perfused fasted livers, using a 
perfusion medium of  Krebs-Henseleit bicarbonate buffer, with bovine serum albumin, and washed human 
erythrocytes, in a recirculated system, with substrate added continuously to the medium. Solid lines are 
simulations, using Eqns. 1,3 and 4 and parameters as given in Tables 1. (a) 0 < t ≤ 30 min: saline pre-
perfusion (no substrate); 30 < t ≤ 100 min: Lactate (10mM) perfusion. ▲ from Frohlich and Wieland 1972;  
simulations calculated with Fperfusate=7 ml/min,  Vperfusate=100 ml. (b)  0 < t ≤ 30 min: saline pre-perfusion 
(no substrate); 30 < t ≤ 100 min: lactate (10mM) + FA perfusion. ▲ from Frohlich and Wieland 1972;   
simulations calculated with Fperfusate=9 ml/min,  Vperfusate=100 ml. (c)  0 < t ≤ 38 min: saline pre-perfusion 
(no substrate); 30 < t ≤ 100 min: lactate (10mM). Symbols are experimental data from perfused fasted 
livers, using a perfusion medium of  Krebs-Henseleit bicarbonate buffer, with bovine serum albumin,  and 
with red blood cells, in a recirculated system, with substrate added as a single dose: ▲ from Hems et al. 
1966;  solid lines are simulations, using Eqns. 1,3 and 4, with Fperfusate=20 ml/min,  Vperfusate=100 ml.  
  
 
     The accuracy of the model’s dynamic response is evaluated in Fig. 3.7, for both lactate 
and pyruvate perfusions.   In the retrograde perfusion data (Bracht et al. 1993), the time 
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constants for the glucose response was 2.5 – 4 min for both the addition and removal of 
substrate, with similar  response times calculated by the model.  The response time from 
the antegrade perfusions (Martins et al. 2006) were slower, with the steady state not 
achieved within 15 min of lactate perfusion.  
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Figure 3.7.  Glucose production dynamics. Solid lines are fluxes calculated from perfusion model using 
Eqns. 1 and 3, with Fperfusate=32 ml/min,  and all other parameters as given in Tables 1.  Symbols are 
experimental data from perfused fasted livers, using a perfusion medium of Krebs-Henseleit bicarbonate 
buffer saturated with a mixture of oxygen and carbon dioxide. (a) Liver was pre-perfused for 10 min, 
followed by lactate infusion for 24 min, followed by perfusion with buffer (no substrate) for another 20 
min. ▲ from Bracht, et al. 1994, using a non-recirculated retrograde perfusion; ■ from Martins et al. 2006, 
using a a non-recirculated anterograde perfusion.  (b) Liver was pre-perfused for 10 min, followed by 
pyruvate infusion for 14 min, followed by perfusion with buffer (no substrate) for another 20 min. ▲ from 
Bracht et al. 1994, using a non-recirculated retrograde perfusion. 
 
3.4 Discussion 
     The aim of this study was to develop a model capable of representing the complexity 
of gluconeogenesis and lipid metabolism and their interactions in the liver.  Parameter 
values were determined from a combination of in vitro enzyme kinetics and data obtained 
from in vivo fasted rats.  One set of experimental perfusion data (Williamson et al. 
1969a) was used for fine-tuning parameters (Fig. 3.3).  This model was then 
independently validated by comparison of model predictions to data obtained from ten 
different experiments from seven different publications.  
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     The glucose production and lactate uptake rates obtained from our simulation are in 
excellent agreement with the values reported by Williamson et al. (Fig. 3.3).  These 
values are 50% lower than those reported by Ross et al. (1967a, 1967b) and Exton and 
Park (1967) with this difference partially attributed to the use of red blood cells in the 
perfusion medium by both of these  groups.  This could lead to higher rates of oxidative 
phosphorylation and thus energy availability for gluconeogenesis.  The higher 
gluconeogenic rates have also been attributed by Exton and Park to the possible presence 
of an activator such as glucagon in the faction V albumin used in their perfusion medium 
(Williamson et al. 1969a; Exton and Park 1967).  Furthermore, Exton and Park used a 
different, non-recycling perfusion system.  
     Conversion to glucose accounts for 60% of lactate uptake (Fig. 3.3); the remaining 
40% is converted to AcCoA through PDC.  This latter rate of conversion is in good 
agreement with the Williamson data, with the small difference due to the fact that our 
model assumes negligible pyruvate formation during perfusion with lactate.  The 
endogenous fatty acid oxidation and the PDC flux constitute the source of AcCoA.  In 
comparison to the experimental data (Williamson et al. 1969b; Ross et al. 1967a,b; Exton 
and Park 1967), our simulation overestimates AcCoA  conversion to ketone bodies and 
underestimates its oxidation via the TCA cycle.  The low ratio of TCA/ketogenesis could 
contribute to a shortage of NADH, however, it does not inhibit gluconeogenesis, since the 
NADH that is required for gluconeogenesis is provided by lactate dehydrogenase  
     A significant amount of futile cycling is calculated to occur through the PK-PC system 
during lactate perfusion, with 60% of the carbon through PC recycled through PK (Fig. 
3.3).  This probably overestimates the actual amount of recycling, but there is 
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considerable disagreement in the literature as to the actual extent of recycling.   
Experiments on livers from fasted rats, perfused with various labeled substrates 
(pyruvate, alanine, propionate) yielded PK recycling values of 26-45% (Freidman et al. 
1971; Petersen et al. 1994; Jones et al. 1997).  Earlier studies done on isolated 
hepatocytes incubated with lactate have reported PK recycling of less than 10% 
(Rognstad and Katz 1977).  In vivo studies using 13C-lactate or  13C-propianate have 
reported  higher PK recycling rates, 45-53% (Katz et al. 1993; Jones et al. 1997; 
Magnusson et al. 1991).  More recently Jin et al. (2004) used a combination of 13C-
propianate and 3,4-12C-glucose to determine an in vivo PK recycling of 70%; however 
this high PK recycling value could be attributed to the amount of glucose infused, which 
could reflect a change in nutritional state of the animal.   
     The addition of fatty acids to the perfusion medium stimulates gluconeogenesis from 
lactate, perfectly matching the experimental data (Fig. 3.3).  Moreover, fatty acids also 
increase the activity of PC and inhibit the activity of PDC, presumably via generation of 
AcCoA and NADH.  The inclusion of the regulatory terms for AcCoA in the kinetic 
expressions for these two enzymes is essential for achieving the correct rate of lactate 
uptake and gluconeogenesis.   
     In the pyruvate perfusions, the simulated glucose/pyruvate ratios (Fig. 3.5) are very 
similar to the average of 45% reported from various researchers (Williamson et al. 
1969a,b; Menahan et al. 1969; Teufel et al. 1967; Ross et al. 1967a,b; Exton and Park  
1967; Williamson et al. 1970), although the calculated pyruvate uptakes and glucose 
productions are generally about 50% lower than that observed experimentally.  The rate 
of pyruvate uptake is determined by several factors, among them, the rate of endogenous 
  87
fatty acid oxidation.  In the model, this rate (RFA-endo) was set to the same values used for 
lactate perfusions, in the absence of information specific to the pyruvate perfusions. A 
simulated increase in RFA-endo does cause an increase in pyruvate uptake as well as 
glucose production (not shown), although not to the extent observed experimentally.  The 
simulations yield 6% conversion of pyruvate to lactate; this value compares well with the 
8% reported by Williamson, et al. (1969a).   
     Pyruvate oxidation through PDC plays a major role during the perfusion of pyruvate 
as the only substrate, since it provides the necessary NADH and ATP (along with 
endogenous fatty acid oxidation) required for conversion of pyruvate to glucose.  Our 
simulation shows that 40% of pyruvate uptake is channeled through PDC in the absence 
of exogenous FA (not shown), which is in good agreement with an average of 30% 
reported previously (Menahan and Wieland 1969; Teufel et al. 1967; Ross et al. 1967a,b; 
Exton and Park 1967).    The addition of fatty acids to the perfusion medium containing 2 
mM pyruvate results in an inhibition of pyruvate oxidation to a value of 5% of pyruvate 
uptake, in agreement with the 9% measured experimentally (Menahan and Wieland 
1969).  This finding demonstrates again the importance of AcCoA, induced by the 
exogenous fatty acid addition, on the control of PDC and the subsequent control of 
hepatic gluconeogenesis.   
     As we noted during lactate perfusion, pyruvate alone does not inhibit ketogenesis in 
our model results, in contrast to most experimental results (Williamson et al. 1969b; 
Menahan and Wieland 1969; Teufel et al. 1967), while the addition of fatty acids 
stimulates ketogenesis both experimentally and in the simulation (Fig. 3.5b).   The 
excessive rate of ketogenesis in the absence of exogenous fatty acids most likely results 
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from the representation of the formation of acetoacetate from AcCoA by means of 
Michaelis-Menten kinetics; this neglects the kinetic parameters of 
hydroxymethylglutaryl-CoA (HMG-CoA) synthase, the rate-limiting reaction in 
ketogenesis. Similarly, it may be necessary to include additional regulatory mechanisms 
and/or reactions in the representation of the TCA cycle.  The rates of AcAc synthesis and 
TCA flux are closely linked via NADH, NAD+ and AcCoA, and inclusion of more 
physiologically-correct kinetic expressions are needed to correct this imbalance.  
     Our model also allows the prediction of dynamic as well as steady state responses of 
the liver to various substrates.  As shown in Figure 3.7, the predicted transient responses 
to both lactate and pyruvate infusions are very similar to that observed experimentally by 
Bracht, et al. (1993), although in the former case, the model underestimated the steady 
state glucose production by about 45%.  It is unclear why the results from Martins, et al. 
(2006) exhibit significantly slower dynamics than that of Bracht, et al. (1993).  The 
calculated pyruvate response (Fig. 3.5b) is characterized by a rapid (1 min) response to 
pyruvate uptake and glucose and lactate production.  However, after 5 min, the rate of 
lactate formation begins to decrease, accompanied by a slight reduction of the rate of 
pyruvate uptake and a gradual increase in glucose production over 30 min.  Very similar 
dynamics have been observed in the experimental data of Williamson, et al. (1969a), also 
shown in Fig. 3.5b.  This transient behavior results from the balance between a very fast 
transport rate (of both pyruvate and lactate), a fast LDH reaction, and relatively slower 
PC kinetics (not shown), which causes some of the initial pyruvate influx to drain out as 
lactate before the gluconeogenic rate has a chance to increase.   
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     This work was limited to the effect of substrates in a fasted liver, and thus the kinetic 
parameters used are reflective of the hormonal concentrations present in the fasted state.  
While the effects of hormones are beyond the scope of this work, some of the effects of 
glucagon and insulin are included indirectly in the model via cAMP.   cAMP 
concentration appears directly in the kinetic expressions for FBPase.  Moreover, cAMP 
affects the concentration of F2,6BP, whose concentration is included in the expression for 
PFK and FBPase.   
     This model represents a promising tool to account for the relationship between 
gluconeogenesis and lipid metabolism and their role in various metabolic disorders.  The 
model predicts with reasonable accuracy the effect of lipids on many of the metabolic 
fluxes in the liver tissue.  The simulations clearly demonstrate that the liver function is an 
elegant balance among the numerous transport and reactions processes, with 
dependencies on both the mechanisms, represented by the structure of the kinetic 
equations, as well as the specific values of some key reaction parameters.  Not 
surprisingly, the balance of NADH/NAD+ is one of the key factors influencing the flux 
distribution.  After modifying the kinetic expressions used for the TCA cycle and 
ketogenesis and the inclusion of a model for gluconeogenesis and urea formation from 
amino acids, such as alanine, this model should serve as an in silico representation of the 
healthy, fasted liver.   
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CHAPTER IV 
 
CYTOSOLIC-MITOCHONDRIAL COMPARTMENTATION IN THE 
PERFUSED LIVER 
 
 
 
 
4.1 Introduction  
 
     The redox ratio (NADH/NAD+) is known to play a key role in the regulation of 
carbohydrate and lipid metabolism in the liver, in particular, the pathways of 
gluconeogenesis, tricarboxylic acid (TCA) cycle, ketogenesis, and oxidative 
phosphorylation.  NADH stimulates gluconegensis mainly through the glyceraldehyde-3P 
dehydrogenase (GAPDH) reaction. The TCA cycle is influenced by the redox ratio 
primarily at two major sites: isocitrate dehydrogenase (Shepherd et al. 1969) and alpha-
ketoglutarte dehydrogense (Smith  et al. 1974), both being inhibited by NADH.  
Experiments with isolated hepatocytes have shown that an increase in the NADH/NAD+ 
ratio caused by fatty acid oxidation is associated with a significant increase in the 
membrane potential, leading to increased oxidative phosphorylation (Nobes et al. 1990). 
The interactions between these major pathways are essential to consider in the 
investigation of energy metabolism regulation in the liver, and more specifically, to 
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quantify the role of the redox ratio in regulating these different pathways. Understanding 
of the interrelationship between these pathways and prediction of the fluxes, in response 
to environmental conditions, is thus predicated upon an accurate quantitative 
representation of the redox ratio and its influence on the reaction kinetics.  The 
quantitative depiction of this system is complicated by three factors: the distribution of 
gluconeogenesis enzymes among both cytosolic and mitochondrial domains; the 
impermeability of the mitochondrial membrane to specific substrates (e.g. NADH, 
NAD+, oxaloacetate (OAA)), which nonetheless exist in both compartments; and the 
significant difference in concentrations of some metabolites between the cytosol and 
mitochondria.  
      Lactate, pyruvate, and amino acids are the main precursors for hepatic 
gluconeogenesis, providing both the carbon skeleton as well as the necessary NADH for 
GAPDH in the cytosol.  Lactate, as substrate, is converted to pyruvate, which is 
converted to OAA in the mitochondria via pyruvate carboxylase.  Since the 
mitochondrial membrane is impermeable to OAA, the carbon skeleton of OAA is 
transferred to the cytosol as either aspartate or malate, where it is converted back to OAA 
for reaction by PEPCK.  The transport of anions across the mitochondrial membrane is 
done by means of specific antiport or symport carriers (Chappell 1969; Klingenberg et al. 
1970a,b; Meijer et al. 1974; Van Dan et al. 1971).   The NADH requirement for GAPDH 
is provided by lactate dehydrogenase in the cytosol, therefore, no inter-compartmental 
transfer of reducing equivalents is necessary. Gluconeogenesis from lactate is said to be 
“NADH-neutral”.   In contrast with lactate, when pyruvate is the main precursor for 
gluconeogenesis, the NADH is generated inside the mitochondria and is transferred to the 
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mitochondria through malate which carries both the carbon skeleton and the reducing 
equivalents for gluconoegenesis.  Gluconeogenesis from pyruvate is thus “NADH-
demanding”.   
     The concentrations of several metabolites common to the TCA cycle and the 
gluconeogenesis pathway differ significantly between the cytosolic and mitochondrial 
compartment.  In particular, the cytoplasmic and mitochondrial redox ratios, which 
significantly affect the rates of NAD-linked dehydrogenase reactions, are more than an 
order-of-magnitude different from each other, with NADH/NAD+  approximately equal 
to 0.001 in the cytosol and 0.05 in the mitochondria (Williamson et al. 1969a) after 24 h 
fasting.   Other species with significant differences in cytosolic and mitochondrial 
concentrations include pyruvate, OAA, AcCoA, and MAL (Table 4.3).    
     The model described in Chapter III, which lumps the cytosolic and mitochondrial 
domains, approximately predicts the total rate of ketone production when perfused with 
lactate; however it overestimates the rate of ketogenesis with respect to pyruvate as a 
substrate. Inaccuracies in the ketone production rate, as well as the ratio of BHB/AcAc 
produced, are likely consequences of cytosolic values used for NADH/NAD+, and to a 
lesser extent, OAA, in mitochondrial-located enzyme kinetics.   It has been suggested that 
the availability of OAA for citrate synthase is the step determining  the fate of 
acetylCoA-- to either proceed into the TCA cycle or into the ketogenesis pathway 
(Wieland et al. 1968).  Thus the incorporation of a detailed and regulated TCA cycle was 
deemed necessary for a better representation of liver metabolism during gluconeogenesis 
from lactate and pyruvate, and during interaction between gluconeogenesis and fatty acid 
oxidation. 
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     There are several published kinetic models of the TCA cycle, but few are specific to 
the liver. Garfinkel et al. (1970) presented a detailed model of the TCA cycle but the 
model lacked integration with other pathways such as gluconeogenesis, fatty acid 
oxidation, and intercompartmental transport.  More recently, Beard et al. (2007) 
developed a comprehensive detailed model of the TCA cycle and metabolite transport 
across the mitochondrial membrane for heart and striated muscle. This model was further 
validated with additional data from ex vivo isolated mitochondria and in vivo data from 
skeletal muscle. The kinetic expressions and parameters are well-documented and the 
model accounts for enzyme regulation by different metabolites. The model is an excellent 
tool to represent the TCA cycle and metabolite transport across the mitochondrial 
membrane; however, as a representation of isolated mitochondria, it lacks the integration 
with glycolysis and gluconoegenesis. Moreover, their model is a representation of heart 
and muscle tissues, rather than liver tissue.  
      Several groups have developed relatively comprehensive models of intermediary 
metabolism in the liver.  Orman et al. (2010, 2011, 2012, 2013) used flux balance 
analysis coupled with thermodynamic and futile cycle constraints and experimental data 
from perfused rat livers to analyze liver metabolism in response to burn injury and 
various oxygenation states.  These models lack reaction kinetics, and therefore are limited 
in their ability to predict fluxes and species concentratins in novel situations.  
     Calvetti et al. (2008) modified our models presented in Chapters II and III  with 
Bayesian Flux Balance Analysis (BFBA) to estimate the range of flux and transport rates 
at steady state, but as this is based on a single compartment, it is limited in its robustness. 
Konig et al. (2012) developed a kinetic model of glucose metabolism in human liver, 
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which includes representation of gluconeogenesis, glycolysis, and glycogen metabolism 
integrated with the hormonal control of these pathways. Even though this model 
considers cytosol-mitochondria compartmentation, it lacks the details of the TCA cycle 
and the shuttle mechanisms. 
     The aim of this work is, firstly, to accurately predict the cytoplasmic and 
mitochondrial redox ratios in a fasted rat liver model during perfusion with lactate, 
pyruvate, and fatty acids. The appropriate representation of the redox ratio can be 
expected to result in better estimation of key metabolic rates such as gluconoegenesis, 
TCA cycle, and ketogenesis.  The second aim is to accurately represent the mechanisms 
for reducing equivalent and metabolite transfer across the mitochondrial membrane, with 
respect to different gluconoegenic precursors.  These aims were met by building a 
comprehensive, detailed, and multidomain metabolic model of the perfused liver from the 
fasted rat.  We modified the model described in Chapter III by incorporating distinct 
domains for cytosol and mitochondria, with metabolite transport across the mitochondrial 
membrane. The model was extended by featuring a detailed TCA cycle pathway, based 
on the work of  Beard et al. (2007). The model was used to simulate the effects of lactate 
and pyruvate, with and without fatty acids, on the cytosolic and mitochondrial redox 
ratios and  rates of gluconoegenesis, ketogenesis, TCA cycle, and oxidative 
phosphorylation, and on the rates and mechanisms of intercompartmental transport. 
These simulations were then validated by comparison to experimental data from different 
ex vivo studies in the literature. 
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4.2 Model Development 
4.2.1 Metabolic Pathways 
     The model of gluconoegenesis in the perfused liver in Chapter III was modified by 
compartmentalizing the tissue into two separate cytosolic and mitochondrial domains. 
This was achieved by incorporating newly functional pathways and reaction fluxes that 
included a detailed tricarboxylic acid cycle, the malate-aspartate shuttle, and inter-
compartmental transport for substrates exchange between the two domains.   The 
complete set of pathways considered here is shown in Fig. 4.1.  The kinetic expressions 
that have been added in the current model are shown in Table 4.1, while the remainder of 
the reactions are found in Table 3.1. 
     The mitochondrial compartment includes the following: eight reactions describing the 
detailed TCA cycle fluxes; two distinctive oxidative phosphorylation reactions; 
mitochondrial aspartate aminotransferase; glutamate dehydrogenase;  and nucleoside 
diphosphokinase. The TCA cycle is regulated at three important sites: citrate synthase 
(CS), isocitrate dehydrogenase (IDH), and alpha-ketoglutarate dehydrogenase (AKGDH); 
therefore these reactions are modeled to appropriately account for activation and 
inhibition (e.g. by ATP, ADP, NADH).  The kinetic expressions for the TCA cycle and 
some anionic transporters reactions were based on the work of Beard et al. (2007) with 
changes in some of the kinetic parameters to better fit and represent the nature of the liver 
tissue.       
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Figure 4.1.  Reaction network considered in tissue model.  Most transport and reaction fluxes are treated as 
reversible, but may be shown here as uni-directional to indicate the pred ominant direction.  Tables 3.1 and  
4.1 indicate whether a reaction is treated as reversible or irreversible.  Detailed stoichiometry and the 
kinetic expression for each reaction shown here are given in Table 3.1 (for red reactions) and  Table 4.1 
(for blue reactions).  Rates of endogenous FA degradation and FA uptake are given in Table 4.3.  To 
simplify notation, NAD+ is written as NAD.  AcAc: acetoacetate; AcCOA: acetyl CoA; ASP: aspartate; 
BHB: β-hydroxybutyrate; CIT: citrate; DHAP: dihydroxyacetone phosphate; FA: fatty acid;  FAcylCoA: 
fatty acyl CoA;  F6P: fructose-6-phosphate; F16BP: fructose 1,6 bisphosphate; FUM: fumarate; GAP: 
glyceraldehyde-3-phosphate; GLUT: glutamate; GLN: glutamine; LAC: lactate; GLC: glucose; Glyc: 
glycogen; G6P: glucose-6-phosphate;  IsoCIT: isocitrate; MAL: malate; PG3: 3-phosphoglycerate; PG2: 2-
phosphoglycerate; PYR: pyruvate; OAA: oxaloacetate; AlphaKG: alpha-ketoglutarate; SucCoA: succinyl 
CoA; SUC: succinate..  
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     The cytosolic compartment includes reaction kinetics for gluconoegenesis, glycolysis, 
and fatty acid synthesis (Table 3.1), plus added reaction for PEPCK,  cytosolic  
nucleoside diphosphokinases (NDK), and cytosolic malate dehydrogenase (MDHc) 
(Table 4.1). 
     The exchange of substrates and cations across the mitochondrial membrane through 
specific transporters are modeled as facilitated diffusion processes. The following 
substrate transporters are included: the pyruvate-hydrogen co-transporter; the citrate-
malate transporter; the malate-phosphate transporter; the glutamate-hydrogen co-
transporter; the hydrogen-phosphate co-transporter; the ATP-ADP translocase; and the 
aspartate/glutamate and the malate/alpha-ketoglutarate exchangers that constitute the 
malate aspartate shuttle responsible for the transfer of NADH through the mitochondrial 
membrane. 
     The kinetic expressions for aspartate/glutamate and the malate/alpha-ketoglutarate 
exchangers are based on the work of Beard et al. (2007). The malate/alpha-ketoglutarate 
kinetic expression features the inhibition factors by the TCA cycle intermediates of 
glutamate, aspartate, and succinate.  
     The kinetic expressions of some reactions include modulation by coupled controllers. 
These controllers are the phosphorylation ratio ADP/ATP (PS) and redox ratio 
NADH/NAD+ (RS). Since the mitochondrial membrane is impermeable to the NADH it 
was necessary to distinguish two different redox ratios, RSc and RSm, corresponding to 
the cytosolic and mitochondrial domains, respectively.  
       As described in Chapter III, reversible, near-equilibrium reactions (e.g. lactate 
dehydrogenase (LDH), MDH) are represented by a simplified form of a reversible, ping-
 98
pong mechanism, with the Haldane equation used to relate kinetic parameter values at 
near-equilibrium and to ensure consistency with thermodynamic constraints.  The rate 
mechanisms for transport between the blood and cytosol domains are described by 
facilitated diffusion. 
     The updated kinetic parameters for this model and the specific approach used for each 
reaction are listed in Table 4.2. The remaining kinetic parameters were kept the same as 
shown in Chapter III.  In this chapter we explicitly accounted for the pH and the Pi 
(inorganic phosphate) concentrations in both cytosol and mitochondrial domains by 
assigning constant values consistent with data reported in the literature (Table 4.3).  
     The initial species concentrations in the cytosol, mitochondria, and blood were mostly 
taken from the literature and they were generally based on measurements from the livers 
of 24-hr fasted rats (Table 4.3). Subcellular distribution of metabolites between cytosol 
and mitochondria were determined from the literature when available.  
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Table 4.1 Reaction rates and kinetic expressions.  Subscripts specify location of species or reaction;  c: cytosol; m: mitochondria; b: blood;  p: perfusate.  Species 
that are located only in a single compartment (either cytosol or mitochondria) have no subscript. Species name abbreviations are given in the caption to Fig. 5.1.  
The “?” indicates that the reaction is treated as irreversible, while  “↔” indicates that the reaction is treated as reversible, with the flux reported with positive 
values in the left-to-right direction.   
 
 
Reaction rate name and stoichiometry Reaction rate kinetic expression 
Cytosolic-Mitochondrial Transport 
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GLUT:OH Transport (c-m) 
GLUT_c + OH_c ↔  GLUT_m +  OH_m 
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Glut-ASP transport 
GLUT_c +  ASP_m ↔  GLUT_m + ASP_c 
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Glutamate transport (c-m) 
GLUT_c ↔ GLUT_m 
( )
( ) ⎟⎟⎠
⎞
⎜⎜⎝
⎛
++
−
mGLUTcGLUTGLUTm
mGLUTcGLUTGLUTmc
CCK
CCV
___
____max,
 
PYR:OH Transport (c-m) 
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PYR transport (c-m) 
PYR_c ↔ PYR_m 
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PYR:AcAc transport (c-m) 
PYR_c + AcAc_m ↔ PYR_m +  AcAc_c 
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AcAc:OH  transport (m-c) 
AcAc_m + OH_m ↔  AcAc_c +  OH_c 
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BHB transport (m-c) 
BHB_m ↔  BHB_c 
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FAcyl transport (c-m) 
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Adenine translocase 
ADP_c +  ATP_m ↔  ADP_m + ATP_c 
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Cytosolic-Blood Transport 
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Cytosolic Reactions 
Aspartate aminotransferase (AST), cytosolic 
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Malate dehydrogenase (MDH), cytosolic 
MAL_c + NAD_c ↔OAA_c + NADH_c 
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ATPase 
ATP_c ? ADP_c + pi_c 
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Phosophoenylpyuvate carboxykinase (PEPCK) 
OAA_c + GTP_c ? PEP + GDP_c 
 
 ⎟⎟
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Enolase 
PEP ↔ PG2 
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Phosphogluomutase (PGM) 
PG2 ↔ PG3 
 
 ⎟⎟
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Phosphoglycerate kinase/Glyceraldehyde-3-P 
dehydrogenase 
PG3 + ATP_c + NADH_c ↔ GAP + ADP_c + 
NAD_c + pi_c 
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Triose-phosphate isomerase (TPI) 
DHAP ↔ GAP 
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Aldolase: 
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Citrate lyase 
CIT_c + CoA_c + ATP_c ? OAA_c + ADP_c + 
AcCoA_c + pi_c 
 
 ⎟⎟
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜⎜
⎜
⎝
⎛
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⎟
⎠
⎞
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cATP
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CLcCIT
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C
C
C
C
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CV
__
_
_
_
_
__
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11
1
 
FA activation 
FA_c + ATP_c +CoA? FacylCoA_c + AMP_c + 
2 pi_c 
( )
( )⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ cATPcFAmcFAm
cATPcFAmcFA
CCK
CCV
_____
____max,
 
Nucleoside diphosphokinase (NDK), cytosolic 
GTP_c + ADP_c ↔ GDP_c + ATP_c 
 ( )
⎟⎟
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎜⎜
⎝
⎛
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −+
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CATPCGDP
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CADPCGTP
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K
CC
K
CC
K
CCCCV
___
__
__
__
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______max,
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Adenylate kinase, cytosolic 
2 ADP_c ↔ ATP_c + AMP_c 
 
⎟⎟
⎟⎟
⎟⎟
⎠
⎞
⎜⎜
⎜⎜
⎜⎜
⎝
⎛
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −+
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −
rcAKm
cAMPcATP
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K
CC
K
C
K
K
CC
CV
___
__
__
2
_
__
_
__2
____max,
1
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Mitochondrial Reactions 
Oxidative phosphorylation of NADH 
O2 + 5 ADP_m + 2 NADH_m + 5 pi_m ? 2 H2O 
+ 5 ATP_m + 2 NAD_m 
 
( )
( )
( )732.99
____
732.99
___,
___
_
___
_
_
_
_
_
___max,
+
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⎟⎟
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mNADH
mATP
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mATP
mADP
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K
oxnirsCC
C
CC
C
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C
C
C
V
 
Oxidative phosphorylation of CoQH2 
O2 + 3 ADP_m + 2 CoQH2 + 3 pi_m ? H2O + 3 
ATP_m + 2 CoQ 
 
( )
( )
( )732.99
____
732.99
___,
2_
2
2_
2
_
_
_
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___max,
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V
 
Aspartate aminotransferase (AST), mitochondrial 
ASP_m + Alpha_KG_m ↔ OAA_m + GLUT_m ⎟⎟⎠
⎞
⎜⎜⎝
⎛=
AsATASPiAsATAKGmAsATeq
AsATmOAAiAsATGLUTmAsATmr
AsATmr KKK
KKV
V
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K
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K
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K
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D
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__,
_
__,
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⎟⎟⎠
⎞
⎜⎜⎝
⎛
⎟⎟⎠
⎞
⎜⎜⎝
⎛ −=
AsATeq
mGLUTmOAA
mKGmASPAsATAKGmAsATmrAsATmf K
CC
AlphaCKVVN
_
__
___,,,  
D
Nrate =  
FA_acylCoa formation 
FAcyl_m + CoA_m ? FAcylCoA_m 
 
( )
( )⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ mCoAmFAcylCoAFAm
mCoAmFAcylCoAFA
CCK
CCV
____
___max,
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FA β-oxidation 
FAacylCoA_m + 7 NAD_m + 7 CoQ + 7 CoA_m 
? 8 AcCoA_m + 7 NADH_m + 7 CoQh2 
reaction: 
 
 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+⎟⎟⎠
⎞
⎜⎜⎝
⎛
++ PSPS
PS
RSRS
RS
CK
CV
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m
acylCoAFAbom
mFAcylCoAbo
/1/1
/1
/1/1
/1
,,__
_max_
 
Citrate synthase (CS) 
AcCoA_m + OAA_m ↔ CIT_m+CoA_m ⎟⎟⎠
⎞
⎜⎜⎝
⎛ +=
CitSaseCITi
mCIT
K
C
AlphaI
__
_11  
⎟⎟
⎟⎟
⎟
⎠
⎞
⎜⎜
⎜⎜
⎜
⎝
⎛
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CitSaseOAAmmAcCoA
CitSaseAcCoAmCitSaseia
mAcCoAmOAACitSase
KCC
CC
CCAlphaIKC
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CCV
rate
___
__
_____
___
___
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1
2
1
1
 
Aconitase 
CIT_m ↔ IsoCIT 
⎟⎟
⎟⎟
⎟⎟
⎠
⎞
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⎜⎜
⎜⎜
⎝
⎛
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Isocitrate dehydrogenase (IDH) 
Iso_cit + NAD_m ↔Alpha_KG_m + NADH_m + 
CO2 
⎟⎟⎠
⎞
⎜⎜⎝
⎛ +
⎟⎟⎠
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K
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C
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K
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K
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_
_
11  
D
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alpha-ketoglutarate dehydrogenase (AKGDH) 
 
Alpha_KG_m + NAD_m + CoA_m ↔ SucCoA + 
NADH_m + CO2 ⎟⎟⎠
⎞
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⎛ +
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Nrate =  
Succinate dehydrogenase (SDH) 
SUC + CoQ ↔ FUM + CoQH2 ( )
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Fumarase 
FUM ↔ MAL_m 
⎟⎟
⎟⎟
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Succinyl-CoA synthetase 
SucCoA + GDP_m + pi_m ↔ SUC + GTP_m + 
CoA_m 
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Malate dehydrogenase (MDH), mitochondrial 
MAL_m + NAD_m ↔ OAA_m + NADH_m 
mMDHeqiamB
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Glutamate dehydrogenase 
GLUT_m + NAD_m ↔ Alpha_KG_m + 
NADH_m + NH4 
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⎟⎟
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Glutamine synthetase 
GLUT_m + NH4 + ATP_m ?GLN_m + ADP_m 
+ Pi_m 
⎟⎟⎠
⎞
⎜⎜⎝
⎛
+ mATPNHmGLUTGLSm
mATPNHmGLUTGLS
CCCK
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Glutaminase 
GLN_m ? GLUT_m + NH4 ⎟⎟⎠
⎞
⎜⎜⎝
⎛
+ mGLNGLasm
mGLNGLas
CK
CV
__
_max_
 
Urea synthesis 
2ATP_m + NH4 ? urea + 2ADP_m + pi_m 
⎟⎟
⎟⎟
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Nucleoside diphosphokinase (NDK), mitochondrial 
GTP_m + ADP_m ↔GDP_m + ATP_m ( )
⎟⎟
⎟⎟
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GTP:AMP Phosphotransferase 
GTP_m + AMP_m ↔ GDP_m + ADP_m 
⎟⎟
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Table 4.2 Kinetic parameters.  Ratio of cytosol to mitochondrial volume is set  to 9.52(Reich and 
Selkov, 1981) 
 
Kinetic parameter Parameter value Source 
Vmax_pdh 25.51  mM/min 
Alpha 0.9 
Beta 25 
Kp 0.35 mM/min 
Gama 0.5 mM/min 
 
 
Chalhoub et al. 2007 
 
 
Vmax_pc 168.67 mM/min 
Ki_adp_pyr_pc 3 mM/min 
K_atp_pc 0.06 mM 
n1_pc 1.03 
n2_pc 0.8 
n3_pc 2.75 
K_pyr_pc 11 mM 
K_accoa_pc 5.10E-05 mM 
Ki_adp_atp_pc 0.9 mM 
 
 
 
Chalhoub et al. 2007 
 
 
 
 
 
Vmax_ldh_b 348.21 mM/min Reich and Selkov, 1981 
Keq_ldh 0.00011 Reich and Selkov, 1981 
Km_ldh_b 1.0857 mM 
Set equal to steady state product of LAC and 
NAD+ concentrations 
Km_ldh_f 3.39E-06 mM 
Calculated from  in vivo LDH flux (Christian 
and Christian, 1983) 
 and steady state product of LAC,  NAD+  (c), 
NADH (c) and PYR concentrations 
Vmax_pk 89.28 mM/min 
K_pep_pk 0.055 mM 
K_atp1_pk 0.0075 mM 
n_pk 3.1 
L_pk 16000 
c_atp 2 
K_ala_pk 0.2 mM 
c_ala_pk 0.2 
K_f16bp_pk 0.0001 mM 
 
 
 
Chalhoub et al. 2007 
 
 
 
 
Vmax_fbpase 20 mM/min 
K_f16bp 0.000827586 mM 
n_fbpase 5.524 
K_f26bp 0.0269 mM 
K_amp 1.82759 mM 
K_cAMP 0.0159138 mM 
L_fbpase 2.76E+06 
c_fbpase 0.5597 
 
 
 
Chalhoub et al. 2007 
 
 
 
Vmax_PFK 5.3571 mM/min 
Kapp_f6p_pfk 0.0007 mM 
K_atp_pfk 0.05 mM 
Alpha_pfk 2 
q1_pfk 100 
n1_pfk 3 
 
 
Chalhoub et al. 2007 
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Kiatp_pfk 1 mM 
Sigma_pfk 3.5 
n2_pfk 3 
Ki_f26bp_pfk 0.03 mM 
Kiamp_pfk 2 mM 
q2_pfk 50 
Vmax_pep_gap 167.857 mM/min Reich and Selkov, 1981 
Keq_pep_gap 16666.7 Reich and Selkov, 1981 
Km_pep_gap 0.00061 mM 
Set equal to product of steady state PG3 and 
NADH(c), and ATP(c)  concentrations 
Km_gap_pep 0.00487 mM 
Calculated from  Rpep_gap and steady state 
product of PG3,  NAD+  (c), NADH (c) and 
GAP concentrations 
Vmax_g6p_f6p 46.873 mM/min 
Calculated from RGI flux from FBA flux 
analysis and steady state F6P and G6P 
Keq_g6p_f6p 2.5 Reich and Selkov, 1981 
K_f6p 0.0665714 mM Set equal to steady state F6P concentration 
K_g6p 0.145714 mM Set equal to steady state G6P concentration 
Vmax_g6p 5.2132 mM/min 
Calculated from RGI flux from FBA flux 
analysis and steady state G6P, Reich and Selkov, 
1981 
Km_g6pase 0.145714 mM Set equal to steady state G6P concentration 
Vmax_gk 3.1279 mM/min 
Calculated from RGI flux from FBA flux 
analysis and steady state GLC and    Shonk and 
Boxer, 1964 
Km_gk 8.9286  mM Set equal to steady state GLC concentration 
ps_i_gk 0.3012 
Set equal to steady state  CADP_c/CATP_c  Seis 
1982 
Vmax_gap_f16bp 42.8571 mM/min Reich and Selkov, 1981 
Km_gap_f16bp 0.0007 mM 
Set equal to steady state product of GAP and 
DHAP concentrations 
Vmax_gr3p_gap 205.357 mM/min Shonk and Boxer, 1964 
Keq_gr3p_gap 0.00013 Reich and Selkov, 1981 
Km_gr3p_gap 0.3571 mM 
Set equal to product  of steady state of GR3P 
and NAD+ concentrations 
Km_gap_gr3p 1.12E-07 mM 
Calculated from  RGr3p_gap and steady state 
product of GR3P,  NAD+  (c), NADH (c) and 
DHAP concentrations 
Vmax_glr_gr3p 1.1279 mM/min 
Calculated from  in vivo flux (Christian and 
Christian, 1983) and steady state product of 
GLR, and  ps_i_glr_gr3p concentrations 
Km_glr_gr3p 0.1786 mM Set equal to steady state GLR concentration 
ps_i_glr_gr3p 0.3012 
Set equal to steady state  CADP_c/CATP_c  Seis 
1982 
Vmax_enolase 30.3571 mM/min Reich and Selkov, 1981 
Keq_enolase 0.25 Reich and Selkov, 1981 
K_eno_f 0.0708929 mM Set equal to steady state PEP concentration 
K_eno_b 0.2679 mM Set equal to steady state PG2 concentration 
Vmax_PGM 178.571 mM/min 
Shonk and Boxer, 1964; Hannon and Vaughan, 
1960 
Keq_PGM 6.66667 mM Reich and Selkov, 1981 
K_PGM_f 0.2679 mM Set equal to steady state PG2 concentration 
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K_PGM_b 0.1357 mM Set equal to steady state PG3 concentration 
Vmax_TPI 8.92857 mM/min Reich and Selkov, 1981 
Keq_TPI 0.04545 Reich and Selkov, 1981 
K_TPI_f 0.0232 mM Set equal to steady state DHAP concentration 
K_TPI_b 0.0303571 mM Set equal to steady state GAP concentration 
Vmax_PEPCK 17.6857 mM/min Reich and Selkov, 1981; Shonk and Boxer, 1964 
Km_PEPCK 0.0040179 mM Set equal to steady state OAA (c) concentration 
ps_i_ndk_c 0.278287 
Set equal to steady state  CGDP_c/CGTP_c  Seis 
1982 
Km_accoa_AcAc 0.981 mM 
Set equal to steady state  AcAc (m) 
concentration 
Vmax_accoa_AcAc 126.327 mM/min 
Calculated from  in vivo flux and steady state 
product of AcAc (m) AcCoA (m), and  CoA(m) 
concentrations 
Vmax_bhb 1020.41 mM/min Reich and Selkov, 1981 
Keq_bhb 20 Reich and Selkov, 1981 
Km_bhb 0.2846 mM 
Calculated from  RBHB and steady state product 
of AcAc(m),  NAD+  (m), NADH (m) and 
BHB(m) concentrations 
Km_bhb_r 4.2857 mM 
Set equal to product  of steady state of AcAc(m) 
and NADH(m) concentrations 
Vmax_bo 91.9048 mM/min 
Calculated from  in vivo flux and steady state of 
FA_acylCoA (m), rs_i_b0, and ps_i_b0 
concentrations 
rs_i_b0 0.25 
Set close to steady state  CNADH_m/CNAD_m  (Reich 
and Selkov, 1981) 
ps_i_b0 0.7514 
Set equal to steady state  CADP_m/CATP_m  Seis 
1982 
Vmax_fat_syn 3.8603 mM/min Reich and Selkov, 1981 
ps_i_fat_syn 0.3012 
Set equal to steady state  CADP_c/CATP_c  Seis 
1982 
Km_fat_syn 0.0809 mM Set equal to steady state  AcCoA(c) 
Vmax_urea 34.0136 mM/min Reich and Selkov, 1981 
Km_urea 9.52 mM Set equal to steady state  NH4 (m) concentration 
ps_i_urea 0.7514 
Set equal to steady state  CADP_m/CATP_m  Seis 
1982 
ps_i_ndk_c 0.278287 
Set equal to steady state  CGDP_c/CGTP_c  Seis 
1982 
Vmax_CL 22.3214 mM/min Reich and Selkov, 1981 
Km_CL 2.52812 mM 
Calculated from  in vivo flux, in vitro Vmax_CL 
and steady state of CIT(c), CoA(c), and ps_i_CL 
concentrations 
ps_i_CL 0.3012 
Set equal to steady state  CADP_c/CATP_c  Seis 
1982 
Vmax_ADP_ATP 154.286 mM/min Hanson and Mehlman, 1981 
Km_ADP_ATP 0.00126 mM Hanson and Mehlman, 1981, Seis 1982 
Vmax_oxd_phosph 514.22 mM/min 
Calculated from RoxPhos flux from FBA and 
steady state O2 concentration 
Km_oxd_phosph 99.7732 mM Set equal to steady state O2 concentration 
ps_i_oxn 0.7514 
Set equal to steady state  CADP_m/CATP_m Seis 
1982 
rs_i_oxn 0.2 Set close to steady state  CNADH_m/CNAD_m (Reich 
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and Selkov, 1981) 
Vmax_oxd_phosph_f 514.612 mM/min 
Calculated from RoxPhos flux from FBA and 
steady state O2 concentration 
Km_oxd_phosph_f 99.7732 mM Set equal to steady state O2 concentration 
ps_i_oxf 0.7514 
Set equal to steady state  CADP_m/CATP_m ( Seis 
1982) 
rs_i_CoQ 0.391753 
Set equal to steady state  CCoQH2_m/CCoQ_m ( Seis 
1982) 
Vmax_CitSase 190 mM Reich and Selkov, 1981 
Keq_CitSase 1.10E+06 Reich and Selkov, 1981 
KmOAA_CitSase 0.002 mM Sheperd and Garland, 1969 
KmAcCoA_CitSase 0.016 mM Sheperd and Garland, 1969 
KiCIT_CitSase 16 mM Smith and Williamson, 1971 
KiCoA_CitSase 0.675 mM Smith and Williamson, 1971 
KiATP_CitSase 0.55 mM Sheperd and Garland, 1969 
KiADP_CitSase 1.4 mM Sheperd and Garland, 1969 
KiAMP_CitSase 6.7 mM Sheperd and Garland, 1969 
KiSucCoA_CitSase 0.14 mM Smith and Williamson, 1971 
Kia_CitSase 0.00333 mM Kohn et al. 1981 
Vmax_aconitase 255.102 mM/min Reich and Selkov, 1981 
Keq_aconitase 0.05555 Reich and Selkov, 1981 
K_CIT 1.43224 mM/min 
Calculated from  in vivo TCA flux  (Jin et al. 
2004), in vitro Vmax_aconitase and steady state 
of CIT(m), and Iso_cit concentrations 
K_Iso_cit 0.15306 mM/min Set equal to steady state Iso_cit concentration 
Vmf_icdh 51.02 mM/min Reich and Selkov, 1981 
Ki_nad_icdh 0.0776 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Ki_nadh_icdh 0.475 mM --- 
Km_nad_icdh 0.5 mM --- 
Km_icit_icdh 0.1489 mM --- 
n_icdh 3 Kohn et al. 1979; Kohn and Garfinkel, 1983 
a_icdh 0.0004 --- 
Ka_ADPm_icdh 61.3 mM Plaut et al. 1979 
Keq_ICDH 1200 Reich and Selkov, 1981 
Vmf_akgdh 204.082 mM/min Reich and Selkov, 1981 
Ki_succoa_akgdh 0.0069 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Ki_nadh_akgdh 0.0006 mM Wu et al. 2007 
Km_akg_akgdh 0.08 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Km_coa_akgdh 0.055 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Km_nad_akgdh 0.021 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Ka_ADPm_akgdh 0.1 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Ki_atp_akgdh 0.05 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Keq_AKGDH 60000 Reich and Selkov, 1981 
Vmax_SCoAsynt 255.102 mM/min Reich and Selkov, 1981 
Km_SCoAsynt 61.4484 mM 
Set equal to +50% of product  steady state of 
GDP(m), SucCoA(m) and Pi(m) concentrations 
Km_SCoAsynt_r 1.21102 mM 
Calculated from  in vivo flux of TCA  (Jin et al. 
2004), and  steady state GDP(m), TP(m), 
SucCoA(m) CoA(m) and Pi(m) concentrations 
Keq_SCoAsynt 3.7037 Reich and Selkov, 1981 
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Vmax_SDH 510.204 mM/min Reich and Selkov, 1981 
Km_SDH 12.2075 mM Kohn et al. 1981 
Km_SDH_r 0.0199182 mM/min Kohn et al. 1981 
Keq_SDH 1.1 Reich and Selkov, 1981 
Vmax_Fumase 3061.22 mM/min Reich and Selkov, 1981 
K_FUM 1.27551 mM Set equal to steady state FUM concentration 
K_MAL 95.4716 mM 
Calculated from  in vivo TCA flux (Jin et al. 
2004),  in vitro Vmax_CL and steady state of  
MAL(m), FUM(m) concentrations 
Keq_Fumase 12 Reich and Selkov, 1981 
Vmf 4591 mM/min Reich and Selkov, 1981; Shonk and Boxer, 1964 
KmA 0.09055 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KmB 0.25 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KmP 0.00613 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KmQ 0.00258 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kia 0.279 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kib 0.36 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kip 0.0055 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kiq 0.00318 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KiATP_MDH 0.1832 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KiADP_MDH 0.3944 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KiAMP_MDH 0.42 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Vmf_c 892 mM/min Reich and Selkov, 1981; Shonk and Boxer, 1964 
KmA 0.09055 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KmB 0.25 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KmP 0.00613 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KmQ 0.00258 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kia 0.279 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kib 0.36 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kip 0.0055 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Kiq 0.00318 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KiATP_MDH 0.1832 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KiADP_MDH 0.3944 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
KiAMP_MDH 0.42 mM Kohn et al. 1979; Kohn and Garfinkel, 1983 
Keq_MDH_c 2.80E-05 Reich and Selkov, 1981 
Vmfc_AsAT 803.571 mM/min Reich and Selkov, 1981 
Km_ASP_AsATc 3.9 mM Henson and Cleland, 1964 
Km_AKG_AsATc 0.43 mM Henson and Cleland, 1964 
Km_OAAm_AsATc 0.0088 mM Henson and Cleland, 1964 
Km_GLUT_AsATc 8.9 mM Henson and Cleland, 1964 
Ki_ASP_AsATc 3.48 mM Henson and Cleland, 1964 
Ki_AKG_AsATc 0.71 mM Henson and Cleland, 1964 
Ki_OAAm_AsATc 0.05 mM Henson and Cleland, 1964 
Ki_GLUT_AsATc 8.4 mM Henson and Cleland, 1964 
KIn_AKG_AsATc 16.6 mM Henson and Cleland, 1964 
Vmf_AsAT 7653.06 mM/min Reich and Selkov, 1981 
Km_ASP_AsAT 3.9 mM Henson and Cleland, 1964 
Km_AKG_AsAT 0.43 mM Henson and Cleland, 1964 
Km_OAAm_AsAT 0.0088 mM Henson and Cleland, 1964 
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Km_GLUT_AsAT 8.9 mM Henson and Cleland, 1964 
Ki_ASP_AsAT 3.48 mM Henson and Cleland, 1964 
Ki_AKG_AsAT 0.71 mM Henson and Cleland, 1964 
Ki_OAAm_AsAT 0.05 mM Henson and Cleland, 1964 
Ki_GLUT_AsAT 8.4 mM Henson and Cleland, 1964 
       KIn_AKG_AsAT          16.6 mM Henson and Cleland, 1964 
Keq_AsAT 0.151515 Reich and Selkov, 1981 
X_AKGMAL 21798 mM/min Wu et al. 2007 
KiAKG_c 0.03 mM Indiveri et al. 1991 
KiAKG_m 0.17 mM Indiveri et al. 1991 
KiMAL_c 1.4 mM Indiveri et al. 1991 
KiMAL_m 0.07 mM Indiveri et al. 1991 
KiASP_c 0.028 mM Dierks et al. 1988 
KiASP_m 2.8 mM Dierks et al. 1988 
KiGLUT_c 0.18 mM Dierks et al. 1988 
KiGLUT_m 1.6 mM Dierks et al. 1988 
Kh_ASPGLUT 3.16E-07 mM Dierks et al. 1988 
Keq_ASPGLUT 0.1 Dierks et al. 1988 
m 1.8 Dierks et al. 1988 
Vmax_AK_c 142.85 mM/min Reich and Selkov, 1981 
Km_AK_c 1.0042 mM Set equal to steady state ADP(c) concentration 
Km_AK_c_r 0.297066 mM 
Set equal to product  steady state of ATP(c) and 
AMP(c) concentrations 
Keq_AK_c 1.2 Reich and Selkov, 1981 
Vmax_ndk_c 75.8929 mM/min Reich and Selkov, 1981 
Km_ndk_c 0.3277 mM/min 
Set equal to product  steady state of GTP(c) and 
ADP(c) concentrations 
Km_ndk_c_r 0.30277 mM 
Set equal to product  steady state of GDP(c) and 
ATP(c) concentrations 
Vmax_ndk_m 127.551 mM/min Reich and Selkov, 1981 
Km_ndk_m 4.35839 mM 
Set equal to product  steady state of GTP(m) and 
ADP(m) concentrations 
Km_ndk_m_r 5.51728 mM 
Set equal to product  steady state of GDP(m) and 
ATP(m) concentrations 
Vmax_GDH 170.068 mM/min Reich and Selkov, 1981 
Km_GDH 17.9592 mM 
Set equal to product  steady state of NAD+(m) 
and GLUT(m) concentrations 
Km_GDH_r 0.176327 mM 
Set equal to product  steady state of NADH(m) 
and AKG(m) concentrations 
Keq_GDH 0.004 Reich and Selkov, 1981 
Vmax_FA_a_m 4.825 mM/min 
Calculated from RFA_a_m flux (Christian and 
Christian, 1983) from FBA and steady state 
FA_a concentration 
Km_FA_a 0.516071 mM Set equal to steady state of FA_a concentration 
Vmax_FA_CoA 7.0068 mM/min Reich and Selkov, 1981 
Km_FA_CoA 0.5126 mM 
Set equal to product  steady state of FA(m) and 
CoA(m) concentrations 
Vmax_GTP_AMP 51 mM/min Reich and Selkov, 1981 
Km_GTP_AMP 0.33 mM 
Set equal to product  steady state of AMP(m) 
and ATP(m) concentrations 
Km_GTP_AMP_r 4.14 mM Set equal to product  steady state of GDP(m) and 
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ADP(m) concentrations
Keq_GTP_AMP 0.8 Reich and Selkov, 1981 
Vmax_b_c_lac 73.1455 mM/min 
Calculated from  in vivo flux (Christian and 
Christian, 1983) and steady state of  LAC(b) 
concentration 
Km_b_c_lac 1.5 mM Set equal to steady state LAC (b) concentration 
Vmax_b_c_glc 9.07893 mM/min 
Calculated from  in vivo flux (Christian and 
Christian, 1983)  and steady state of  GLC(b) 
concentration 
Km_b_c_glc 5.07 mM Set equal to steady state GLC (b) concentration 
Vmax_b_c_PYR 8.375 mM/min 
Calculated from  in vivo flux (Christian and 
Christian, 1983) and steady state of  PYR(b) 
concentration 
Km_b_c_PYR 0.075 mM Set equal to steady state PYR (b) concentration 
Vmax_c_b_BHB 50.0085 mM/min 
Calculated from  in vivo flux (Christian and 
Christian, 1983) and steady state of  BHB(b) 
concentration 
Km_c_b_BHB 0.85 mM Set equal to steady state BHB (b) concentration 
Vmax_c_b_AcAc 23.6504 mM/min 
Calculated from  in vivo flux (Christian and 
Christian, 1983  and steady state of  AcAC(b) 
concentration 
Km_c_b_AcAc 0.7 mM Set equal to steady state Ac Ac(b) concentration 
Vmax_c_m_PYR 42.85 mM/min *adjusted to maintain Pyruvate flux 
Km_c_m_PYR_PYR 0.175 mM *adjusted to maintain Pyruvate flux 
Km_c_m_PYR_OH 1.58E-05 mM 
Set equal to product  steady state of PYR(c) and 
OH(m) concentrations 
Km_c_m_PYR_AcAc 0.61 mM 
Set equal to product  steady state of PYR(c) and 
AcAc(m) concentrations 
Vmax_c_m_CIT 2.25633 mM/min 
Calculated from RCIT_c_m flux from FBA and 
steady state  CIT(c) CIT(m), MAL(c), and 
MAL(m) concentrations 
Km_c_m_CIT 0.019425 mM Seis 1982 
Vmax_c_m_MAL 257.143 mM/min Hanson and Mehlman, 1981 
Km_c_m_MAL 0.02415 mM Hanson and Mehlman, 1981; Seis 1982 
Vmax_c_m_GLUT 99.6429 mM/min Hanson and Mehlman, 1981 
Km_c_m_GLUT 0.4725 mM Hanson and Mehlman, 1981; Seis 1982 
Vmax_FA_c_m 4.825 mM/min 
Calculated from RFA_a_m flux from FBA and 
steady state FA_a concentration 
Km_FA_c_m 0.5161 mM Set equal to steady state of FA_a concentration 
Vmax_c_m_AcAc 43.0581 mM/min *adjusted to maintain AcAc flux 
Km_c_m_AcAc 10.7143 mM 
Set equal to steady state of AcAc(m) 
concentration 
Vmax_c_m_pi 209.184 mM/min Hanson and Mehlman, 1981 
Km_c_m_pi 0.168 mM Hanson and Mehlman, 1981 
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Table 4.3.  Initial cytosolic, mitochondrial and blood concentrations, representing 24 hour fasted state. The 
following concentrations were set as constants: NADH_total_c= 0.801361mmol/L cyt water1,4,5,7,9; 
NADH_total_m= 2.4 mmol/L mit water1,4,5,7,9; F26BP=0.000143 mmol/L cyt water1; cAMP=0.0075 
mmol/L cyt water; Pi_c= 8.5 mmol/L cyt water1; Pi_m=9.5 mmol/L mit water1; OH_c= 0.00016 mmol/L 
cyt water1; OH_m= 0.000251mmol/L mit water1; CoQ_total= 1.35 mmol/L mit water1. 
*: subcellular metabolie distribution in isolated hepatocytes from 48 hr starved rats incubated with lactate 
Mitochondrial metabolite concentrations 
mmol/L mit water 
PYR_m 0.13581,3,4,x* 
OAA_m 0.00111 
AcCoA_m 0.98091 
CIT_m 3.19891 
MAL_m 1.23461 
Alpha_KG_m 0.44081 
ASP_m 1.93871 
GLUT_m 8.97951 
ATP_m 14.91161,8 
ADP_m 11.20411,8 
AMP_m 0.85031,8 
GTP_m 0.3897 
GDP_m 0.377 
BHB_m 30.44211,3,5 
AcAc_m 10.71421,3,5 
NADH_m 0.41,4,5,7,9 
CoA_m 2.82141,7* 
Iso_cit 0.1531,7 
SucCoA 12.58501,7 
SUC 12.58501,7 
FUM 1.27551,7 
FA_m 0.18711,7 
FA_acylCoa 0.18711,7 
CoQh2 0.38c,7 
CoQ 0.971,7 
   
 
 
 
 
         
  
 
                                                                   
Citations: 
1: Bergmeyer 1994       6: Huang 1997      
2: Christian and Christian 1983  7: Sies 1982 
3: Krebs 1967    8: Hems et al. 1966 
4: Stubs et al. 1972    9:Williamson et al. 1969a 
5: Williamson et al. 1970                                               
 
Cytosolic metabolite concentrations 
mmol/L cyt water 
PYR_c 0.06961,3,4,7* 
OAA_c 0.0004171c7* 
AcCoA_c 0.080931,7* 
CIT_c 0.25341,7* 
MAL_c 0.18431,7* 
Alpha_KG_c 0.14651,7* 
ASP_c 1.15361,7* 
GLUT_c 3.77141,7* 
ATP_c 3.32711,8,7* 
ADP_c 1.00211,8,7* 
AMP_c 0.08931,8,7* 
GTP_c 0.3277,7* 
GDP_c 0.0917,7* 
BHB_c 2.67861,3,5 
AcAc_c 0.89291,3,5 
NADH_c 0.001361,4,5,7,9 
CoA_c 0.05641,7* 
LAC_c 1.35712 
PEP 0.07091 
PG2 0.26791 
PG3 0.13571 
DHAP 0.02321 
GAP 0.030364,5 
F16BP 0.023211 
F6P 0.066071 
G6P 0.14641 
GLC_c 8.92851 
GR3P 0.44641 
GLR_c 0.17851 
FA_c 0.51611 
glycogen 157.1431 
Blood metabolite 
concentrations mM 
FA_b 0.6732c 
LAC_b 1.51,3,5 
ALA_b 0.72 
GLC_b 5.072 
BHB_b 0.852,6 
AcAc_b 0.72,6 
PYR_b 0.0752 
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4.2.2 Model of the Perfused Liver  
     The liver tissue is represented by four distinct compartments, representing the cytosol, 
the mitochondria, the blood, and the perfusate.  Each compartment is assumed to be well-
mixed. The dynamic mass balance for each species i in the blood domain is given by: 
 
 
The content of the blood domain is actually the saline perfusion medium rather than 
blood, and Eqn. 4.1 is only written for those metabolic intermediates expected to occur in 
the blood/saline perfusate (i.e. GLC, LAC, ALA, AcAc, BHB, GLR, PYR, FA). 
     In the cytosol the dynamic mass balance equation for species i is decribed as: 
 
 
In the mitochondrial domain, the dynamic mass balance equation for species i is given 
by: 
                                                                                                    
 
The perfusion medium is represented by the following mass balance for each metabolic 
intermediate that exists in the blood domain:  
                                                                                            
                         
Ci,cytosol,  Ci,mitochondria,  Ci,blood,  and Ci,perfusate  are concentrations of species i in the cytosol, 
mitochondria, blood, and perfusate domains, respectively;  J i,b-c  is the transport rate 
between the blood and cytosol domains, while J i,c-m  is the transport rate between the 
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cytosol and the mitochondria domains.  J i,b-c  and J i,c-m  are both expressed in units of 
mΜ(cytosol) min-1;  Ri,j,c  is the rate of each reaction j,  with species i as substrate or 
product,  taking place in the cytosol; Ri,k,m  is the rate of each reaction k, with species i as 
substrate or product,  taking place inside the mitochondrial compartment;  Fblood  is the 
flow rate through the liver.  The ratio of cytosol volume to blood volume (Vcytosol/Vblood ) 
is used for conversion of units of J i,b-c  from cytosol volume units to blood volume units, 
whereas (Vcytosol/Vmitochondria ) is used for conversion of units of J i,c-m  from cytosol volume 
units to mitochondria volume units. 
     The model consisted of a total of 108 mass balances (Equations 4.1-4.4), representing 
40 different species distributed among the four different compartments (Table 4.3). The 
set of differential equations were solved simultaneously using ODE 45 in Matlab.  
 
4.2.3 Parameter Estimation and Simulation Strategy 
     Since there are few experimental data compared to the large amount of model 
parameters, it is infeasible to perform a complete parameter estimation process.  As 
determined in Chapter III, the distribution of NADH and NAD+ between the cytosol and 
mitochondria is a critical aspect in controlling gluconeogenesis and predicting more 
accurate flux distributions.  To reconcile the simulated redox ratios with experimental 
ones during gluconeogenesis, the sensitivities of concentrations of NADHc and NADHm 
to each kinetic parameter were calculated at the overnight fasted in vivo steady state 
condition, using: 
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Partial derivatives were estimated by central finite differences.  The parameters with the 
greatest sensitivities, shown in Fig. 4.2, were then manually tuned such that the model 
simulations yielded the best fit for both cytosolic and mitochondrial NADH 
concentrations at the quasi steady states representing overnight fasted (Table 4.3), lactate 
perfusion, and lactate plus oleate perfusion (Fig 4.3A).  In addition, several other 
parameters were found to significantly affect the predicted redox ratios and important 
fluxes.  Altogether, a total of nine parameters were adjusted from the original values 
(from either in vitro data or from use in previous models). These nine parameter values 
are given in Table 4.4.  
 
Table 4.4  Parameters with the largest magnitude of sensitivity to NADHc and NADHm, with original 
values and after model tuning. Units are given in Table 4.2. 
Kinetic 
parameters 
Original kinetic 
values 
Kinetic values 
after tuning 
n3_pc 1.65 2.75 
Vmax_atp_adp_c 35.4104 55.41 
Km_atp_adp_c 3.32 17.2 
Keq_MDH_m 0.000028 0.00028 
Km_PEPCK 0.00040179 0.0040179 
X_ASPGLUT 44.88 448.8 
Km_bhb 2.846003 0.2846 
K_amp 0.182758621 1.8759 
K_atp1_pk 0.75 0.0075  
      
 
     The mathematical model, with the fine tuned parameters as described above, was then  
used to simulate the perfused rat liver, with additions of lactate and pyruvate, without and 
with  fatty acids, according to different perfusion protocols. These perfusion protocols 
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with input functions are summarized in Table 4.5.  The initial conditions for the variables 
in Eqns. 4.1-4.3 are given in Table 4.3.  Initial conditions for Eq. 4.4 are: 
 
                    Ci,perfusate (0)  =0 for i=Glc, LAC, PYR, BHB, AcAc                  (4.6) 
 
(i.e. the saline pre-perfusion contains no substrate). The simulations were used to 
investigate the effects of lactate, pyruvate, and fatty acids on the dynamics of cytosolic 
and mitochondrial NADH  and a wide range of fluxes reflecting rates of gluconoegenesis, 
TCA cycle, ketogenesis, and specific carbon shuttles.  No parameters were changed 
between all the subsequent simulations, unless explicitly stated.   
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.2.  Absolute values of the normalized sensitivities of the most sensitive parameters to  NADH for 
the lactate perfusion model; (A) cytosolic NADH; (B) midochondrial NADH. 
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Table 4.5.  Input functions used in simulation of the perfused liver. RFA-endo=rate of endogenous fatty acid 
oxidation, normalized to µmol C16 (palmitate); J*FA-b-t = the sum of the uptake rate of FFA and rate of 
endogenous fatty acid oxidation  
Lactate Perfusion 
Saline pre-perfusion; 
 0 < t ≤ 30 
Lactate infusion;  
30 < t ≤  120 
Lactate + FA;  
90 < t ≤ 120 
RFA-endo = 0.15 
µmol(Lcyt water )-1min-1, 
assumed to be equal to  
experimental 
measurements of ketone 
production during this 
period26.   
 
RFA-endo = 0.08178 
µmol(Lcyt water )-1min-1, 
 as estimated26 from ketone 
production.   
 
CLAC,,perfusate = 
10(1-exp(-(t-30)/τ) mM 
(constant LAC 
concentration of 10 mM in 
perfusate); τ is time constant 
for achieving change in 
susbstrate concentration, set 
to 4 min. 
J*FA-b-t=  
0.08178+0.466(1-exp(-(t-90) /τ), 
τ=2.5 min; total rate of 0.5874 
µmol(Lcyt water )-1min-1 determined  
from experimental measurements of 
oleate infusion26.  
 
CLAC,,perfusate =10 mM 
 
 
Pyruvate Perfusion 
Saline pre-perfusion; 
 0 < t ≤ 30 
Pyruvate infusion;  
30 < t ≤  120 
Pyruvate + FA;  
90 < t ≤ 120 
RFA-endo = 0.15 
µmol(Lcyt water )-1min-1 
RFA-endo =0.08178 
µmol(Lcyt water )-1min-1 
CPYR,,perfusate = 
2(1-exp(-(t-30)/ τ) mM 
(constant PYR 
concentration of 2 mM in 
perfusate); τ=3 min. 
 
CLAC,,perfusate calculated from 
Eqn. 3.  
J*FA-b-t = 
0.08178+0.466(1-exp(-(t-90) /τ), 
τ=2.5 min; total rate of 0.5874 
µmol(Lcyt water )-1min-1 determined  
from experimental measurements of 
oleate infusion26.  
 
CPYR,,perfusate =2 mM 
 
 
 
4.3 Results 
     Fig. 4.3A shows that the predicted redox ratios in both the cytoplasm and the 
mitochondria are in very good agreement with the experimental results with lactate and 
fatty acids (Williamson et al. 1969). The simultaneous shift in the mitochondrial and the 
cytosolic redox ratios are obvious upon stimulation with fatty acid, and these correlate 
extremely well with the experimental observations.   Also note that the order-of-
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magnitude difference between cytosol and mitochondria ratios is predicted accurately by 
the model.   The results with 2 mM pyruvate in place of lactate (Fig. 4.3B) further 
confirm that the model gives results in general agreement with the physiological findings, 
both before and after addition of fatty acids.  This reflects an improvement from the 
single-tissue compartment model (Chapter III), which could not distinguish between 
cytoslic and mitochondrial redox ratios.  
     While the lumped-tissue model of Chapter III closely predicted  the  gluconeogenesis 
flux during simulation with lactate and fatty acid,  the rates of glucose production, 
ketogenesis, and several other metabolic rates were underestimated under pyruvate 
simulation (Fig. 3.5).   We attributed the discrepancy of these results between lactate and 
pyruvate to a different scheme for metabolite and reducing equivalent transport across the 
mitochondrial membrane in each case. While lactate provides directly the reducing 
equivalent to the GAPDH in the cytosol through LDH, pyruvate, on the other hand, needs 
to use a specific shuttling mechanism to provide the necessary reducing equivalents for 
GAPDH.  
     The calculated net malate transport in the pyruvate perfusion agrees closely with 
experimental value and transport direction from the mitochondria to the cytosol (Fig. 
4.3B). Moreover the model predicts a larger transport rate through the malate-phosphate 
shuttle compared to malate alpha-ketoglutarate exchange (Fig. 4.4B).  This latter result 
corresponds well with experimental observations (Robinson et al., 1967; Meijer et al. 
1969) on the important role of malate-phosphate exchange in malate efflux and its 
relative role in driving the gluconoegenesis pathway.   
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Figure 4.3.  Redox ratio (NADH/NAD) and fluxes calculated from perfusion model with (A) lactate and 
(B) pyruvate as substrate.  Initial conditions represent the in vivo 24-hour fasted state. Symbols are 
experimental data from perfused fasted livers, from Williamson, et al. 1969a, 1969b, 1970a, using a 
perfusion medium of  Krebs-Henseleit bicarbonate buffer, with 4% bovine serum albumin, in a recirculated 
system. Closed circle: pre-perfusion with no substrate; open circle: perfusion with (A) 10 mM lactate or (B) 
2 mM pyruvate; star (*, at 120 min): perfusion with 1.5 mM oleate added to previous substrate.  Solid and 
dashed lines are simulations, using Eqns. 4.1,3 and 4, with Fperfusate=50 ml/min and Vperfusate=100 ml 
(corresponding to the experimental protocol), and all other parameters as given in Tables 4.1. Solid lines: 
10 < t ≤ 30 min: saline pre-perfusion (no substrate); 30 < t ≤ 120 min: perfusion with 10 mM lactate or 2 
mM pyruvate. Dashed lines: 90 < t ≤ 120 min: lactate or pyruvate plus 1.5 mM FA perfusion.  
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     Aspartate efflux from the mitochondria was found to be negligible during pyruvate 
perfusion alone (Fig. 4.3B, GLUT:ASP transport), while the GLUT:ASP exchange is 
four-fold greater than net malate transport during lactate perfusion (Fig. 4.3A), in good 
agreement with several studies (Wieland 1968; Krebs et al. 1967; Williamson et al. 1968, 
1969a, 1969b, 1969c, 1969d).  The movement of aspartate into and out of the 
mitochondria is tightly linked to the rate of transamination between aspartate and 
glutamate on both sides of the membrane. As Fig. 4.3A indicates for lactate perfusion, the 
OAA formed in the mitochondria is converted to aspartate, and after being transported to 
the cytosol, aspartate is converted back to OAA, by the mitochondrial and cytosolic 
aspartate aminotransferases, respectively. Therefore the carbon requirements for 
gluconoegenesis are met by the transport of asparate to the cytosol.  Note that the value 
of the flux in the mitrochondria appears to be 10 times that of the cytosolic flux; this 
results from the different compartment volume units used,  since the mitochondrial 
volume is about 1/10 that of the cytosolic volume. However, during pyruvate simulation, 
malate acts both as transporter of the carbon and the reducing equivalents from the 
mitochondria to the cytosol.  The computed rates and directions of the cytosolic and 
mitochondrial MDH agree with the estimated rates provided by Williamson et al. (1970) 
during the lactate and pyruvate perfusions with and without oleate (Fig. 4.3A,B).  
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Figure 4.4.  Fluxes calculated from perfusion model with (A) lactate and (B) pyruvate as substrates.  
Simulation and experimental details given in Figure 4.3 caption.  
 
       
     Cytosolic pyruvate, whether from the perfusion medium, or from oxidation of lactate 
by LDH,  is transported to the mitochondria by specific carriers, the most notable one 
being the pyruvate-hydroxyl ion carrier (Brouwer et al. 1973; Halestrap, 1975; Halestrap 
et al. 1974; Papa et al. 1974, 1971; Mowbray, 1975).  Fig. 4.4 shows a net transport of 
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pyruvate from cytosol to mitochondria during lactate and pyruvate simulations. The 
subsequent addition of fatty acids to either lactate or pyruvate further increased the rate of 
pyruvate transport to the mitochondria, agreeing well with fluxes estimated by 
Williamson.  A continuous supply of pyruvate to the mitochondria is necessary for many 
metabolic rates, most importantly the pyruvate carboxylase which is an important 
intermediate step in gluconoegenesis.  
      The rate of pyruvate carboxylase (PC) increases upon addition of oleate to lactate and 
pyruvate (Fig. 4.4), in coordination with the  increase in the rate of  pyruvate entry from 
the cytoplasm to the mitochondria.  However, this increase in PC flux is not primarily 
due to the greater availability of pyruvate.  Instead,  the current model (as did the Chp III 
model) accounts for the activation of PC by AcCoA.  The addition of exogenous oleate 
enhances the rate of fatty acid oxidation in the mitochondria, subsequently increasing the 
mitochondrial redox ratio and the concentration of the mitochondrial AcCoA (not 
shown).  Conversely, the rate of pyruvate dehydrogenase (PDC) is inhibited during the 
addition of fatty acids in both the lactate and pyruvate scenarios, due to inhibition of PDC  
by mitochondrial redox ratio and  AcCoA.  
     The rates of gluconoegenesis produced under the two different gluconoegenic 
substrates correspond well with the experimental data (Fig. 4.5). The glucose production 
rate approximately doubles in response to oleate addition. The conversions, by mass, of 
pyruvate and lactate to glucose are 80 % and 70% respectively, compared to 55 and 65% 
found by Williamson et al. (1970, 1969). However, a higher conversion of pyruvate to 
glucose (around 80%) was reported when oleate was added to the perfusion medium. 
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Figure 4.5.  Fluxes calculated from perfusion model with (A) lactate and (B) pyruvate as substrates.  
Simulation and experimental details given in Figure 4.3 caption.  
 
     The rates of ketogenesis (i.e. total ketones, as measured by the rate of synthesis of 
AcAc, and BHB production) agree very closely with the experimental data (Fig. 4.5), 
showing a reduction during the perfusion period of pyruvate or lactate and a rapid 
increase upon stimulation with fatty acids.  
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     The citric acid cycle estimated in the model appears to be less active than the 
experimental results during lactate and pyruvate perfusions; however these results are 
still consistent with the directional change of the cycle, especially during enhanced fatty 
acid oxidation (Fig. 4.6).  The simulations overestimate the activation of the TCA cycle 
by oleate compared to the data as measure by citrate synthase (i.e. lactate: 117% 
simulated vs. 9% data;  pyruvate: 105% simulated vs.40% data). It is worth noting that 
the TCA fluxes  in Williamson et al. were not measured directly; rather, they were 
calculated from measurements of the respiratory activity and the metabolic balance of 
substrates across the liver, and involved several assumptions that might alter the 
estimates of the fluxes. Moreover, the authors themselves mentioned the need for 
reinterpretation of their TCA cycle flux calculation, especially in the case of lactate 
perfusion, where oleate addition appeared to cause only a small increase in the TCA 
cycle rate. 
     The calculated rate of oxygen consumption matches closely the data during the lactate 
plus oleate perfusion (Fig. 4.6), however the calculated baseline after the pre-perfusion is 
lower than the data; therefore the model seems to overestimate the stimulation of oxygen 
uptake by lactate and oleate. The model predicts an increase in oxygen consumption by 
115% upon lactate addition compared to a measured 23% increase. The subsequent 
addition of oleate caused a 50% increase as reported by Williamson, while our model 
predicts an increase of 130%.  
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Figure 4.6.  Fluxes and ATP/ADP ratios calculated from perfusion model with substrates: (A) lactate and 
(B) pyruvate. Simulation and experimental details given in Figure 4.3 caption.  
 
     The ADP:ATP transport across the mitochondrial membrane requires a carrier known 
as the ADP:ATP translocase. It is highly specific and permits the efflux of ATP 
synthesized in the mitochondria in exchange for ADP.  The simulated translocation flux 
(Fig. 4.6)  indicates a clear transport of ADP from the cytosol into the mitochondria in 
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exchange for ATP, in accordance with various experimental results. The addition of 
oleate increases the rate of respiration, increasing the amount of mitochondrial ATP, 
therefore increasing the rate of ADP:ATP translocase.  The model results agree well with 
this expected chain of events. The model supports the non-uniform distribution of 
adenine nucleotides between the cytosol and the mitochondria, with 40% of the overall 
tissue adenine nucleotides found in the mitochondria, compared with 27% reported 
experimentally (Soboll et al. 1978). The overall tissue ATP/ADP ratio predicted by the 
model (Fig. 4.6) is equal to 1.5 and 0.84 for lactate and pyruvate perfusion, respectively. 
The ratio was significantly lower than the one found by Williamson et al. We then 
examined the cytosolic and mitochondrial ATP/ADP ratios. Our model predicts the 
cytosolic and mitochondrial ATP/ADP ratios to be similar, at 1.4 and 1.6, respectively, 
(Fig. 4.6) during lactate perfusion, while most studies show an asymmetry between the 
two ratios, with higher cytosolic ratio compared to the mitochondrial ratio.  Experiments 
with hepatocytes showed a much higher mitochondrial ATP/ADP ratio of about 2.0, 
compared to perfused tissues or intact animals (Akerboom et al. 1978; Sies and Wieland 
1976;  Sobol et al, 1980). It is generally known that during the state of low-energizing, or 
even de-energized mitochondria, the mitochondrial ATP/ADP ratio is increased and the 
difference between cytosolic and mitochondrial ATP/ADP ratios is greatly decreased. 
Livers from starved animals are unable to meet their ATP requirements due to lack of 
glycogen, and the energization of their mitochondria is much lower than in fed animals,  
and thus one may expect a reduced difference in ATP/ADP ratios between the cytosol 
and the mitochondrial compartment.  
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     Fig. 4.7  Adenine nucleotide concentrations calculated from perfusion model with lactate as substrate.  
Details given in Fig. 4.3 caption.  
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    The addition of oleate to either lactate or pyruvate causes an increase in the tissue ATP 
concentration, and a rapid decrease in the AMP concentration and a decrease in the ADP 
concentration (Fig. 4.7); this seems to be in contrast to the experimental data which 
shows insensitivity to the addition of oleate to substrate.  
     The model was then used to simulate perfusions with both lactate and pyruvate 
simultaneously, with total concentration of lactate and pyruvate from 1 to 10 mM, and the 
lactate to pyruvate ratio maintained at  9.0.  Fig. 4.8 compares the predicted rates of 
glucose production and ketone formation to that found in different studies from 24 to 48-
hour-starved isolated liver cells. The results are in good agreement with experimental 
data, further validating our computational model’s ability to predict metabolic rates of the 
liver near physiological level conditions. 
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Figure 4.8.  Rates of glucose production and ketogenesis at different total concentrations of lactate and 
pyruvate in perfusion medium, with lactate/pyruvate ratio constant at  9/1.  Red bars are experimental data 
from starved liver slices incubated with lactate and pyruvate (Soling et al., Kuhn et al.,  Janson et al). Blue 
bars are simulations, using Eqns. 4.1,3 and 4, with Fperfusate=50 ml/min and Vperfusate=100 ml and all other 
parameters as given in Tables 4.1. The x-axis represents the total concentration of lactate and pyruvate in 
the perfusion medium, with a lactate/pyruvate ratio of 9/1 at all times. 
 137
4.4 Discussion 
     The compartmental model developed in this work successfully simulates the perfusion 
of a starved rat liver with substrates of lactate, perfusion, and oleate. It mimics the key 
metabolic rates involved in the liver metabolism and provides predictions of all the  
intermediate steps and their interactions.  The model successfully predicts the preferred 
mechanisms for anion transport and the indirect transfer of reducing equivalents across 
the mitochondrial membrane with respect to the perfused substrate.  When lactate is the 
gluconoegenic substrate, the model predicts that NADH is formed directly in the cytosol 
by oxidation of lactate to pyruvate, and aspartate is used to transport the carbon backbone 
from the mitochondria to the cytosol. This is consistent with the experimental 
observations  (Williamson et al 1968; Krebs et al 1976). The pyruvate model predicts the 
following scheme: transport of pyruvate to the mitochondria, formation of OAA through 
the pyruvate carboxylase, conversion of OAA to malate through the mitochondrial MDH, 
a net malate efflux toward the cytosol, and reconversion of malate to OAA in the cytosol. 
Therefore malate transport from the mitochondria provides both the carbon and reducing 
equivalents to support the gluconeogenesis metabolism in the rat liver, in accordance 
with several experimental observations (Meijer et al. 1974; Rongstad et al. 1972; Soling 
et al.1973).  
     The model serves as a tool to monitor the values of intermediate fluxes which are 
difficult to measure directly.   Transamination between glutamate and aspartate was noted 
in both perfusion models. However these rates are higher with lactate than with pyruvate, 
while the net malate efflux is obviously higher with pyruvate than with lactate.  Malate 
exchange can be accomplished through specialized carriers, such as MAL:Pi, 
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MAL:AKG, and Mal:CIT.  The efflux through MAL:Pi was predominant over the other 
carriers with pyruvate as substrate. This is consistent with observations on the role of 
MAL:Pi in supporting gluconoegenesis, where the use of MAL:Pi inhibitors lead to 
inhibition of  gluconeogenesis from pyruvate and alanine in rat liver (Chamalaun et al. 
1971; Williamson et al. 1970).  Thus, the model can provide insight into the function and 
directional movement of the cytosol-mitochondrial transporters in other situations where 
direct measurements are not available.      
     The simulation with fatty acids results in an increase in the rate of malate transport 
from the mitochondria. The NADH generated by the cytsolic malate dehydrogenase 
increases the redox ratio and allows the glyceraldehyde dehydrogenase reaction to use the 
extra NADH to drive further the rate of gluconoegenesis. It is evident that the addition of 
fatty acid has increased both the cytosolic and mitcochondrial redox ratios; these ratios in 
turn  increase the rates of gluconoegenesis and ketogenesis, respectively. In addition,  
simulations of  fatty acid perfusion with either lactate or pyruvate resulted in an 
appropriate increase in oxidative phopsphorylation and the TCA cycle fluxes.   
     The model was able to predict a cytosolic ATP/ADP ratio which reflects the tissue-
average ATP/ADP ratio according to Soboll et al. (1978). The major limitations of the 
model are: its inability to mimic an asymmetry in ATP/ADP between the mitochondria 
and cytosol; and its underestimation of the ratio compared to experimental data (Fig. 4.6).  
A simplification of the oxidative phosphorylation mechanism representation which lumps 
the ATPase reaction with the oxygen consumption rate is possibly responsible for the 
mismatch between the simulations and the expected experimental data.  Furthermore, it 
has been suggested that the rate of respiration of isolated mitochondria is controlled by 
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the external phosphate potential (Davis et al. 1974, 1975; Owen and Wilson, 1974; Slater 
et al, 1973).  It has also been shown that the mitochondrial ATP/ADP ratio is independent 
of the cytosolic ATP/ADP ratio and the respiratory rate (Klingenberg, 1972 and Davis et 
al., 1974, 1975). The model predicts higher concentrations of ADP and AMP in the 
mitochondria than in the cytosol, which correspond well with Soboll et al.   The difficulty 
in accurately predicting ATP and ADP levels in each compartment indicates the need for 
a better representation of the ADP translocase. 
     The ADP translocase reaction is partially electroneutral and partially electrogenic with 
a 50 to 70 % proportion for the latter. This implies that the membrane potential plays an 
important role in the transport of the nucleotides and results in a higher ATP/ADP ratio 
on the outside of the membrane than on the inside of the mitochondria (Klingenberg 
1970, 1972, 1973).  The cytosolic and mitochondrial Pi concentrations in the model were 
assigned constant values, with the mitochondrial value slightly higher than in the 
cytosolic (Table 4.3).  
     The model is able to account for the rate of pyruvate recycling through the pyruvate 
kinase without affecting the overall rate of gluconoegenesis, therefore giving more 
credibility to the model. The estimated rate of pyruvate kinase during the pyruvate 
simulation constituted 30% of the rate of gluconeogenesis (Fig. 4.4), which agrees well 
with various observations from (Friedman et al .1971; Petersen et al. 1994; Jones et al. 
1997). The incorporation of pyruvate kinase in our model predicts higher rates of PC and 
PEPCK when compared to Williamson et al. since these authors neglected the presence 
of recycling in their calculations.  
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     The computer simulation predicted a lower rate of TCA cycle than that reported in the 
experimental results from Williamson et al  (1969) for either lactate or pyruvate 
perfusion; however, many uncertainties accompanied their method of TCA estimation, as 
admitted by the authors.    
     This enhanced version of the model of liver metabolism solidifies our ability to 
represent the interrelationship between the gluconoegenesis and lipid metabolism under 
different substrates and with varying concentrations by using a single set of parameters 
and reactions to simulate all these different conditions.  More importantly the model 
gives a reliable source for estimating the redox ratio in the cytosolic and the 
mitochondrial compartment allowing for better estimation of dependent metabolic rates. 
While the model does not explicitly account for hormonal regulation,  many of the 
regulated enzyme kinetic expressions account for regulation by cAMP, which is an 
indirect signal for insulin and glucagon effects.  The model successfully represents the 
elegant and specific transport mechanisms of metabolites, reducing equivalents, and 
anions across the mitochondrial membrane which is deemed essential for mammalian 
metabolism. The model will allow us to explore the specific distribution of metabolites in 
the different compartments and bridge the gap in the experimental data.  Moreover 
modeling these specific carriers will provide us a tool to predict the effect of transport of 
other metabolites or ions, such as those involved in calcium metabolism, which plays an 
important role in mitochondrial activities as an inhibitor and activator of PC and PDH, 
respectively. Also, the modeling of these carriers is important for modeling the 
interactions of various pharmaceutical agents with carbohydrate and lipid metabolism in 
the liver.  
 141  
 
 
 
 
 
 
 
 
 
CHAPTER V 
 
ETHANOL OXIDATION IN THE PERFUSED LIVER 
 
 
 
5.1 Introduction 
 
     Fourteen million Americans meet the criteria for alcohol abuse and/or dependence 
(Kim et al. 2002) and over 90% of these suffer from some aspect of  alcoholic liver 
disease (ALD) (Stickel et al. 2003).   Ten thousand Americans die each year from ALD  
(Kim et al. 2002).  The risk of being affected by ALD depends on a wide variety of 
factors and differs greatly between individuals, even when consuming similar amounts of 
alcohol.  Genetic factors, gender, and the existence of hepatitis C are some of the factors 
that influence a patient’s susceptibility to liver damage.   
     Dietary factors can influence the development and treatment of ALD. It has been 
shown that a high-fat, low-carbohydrate diet promotes liver damage in alcohol-fed rats 
(French et al.1995; Badger et al. 1998).  In humans, high amounts of polyunsaturated fats 
positively correlated with development of cirrhosis in humans, while cholesterol and 
saturated fats were negatively correlated (Nanjii et al. 1986).  Diets high in carbohydrates 
and protein and supplements of branched-chain amino acids have been shown to 
ameliorate ALD (Stickel et al. 2003).   
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      Pharmaceutical agents such as metadoxine and S-adenosyl-l-methionine have shown  
success in treatment of ALD  (Stickel et al. 2003).  Therapeutic use of antibodies to 
eliminate inflammatory cytokines have resulted in decreased liver injury in rats. The 
suppression of endotoxins in alcohol-fed rats has reduced the signs of liver damage 
(Nanji et al. 1994; Adachi et al. 1995). 
      Alcohol consumption also affects the liver and other organs indirectly by interfering  
with the metabolism of various drugs, and thus decreasing their effectiveness and 
increasing the risk of side effects. The most common alcohol-medication interaction is 
with acetaminophen. Ethanol is known to activate the CYP2E1 enzyme which is 
responsible for transforming acetaminophen into toxic products which can lead to serious 
liver damage (Whitcomb 1998).  
     An in silico model of ethanol metabolism in the liver can provide a tool to test 
potential nutritional and pharmaceutical therapies for ALD, and to predict ethanol-related  
side effects of various drugs in the liver, thus accelerating research results and reducing 
costs for clinical trials.  Moreover, this model can be modified to represent specific sub-
population genotypes, leading to more personalized drug and dosage guidelines.  
     Ethanol is primarily metabolized in the liver by means of two separate pathways. The 
predominant pathway involves two enzymes:  alcohol dehydrogenase (ADH) and 
acetaldehyde dehydrogenase (ALDH). ADH is expressed in high concentrations in the 
liver and is localized in the cytosol. The oxidation of ethanol by ADH results in the 
formation of acetaldehyde, a highly toxic and carcinogenic substance. The acetaldehyde 
is oxidized into a less active byproduct, acetate, by the mean of ALDH, which exists in 
both cytosolic and mitochondrial form. The majority of the acetaldehyde is oxidized by 
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the mitochondria ALDH.  The second major pathway for ethanol metabolism is the 
microsomal ethanol oxidizing system (MEOS) which involves mainly the cytochrome 
P450 and CYP2E1. This pathway becomes more active in individuals with chronic 
alcohol consumption.  
     Individual variations in ADH and ALDH structures and rates of expression are 
significant, leading to variations among populations and individuals with regard to 
tolerance to alcohol (Pastino et al. 2000).  Several ADH isoforms (ADH1A, ADH1B, 
AQDH1C, ADH5, ADH6, ADH7), with various Km’s for ethanol, and two primary 
ALDH isoforms (ALDH1, ALDH2) exist in the liver (Ehrig et al. 1990). 
     Since the liver is the major organ for metabolizing alcohol, it is most vulnerable to 
damage from excessive alcohol consumption. The acute effects of ethanol metabolism are 
mainly the consequences of alterations in the NADH/NAD+ ratio, resulting from the 
oxidation of ethanol and acetaldehyde by ADH and ALDH respectively. The fate of the 
cytosolic NADH is dependent on the capacity of the malate-aspartate shuttle or the 
glycerol-phosphate shuttle to convert the NADH back to NAD+, which in turn is affected 
by the rate of the TCA cycle. The additional amount of mitochondrial NADH produced 
by ALDH reduces the TCA cycle activity. The increased amount of cytosolic NADH 
production affects the direction of lactate dehydrogenase, resulting in production of 
lactate, mainly by diverting pyruvate from gluconeogenesis, and leading to reduction in 
glucose production (Kreisberg 1967; Kreisberg et al. 1971). 
     Another consequence of ethanol-induced elevated NADH/NAD+ is liver hypoxia, 
especially in the perivenous hepatocytes. Some of the NADH produced by mitochondrial 
ALDH is oxidized through the oxidative phosphorylation pathway, causing an increase in 
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the uptake rate of oxygen from the circulating blood in the pericentral region, and thus 
leading to hypoxia in the perivenous region. It has been found that the expression rates of 
certain genes are dependent on the redox state of the cell, where NAD+ may act as sensor 
in up-regulating their level of expression. The NAD+-regulated genes have been 
demonstrated to extend the life span of some organisms, and reduce the frequency of 
some diseases, notably diabetes, some cancers, and immune deficiencies (Bordone and 
Guarente 1995) 
     Liver diseases related to chronic alcohol consumption usually progress through three 
conditions: fatty liver syndrome, associated with fat deposits in the liver; alcoholic 
hepatitis, associated with the widespread  inflammation and  destruction of  healthy liver 
tissues and replacement  by  scar tissue known as fibrosis; and alcoholic cirrhosis,  the 
last and  most fatal stage of liver disease. While the first two disorders can be reversed by 
stopping drinking, the latter is irreversible. 
     Fatty liver syndrome results from the redirection of AcCoA and glycerol 3-phosphate 
towards triglyceride synthesis.  Acetaldehyde oxidation in the mitochondria leads to an 
increase in the level of acetyl-CoA, which is diverted to the fatty acid synthesis due to the 
NADH-inhibition of the TCA cycle.   The reduction of cytosolic NAD+, as a consequence 
of  ethanol metabolism, leads to a reduction in glycerol-3 phosphate dehydrogenase 
activity,  resulting in a greater amount of glycerol 3-phospahate being  transformed into  
triglycerides.   Acetaldehyde also interacts with specific proteins to form the so-called 
acetaldehyde-protein adducts. These adducts are recognized by the immune system as 
foreign bodies, resulting in a cascade of antibody production leading to prolonged 
inflammation and the destruction of hepatocytes.  
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      Mathematical models of ethanol metabolism in the mammalian organism have 
primarily been restricted to simple pharmacokinetic models (Levitt and Levitt 2000) and 
physiological-based pharmacokinetic models (Pastino and Conolly 2000)  of alcohol 
clearance in the organism.  More recently, a physiologically-based multi-organ 
compartmental model has been developed which includes simplified kinetic expressions 
for ADH and ALDH (Umulis 2005).   None of these models are capable of investigating 
the interactions of ethanol with carbohydrate and lipid metabolism in the liver.  
      Previous models presented in Chapters III and IV demonstrate the complex interplay 
between gluconoegenesis and lipid metabolism in the liver. The most recent model in 
Chapter IV considers cytosolic and mitochondrial compartmentation by including 
kinetics for the malate-aspartate shuttle, inter-compartmental transports, and a detailed 
citric acid cycle. The model successfully predicts the effects of various gluconeogenic 
precursors such as lactate and pyruvate in combination with fatty acids on the cytosolic 
and mitochondrial redox ratios. The model also predicts the directional movement of the 
complex malate-aspartate shuttle.  
     In the present chapter we present a model of ethanol metabolism in the fasted, 
perfused, rat liver, based on the model presented in Chapter IV.  The production of the 
extra NADH by ethanol metabolism can significantly shift the redox state, resulting in 
changes in gluconeogenesis, ketogenesis, and citric acid cycle rates.   The reactions 
representing the ethanol metabolism are based in part on an earlier model developed by  
Pande (2001).  The model is then used to represent the ex vivo liver in a recirculated 
perfusion system. The model predicts the effects of ethanol in the liver perfused with 
either lactate or pyruvate, with and without oleate, on the redox ratio both in the cytosol 
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and the mitochondria. In addition, the model is used to predict the interrelationships 
between ethanol oxidation and pathways of gluconeogenesis, the citric acid cycle, and the 
shuttle mechanisms between cytosol and mitochondria. The simulations are compared to 
experimental data when available in the literature. 
 
5.2 Model Development 
 
     The ethanol model is built upon the liver model presented in Chapter IV with the same 
set of kinetic parameters presented there, and using the general mass balance equations 
given by Eqns. 4.1-4.4.  Figure 5.1 shows the metabolic pathway of ethanol in the liver 
and its interaction with the other metabolic pathways.  Species abbreviations are defined 
in the caption of Fig. 5.1.  The ethanol-related metabolic reactions (Table 5.1) and kinetic 
parameters (Table 5.2) were obtained from the literature from in vitro experiments.  The 
reversibility of each reaction is indicated in Table 5.1.  The effects of ethanol on the 
fasted rat liver, perfused with lactate, pyruvate and oleate in multiple scenarios as 
described in Table 5.3, were simulated.  The set of differential equations were solved 
using ODE 45 in Matlab.  No additional parameter tuning was performed. The initial 
conditions for the variables in Eqns. 4.1-4.3 are given in Table 4.3.  Initial conditions for 
Eq. 4.4 are: 
   Ci,perfusate (0)  =0 for all species i                                                  (5.1) 
i.e. the saline pre-perfusion contains no substrate. 
 
 147  
Fig. 5.1 Metabolic pathway of the liver including ethanol metabolism.  Most transport and reaction fluxes 
are treated as reversible, but may be shown here as uni-directional to indicate the predominant direction.  
Tables 3.1, 4.1, and 5.1 indicate whether a reaction is treated as reversible or irreversible.  Detailed 
stoichiometry and the kinetic expression for each reaction shown here are given in Tables 3.1,  4.1, and 5.1.   
To simplify notation, NAD+ is written as NAD.   Reactions in green are new to this chapter. Species 
abbreviations: ACTAL: acetaldehyde; ACT: acetate; AcAc: acetoacetate; AcCOA: acetyl CoA; ALA: 
alanine; AlphaKG: alpha-ketoglutarate; ASP: aspartate; BHB: β-hydroxybutyrate; CIT: citrate; ETOH: 
ethanol; FA: fatty acid; F6P: fructose-6-phosphate; F16BP: fructose 1,6 bisphosphate; FUM: fumarate; 
GLC: glucose; GLN: glutamine; GLR: glycerol; GAP: glyceraldehyde-3-phosphate; G6P: glucose-6-
phosphate; GLUT: glutamate; Glyc: glycogen; GR3P: glycerol-3-phosphate; IsoCIT: isocitrate; LAC: 
lactate; MAL: malate; PYR: pyruvate; OAA: oxaloacetate; SucCoA: succinyl CoA; SUC: succinate.  
Reaction abbreviations: ADH: Alcohol dehydrogenase; ALDH: aldehyde dehydrogenase; ACS: acetyl CoA 
synthetase. 
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Table 5.1. Kinetic reactions for the ethanol model. Subscripts specify location of species or reaction;  c: cytosol; m: mitochondria; b: blood;  p: 
perfusate.  Species name abbreviations are given in the caption to Fig. 5.1.  The “?” indicates that the reaction is treated as irreversible, while  “↔” 
indicates that the reaction is treated as reversible, with the flux reported with positive values in the left-to-right direction.   
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Table 5.2 Kinetic parameters used in the ethanol model. 
 
Kinetic parametrs Kinetic values Units  Source 
Vmax_b_c_ETOH 6.14286 mM/min 
 From in vivo study (Huang et al. 
1993) 
Km_b_c_ETOH 0.142857 mM 
 Assumed based on expected ethanol 
concentration in vivo 
Vmax_b_c_ACT 5.77143 mM/min 
 From in vivo study (Huang et al. 
1993) 
Km_b_c_ACT 0.142857 mM 
 Assumed based on expected ethanol 
concentration in vivo 
Vmax_c_m_ACT 5.77143 mM/min 
 From in vivo study (Huang et al. 
1993) 
Km_c_m_ACT 0.142857 mM 
 Assumed based on expected ethanol 
concentration in vivo 
Vmax_c_m_ACTAL 5.77143 mM/min 
 From in vivo study (Huang et al. 
1993) 
Km_c_m_ACTAL 0.142857 mM 
 Assumed based on expected ethanol 
concentration in vivo 
Vmax_ACS 5.4 mM/min Reich and Selkov, 1981 
Km_ACS 0.15 mM 
 Assumed based on expected ethanol 
concentration in vivo 
Vmax_ADH_f 9.58571 mM/min 
Vmax_ADH_r 48.0286 mM/min 
Km_ETOH_ADH 0.685714 mM 
Km_nad_ADH 0.0471429 mM 
Km_ACTAL_ADH 0.0528571 mM 
Km_nadh_ADH 0.00571429 mM 
Ki_ETOH_ADH 1.15714 mM 
Ki_nad_ADH 0.0828571 mM 
Ki_ACTAL_ADH 0.0171429 mM 
Ki_nadh_ADH 0.00128571 mM 
Ki_ADH 242.857 mM 
 Crabb et al. 1983 
  
  
  
  
  
  
  
  
Keq_ADH 0.0003   Reich and Selkov, 1981 
Vmax_ALDH 72.1088 mM/min 
Km_ACTAL_ALDH 0.00462585 mM 
Km_nad_ALDH 0.126259 mM 
Svanas and Weiner, 1985 
 
  
Vmax_ALDH_c 1.5028 mM/min 
Km_ACTAL_ALDH_c 0.00462585 mM 
Km_nad_ALDH_c 0.126259 mM 
  
Svanas and Weiner, 1985 
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Table 5.3.  Input functions used in simulations of the perfused liver. (RFA-endo=rate of endogenous fatty acid 
oxidation, normalized to µmol C16 (palmitate); J*FA-b-t = the sum of the uptake rate of FA and rate of 
endogenous fatty acid oxidation).   
Lactate Perfusion 
Saline pre-perfusion; 
 0 < t ≤ 30 
Lactate infusion;  
30 < t ≤  120 
Lactate + Ethanol;  
90 < t ≤ 120 
RFA-endo = 0.15 
µmol(Lcyt water )-1min-1, 
assumed to be equal to  
experimental 
measurements of ketone 
production during this 
period26.   
 
RFA-endo = 0.08178 
µmol(Lcyt water )-1min-1, 
 as estimated26 from ketone 
production.   
 
CLAC,,perfusate = 
10(1-exp(-(t-30)/τ) mM 
(constant LAC concentration of 
10 mM in perfusate); τ is time 
constant for achieving change 
in susbstrate concentration, set 
to 4 min. 
RFA-endo = 0.08178 
µmol(Lcyt water )-1min-1, 
 as estimated26 from ketone 
production.   
 
CETOH,,perfusate = 
10(1-exp(-(t-90)/τ) mM 
(constant ETOH concentration of 10 
mM in perfusate); τ is time constant 
for achieving change in susbstrate 
concentration, set to 4 min. 
CLAC,,perfusate =10 mM 
Pyruvate Perfusion 
Saline pre-perfusion; 
 0 < t ≤ 30 
Pyruvate infusion;  
30 < t ≤  120 
Pyruvate + Ethanol  
90 < t ≤ 120 
RFA-endo = 0.15 
µmol(Lcyt water )-1min-1 
RFA-endo =0.08178 
µmol(Lcyt water )-1min-1 
 
CPYR,,perfusate = 
2(1-exp(-(t-30)/ τ) mM 
(constant PYR concentration of 
2 mM in perfusate); τ=3 min. 
 
CLAC,,perfusate calculated from 
Eqn. 4.3.  
RFA-endo = 0.08178 
µmol(Lcyt water )-1min-1, 
 as estimated26 from ketone 
production.   
 
CETOH,,perfusate = 
10(1-exp(-(t-90)/τ) mM 
(constant ETOH concentration of 10 
mM in perfusate); τ is time constant 
for achieving change in susbstrate 
concentration, set to 4 min. 
 
CPYR,,perfusate =2 mM 
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Table 5.4 Input functions used in simulation of the perfused liver, with fatty acids. (RFA-endo=rate of 
endogenous fatty acid oxidation, normalized to µmol C16 (palmitate); J*FA-b-t = the sum of the uptake rate of 
FFA and rate of endogenous fatty acid oxidation).   
Lactate + Fatty Acid Perfusion 
Saline pre-
perfusion; 
 0 < t ≤ 30 
Lactate infusion;  
30 < t ≤  60 
Lactate + FA  
60 < t ≤ 120 
Lactate + FA+ 
Ethanol;  
90 < t ≤ 120 
RFA-endo = 0.15 
µmol(Lcyt water)-1min-
1, 
assumed to be equal to  
experimental 
measurements of ketone 
production during this 
period26.   
 
RFA-endo = 0.08178 
µmol(Lcyt water)-1min-1, 
 as estimated26 from 
ketone production.   
 
CLAC,,perfusate = 
10(1-exp(-(t-30)/τ) mM 
(constant LAC 
concentration of 10 mM 
in perfusate); τ is time 
constant for achieving 
change in susbstrate 
concentration, set to 4 
min. 
J*FA-b-t=  
0.08178+0.466(1-
exp(-(t-60) /τ), 
τ=2.5 min; total rate 
of 0.5874 µmol(Lcyt 
water )-1min-
1determined  from 
experimental 
measurements of 
oleate infusion26.  
 
CLAC,,perfusate =10 mM 
 
RFA-endo = 0.08178 
µmol(Lcyt water)-1min-1, 
 as estimated26 from 
ketone production.   
 
CETOH,,perfusate = 
10(1-exp(-(t-90)/τ) mM 
(constant ETOH 
concentration of 10 mM 
in perfusate); τ is time 
constant for achieving 
change in susbstrate 
concentration, set to 4 
min. 
CLAC,,perfusate =10 mM 
 
Pyruvate + Fatty Acid Perfusion 
Saline pre-
perfusion; 
 0 < t ≤ 30 
Pyruvate infusion;  
30 < t ≤  60 
Pyruvate + FA  
60 < t ≤ 120 
Pyruvate + FA+ 
Ethanol ;  
90 < t ≤ 120 
RFA-endo = 0.15 
µmol(Lcyt water)-1min-
1 
RFA-endo =0.08178 
µmol(Lcyt water )-1min-1 
 
CPYR,,perfusate = 
2(1-exp(-(t-30)/ τ) mM 
(constant PYR 
concentration of 2 mM 
in perfusate); τ=3 min. 
 
CLAC,,perfusate calculated 
from Eqn. 4.3. 
 J*FA-b-t=  
0.08178+0.466(1-
exp(-(t-60) /τ), 
τ=2.5 min; total rate 
of 0.5874 µmol(Lcyt 
water)-1min-
1determined  from 
experimental 
measurements of 
oleate infusion26.  
 
Cpyr,,perfusate =2 mM 
 
RFA-endo = 0.08178 
µmol(Lcyt water)-1min-1, 
 as estimated26 from 
ketone production.   
 
CETOH,,perfusate = 
10(1-exp(-(t-90)/τ) mM 
(constant ETOH 
concentration of 10 mM 
in perfusate); τ is time 
constant for achieving 
change in susbstrate 
concentration, set to 4 
min. 
CPYR,,perfusate =2 mM 
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5.3 Results 
 5.3.1 Lactate Perfusions 
    Figs. 5.2-3 show the results from the simulation of 10 mM lactate perfusion with 
subsequent addition of 10 mM ethanol at 90 minutes (Table 5.3).    The addition of 
ethanol causes 6-fold increases in both cytosolic and mitochondrial redox ratios (Fig. 
5.2), due to increased supply of NADH by the oxidation of ethanol through ADH and 
oxidation of acetaldehyde by ALDH.  A high cytosolic redox ratio is expected to drive 
the transfer of reducing equivalents to the mitochondria through various mechanisms, of 
which the malate-aspartate cycle is hypothesized to be the main mechanism.  The first 
step in this process is seen with the increase in the rate of conversion of OAA to malate in 
the cytosol (MDH reaction, Fig. 5.2), driven by the high cytosolic redox ratio.  This 
surplus in cytosolic malate drives its transport into the mitochondria, causing a 4-fold 
increase in the forward flux of mitrochondrial MDH. 
     Fig. 5.2 shows that ethanol perfusion causes an approximate seven-fold increase in net 
malate transport from cytosol to mitochondria, correlating well with the increase in the 
cytosolic redox ratio.  Inter-compartmental transport of malate can be accomplished via 
three transporters: MAL:AlphaKG (as part of the malate-aspartate shuttle), MAL:Pi, and 
MAL:CIT.  Fig. 5.2 shows that the  transporters MAL:AlphaKG and MAL:Pi have 
different directions, with  MAL:AlphaKG  predominating, while the flux through 
MAL:CIT is very low.  This is accompanied by two-fold increase in the concentration of 
malate in both compartments (not shown). Thus the net malate transport into the 
mitochondria is responsible for the transport of reducing equivalents from the cytosol to 
the mitochondria, with the carbon returned to the cytosol in the form of AlphaKG.  The  
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Figure 5.2.  Redox ratios and fluxes calculated from perfusion model with lactate, and lactate + ethanol as 
substrates.  Initial conditions represent the in vivo 24-hour fasted state. Symbols are experimental data from 
perfused fasted livers, from Williamson, et al. 1969b, using a perfusion medium of  Krebs-Henseleit 
bicarbonate buffer, with 4% bovine serum albumin, in a recirculated system.  Lines are simulations, using 
Eqns. 4.1-4, with Fperfusate=50 ml/min and Vperfusate=100 ml (corresponding to the experimental protocol), 
and all other parameters as given in Tables 4.2 and 5.2. Solid lines: 10 < t ≤ 30 min: saline pre-perfusion 
(no substrate); 30 < t ≤ 120 min: 10 mM lactate perfusion. Dashed lines: 90 < t ≤ 120 min: 10 mM lactate 
plus 10 mM ethanol perfusion.  To view details of the lactate and ethanol perfusions, the x-axis scale was 
started at 10 min.  Net malate transport and net glutamate transport are each calculated from the sum of 
their three respective transporters.   
 
20 40 60 80 100 120
0
0.01
0.02
time(min)
(NADH/NAD)cyt 
20 40 60 80 100 120
-4
-2
0
2
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
Malate dehydrogenase cyt
20 40 60 80 100 120
0
2
4
6
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
MAL:AlphaKG transport
20 40 60 80 100 120
0
0.1
0.2
time(min)
(NADH/NAD)mit 
20 40 60 80 100 120
0
20
40
time(min)
m
m
ol
*(
L 
m
it*
m
in
)-1
Malate dehydrogenase mit
20 40 60 80 100 120
-2
0
2
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
MAL:Pi transport
20 40 60 80 100 120
-1
-0.5
0
time(min)
m
m
ol
*(
L 
m
it*
m
in
)-1
MAL:CIT transport
20 40 60 80 100 120
-2
0
2
4
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
Net Malate transport c->m
20 40 60 80 100 120
0
2
4
6
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
GLUT:ASP transport
 
20 40 60 80 100 120
0
2
4
6
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
Net Glutamate tarnsport c->m
20 40 60 80 100 120
0
2
4
6
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
PYR transp c->m
20 40 60 80 100 120
0
10
20
time(minutes)
m
m
ol
*(
L 
m
it*
m
in
)-1
Pyruvate carboxylase
20 40 60 80 100 120
0
0.5
1
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
Glucose production
20 40 60 80 100 120
-2
0
2
4
time(min)
m
m
ol
*(
L 
cy
t w
at
er
*m
in
)-1
Lactate uptake
20 40 60 80 100 120
-2
-1
0
1
time(min)
m
m
ol
*(
L 
cy
t*
m
in
)-1
Pyruvate production
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
m
it*
m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
m
it*
m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
m
it*
m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
m
m
ol
*(
L 
cy
t w
at
er
*m
in
)-1
m
m
ol
*(
L 
cy
t*
m
in
)-1
 155  
other part of the MAL-ASP cycle, the glutamate-aspartate exchange, increases over two-
fold (Fig. 5.2) in response to ethanol.  These simulations indicate the important role of the 
malate-aspartate cycle during ethanol metabolism and are corroborated qualitatively by 
experimental observations from various researchers (Williamson et al. 1974a, 1974b; 
Meijer et al. 1975a), whose studies revealed an increase in ethanol uptake by isolated 
liver cells from starved rats upon addition of external MAL and alphaKG. Moreover the 
use of aminooxyacetate, an inhibitor of the malate-aspartate cycle, inhibited the increase 
in ethanol uptake, showing a clear relationship between the malate-aspartate cycle and 
ethanol oxidation. 
     Other than the rate of transfer of reducing equivalents, the simulations show, in 
general, that ethanol decreases the metabolic rates of the liver.  Ethanol causes a 32% 
reduction in the rate of pyruvate transport to the mitochondria (Fig. 5.2) with a 
simultaneous reduction of the mitochondrial pyruvate concentration (data not shown).  
Ethanol reduces the TCA cycle flux by 41% (as measured by IDH, Fig. 5.3), 
gluconeogenesis by 15 % (as measured by glucose production, Fig. 5.2), and lactate 
uptake and oxidation by 33% (Fig. 5.2).  Conversely, the rate of ketogenesis is stimulated 
by the addition of ethanol (Fig. 5.3), due to the increase in the AcCoA production from 
acetate. 
     The rate of ethanol uptake by the liver is predicted by the model to be 2.2 μmol (L cyt 
water)-1 min-1 at 10 mM ethanol and 10 mM lactate (Fig. 5.3), which agrees well with the 
maximum rate of ethanol utilization of  3.5 μmol (L cyt water)-1 min-1 found at ethanol 
concentrations above 2 mM in fed rats but with no added lactate (Lindros et  al. 1972). 
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 Figure 5.3.  Metabolic fluxes calculated from perfusion model with lactate, and lactate + ethanol as 
substrates.  Simulation and experimental details are the same as in Fig. 5.2.  
 
     The results from the addition of ethanol to perfusion medium containing both oleate 
and lactate are shown in Figs. 5.4-5, with simulation conditions described in Table 5.4. 
The simulated results indicate a 6- and 4-fold increase in the cytoplasmic and the 
mitochondrial redox ratios, respectively, upon addition of ethanol to the lactate-oleate 
mixture (Fig. 5.4).  Inhibition of gluconeogenesis by ethanol is much more pronounced in 
the presence of oleate, with 50% reduction (Fig. 5.4), compared to 20% reduction in the 
absence of oleate (Fig. 5.2).   
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Figure 5.4  Redox ratio (NADH/NAD+) and fluxes calculated from perfusion model with lactate, lactate + 
oleate, and lactate + oleate + ethanol as substrates.  Initial conditions represent the in vivo 24-hour fasted 
state. Symbols are experimental data from perfused fasted livers, from Williamson, et al. 1969b, using a 
perfusion medium of  Krebs-Henseleit bicarbonate buffer, with 4% bovine serum albumin, in a recirculated 
system: preperfusion with no substrate; and perfusion with 10 mM lactate and 1.5 mM oleate respectively. 
Solid and dashed lines are simulations, using Eqns. 4.1- 4, with Fperfusate=50 ml/min and Vperfusate=100 ml 
(corresponding to the experimental protocol), and all other parameters as given in Tables 4.1 and 5.2. Solid 
lines: 10 < t ≤ 30 min: saline pre-perfusion (no substrate); 30 < t ≤ 60 min: 10 mM lactate;  60 < t ≤ 120 
min: 10 mM lactate and 1.5 mM oleate perfusion. Dashed lines: 90 < t ≤ 120 min: 10 mM lactate, 1.5 mM 
oleate and 10 mM ethanol perfusion.  Details given in Table 5.4. 
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Figure 5.5.  Rates of TCA cycle, oxygen consumption, ethanol production (-uptake), and ketone production 
calculated from perfusion model with lactate, lactate + oleate, and lactate + oleate + ethanol as substrates 
respectively.  Simulation and experimental details are the same as in Fig. 5.4.  
 
5.3.2 Pyruvate Perfusions 
    The effect of ethanol on pyruvate metabolism was examined using the same model 
with the same set of kinetic parameters as described above, with initial conditions and 
inputs described in Table 5.3.   As expected, the addition of 2 mM ethanol to the pyruvate 
perfusion significantly increases both cytosolic and mitochondrial redox ratios (Fig. 5.6).  
In contrast with the results from lactate perfusion, gluconoegenesis from pyruvate is not 
inhibited by ethanol addition (Fig. 5.6); on the contrary, significant stimulation of glucose 
production is observed. This is corroborated by Williamson et al. (1969c) who observed 
that ethanol stimulated gluconeogenesis  
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Figure 5.6.  Redox ratio (NADH/NAD+) and fluxes calculated from perfusion model with pyruvate, and 
pyruvate + ethanol as substrates.  Initial conditions represent the in vivo 24-hour fasted state. Symbols are 
experimental data from perfused fasted livers, from Williamson, et al.1970a, using a perfusion medium of  
Krebs-Henseleit bicarbonate buffer, with 4% bovine serum albumin, in a recirculated system; open circle-0: 
Preperfusion with no substrate; and  perfusion with 2 mM pyruvate respectively. Solid and dashed lines are 
simulations, using Eqns. 4.1-4, with Fperfusate=50 ml/min and Vperfusate=100 ml (corresponding to the 
experimental protocol), and all other parameters as given in Tables 4.1 and 5.2. Solid lines: 10 < t ≤ 30 
min: saline pre-perfusion (no substrate); 30 < t ≤ 120 min: 2 mM pyruvate perfusion. Dashed lines: 90 < t ≤ 
120 min: 2 mM pyruvate plus 10 mM ethanol perfusion.  Details given in Table 5.3.  In order to view the 
details of the pyruvate and ethanol perfusion, the x-axis scale was started at 10 min. 
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when alanine (which produces pyruvate via alanine aminotransferase) was the substrate.   
The extra cytosolic NADH produced by ethanol oxidation is used to drive the reduction 
of pyruvate to lactate by mean of LDH, as shown in Fig. 5.6. 
Fig. 5.7. TCA cycle fluxes, oxygen uptake, ethanol uptake (-production), and ketogenesis, calculated from 
perfusion model with pyruvate, and pyruvate + ethanol as substrates.  Simulation and experimental details 
are the same as in Fig. 5.6.  
 
      The effects of ethanol after prior addition of oleate to pyruvate are illustrated in Figs 
5.8-9. In contrast with lactate perfusion, pyruvate perfusion causes a net efflux of MAL 
out of the mitochondria (Fig. 5.8).   Ethanol oxidation causes a further increase in the 
cytoplasmic and mitochondrial redox ratios, which significantly reduces the MAL efflux.   
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    Figure 5.8.  Redox ratio (NADH/NAD), intercompartmental fluxes, and gluconeogenesis rates 
calculated from perfusion model with pyruvate, pyruvate + oleate, and pyruvate + oleate + ethanol as 
substrates respectively.  Initial conditions represent the in vivo 24-hour fasted state. Symbols are 
experimental data from perfused fasted livers, from Williamson, et al. 1970a, using a perfusion medium of  
Krebs-Henseleit bicarbonate buffer, with 4% bovine serum albumin, in a recirculated system; open circle-0: 
Preperfusion with no substrate; and perfusion with 2 mM pyruvate and 1.5 mM oleate respectively. Solid 
and dashed lines are simulations, using Eqns. 1,3 and 4, with Fperfusate=50 ml/min and Vperfusate=100 ml 
(corresponding to the experimental protocol), and all other parameters as given in Tables 4.1. Solid lines: 
10 < t ≤ 30 min: saline pre-perfusion (no substrate); 30 < t ≤ 120 min: 2 mM pyruvate and 1.5 mM oleate 
perfusion. Dashed lines: 90 < t ≤ 120 min: 2 mM pyruvate, 1.5 mM oleate and 10 mM ethanol perfusion.  
Details given in Table 5.3.  In order to view the details of the pyruvate and ethanol perfusion, the x-axis 
scale was started at 10 min. 
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 Fig. 5.9. TCA cycle fluxes, oxygen uptake, ethanol production (-uptake), and ketogenesis, calculated from 
calculated from perfusion model with pyruvate, pyruvate + oleate, and pyruvate + oleate + ethanol as 
substrates.  Simulation and experimental details are the same as in Fig. 5.8.  
 
     Simulations using near-physiological pyruvate concentration of 0.1 mM in 
combination with oleate are shown in Fig. 5.10.  Ethanol increases the rate of pyruvate 
reduction to lactate (in LDH) and thus decreases glucose production.  As expected, the 
rate of ketogenesis (Fig. 5.10) is further increased by the expected increase in the 
mitochondrial redox ratio (not shown).  
     The model was further validated with dynamic data in which fasted rat livers were 
perfused with 2.5 mM lactate and 10 mM ethanol in a non-recirculated perfusion system 
(Lopez et al. 2009).  Using the same parameters as in all the previous results, the model 
underestimates both glucose production and the ethanol-induced inhibition of glucose 
production (Fig. 5.11A).  However, when the rate of endogenous fatty acid oxidation is 
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increased from  0.085 to 0.15 micromol/(L cyt water*min),  the steady state and dynamic 
glucose production agrees more closely with the experimental data (Fig. 5.11B).   The 
rate of inhibition of glucose production by ethanol is predicted to be 41%, compared to 
measured inhibition of 60%.  The larger FA rate also increases the BHB production rate, 
to better match the data, especially during ethanol perfusion.  Since endogenous FA 
oxidation is not directly measurable, and can vary depending on the state of the liver, it 
can be considered an adjustable parameter that closely correlates with ketone production.   
The dynamic responses to ethanol of  AcAc and BHB production correspond well with 
the experimental data, with an increase of BHB production  and a decrease in AcAc 
formation. 
 
Figure 5.10. Fluxes calculated from perfusion model with near physiological level of pyruvate (0.1 mM), 
pyruvate + oleate, and pyruvate +oleate+ ethanol as substrates, respectively. Initial conditions represent the 
in vivo 24-hour fasted state. Solid and dashed lines are simulations, using Eqns. 5.1,3 and 4, with 
Fperfusate=50 ml/min and Vperfusate=100 ml (corresponding to the experimental protocol), and all other 
parameters as given in Tables 4.1. Solid lines: 10 < t ≤ 30 min: saline pre-perfusion (no substrate); 30 < t ≤ 
120 min: 0.1 mM pyruvate and 1.5 mM oleate perfusion. Dashed lines: 90 < t ≤ 120 min: 0.1 mM pyruvate, 
1.5 mM oleate and 10 mM ethanol perfusion
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Figure 5.11.  Dynamics of glucose, pyruvate, and ketone production calculated from perfusion model with 
lactate and lactate + ethanol as substrates. Symbols are experimental data from perfused fasted livers, from 
Lopez, et al. 2009, using a perfusion medium of  Krebs-Henseleit bicarbonate buffer, with 25% bovine 
serum albumin, in a non-recirculated system; open circle-o: Pre-perfusion with no substrate; and  perfusion 
with 2.5 mM lactate respectively. Star-*: Perfusion with 2.5 mM lactate and 10mM ethanol.  Solid and 
dashed lines are simulations, using Eqns. 4.1-4, with Fperfusate=24.5 ml/min and Vperfusate=100 ml 
(corresponding to the experimental protocol), and all other parameters as given in Tables 4.1 and 5.2. Solid 
lines: 10 < t ≤ 60 min: perfusion with 2.5 mM lactate. Dashed lines: 40 < t ≤ 60 min: 2.5 mM lactate and 10 
mM ethanol perfusion.  (A) Rate of endogenous fatty acid oxidation set to 0.085 micromol/(L cyt 
water*min).   (B) Rate of endogenous fatty acid oxidation set to 0.15 micromol/(L cyt water*min).                                     
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5.4 Discussion 
     While the literature contains a vast amount of information on ethanol metabolism in 
perfused rat livers, especially in the fed state, specific data related directly to the fasted 
rat liver is lacking.  In particular, there is shortage of data with respect to lactate and 
pyruvate perfusion with ethanol in the fasted liver. For instance, Lindros et al. 1972 
conducted experiments on rat livers perfused with combinations of lactate and pyruvate, 
but with additions of glucose.  Forsander et al. (1965) studied the effect of ethanol on 
liver metabolism in fed and starved rats, but their medium contained 5 to 6 mM of 
glucose in bovine blood.  Krebs et al. (1969) also used red blood cells (causing high rates 
of gluconeogenesis).  All of these experimental setups are incompatible with our 
perfusion model conditions.   However, alanine and ethanol have been widely studied in 
both fasted and fed rat livers.  Alanine constitutes one of the three main gluconeogenic 
precursors in vivo.  Alanine is expected to affect the liver metabolism in a manner similar 
to that of lactate and pyruvate, since they share many pathways and transporters.  Within 
the cytosol, alanine is transaminated to pyruvate, which can then be reduced to lactate 
and exported from the cell, or transferred to the mitochondria for oxidation or as substrate 
for gluconeogenesis.  Thus, we used data on alanine and ethanol perfusions in starved rats 
from Williamson et al. (1969c) to qualitatively validate some of the responses of our 
model to lactate and pyruvate with ethanol in the starved state.    
We have demonstrated earlier (Chapter IV) the validity of the liver model in 
terms of transferring reducing equivalents and carbon via the malate shuttle.  Ethanol 
oxidation in the liver provides an enhanced supply of reducing equivalents in the cytosol 
as has been observed experimentally from different studies (Forsander et al. 1965, 1966; 
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Freinkel et al. 1965).  Since the mitochondrial membrane is impermeable to the NADH 
generated in the cytosol, the evidence indicates that reducing equivalents are transferred 
to the mitochondria by a specialized shuttle mechanism (Williamson et al. 1969a, 1969b; 
Chappell et al. 1968; Borst et al. 1963). The most prominent shuttle is the malate-
aspartate cycle which involves the influx of malate and glutamate to the mitochondria 
and efflux of aspartate and alphaKG coupled to aspartate aminotransferase on both sides 
of the membrane.  Our model successfully predicts that ethanol added to lactate causes 
the following sequence of events: an increase in the rate of NADH supply in the 
cytoplasm; malate transport to the mitochondria predominantly via the MAL:alphaKG 
transporter coupled  with stoichiometric glutamate transport via the GLUT:ASP shuttle 
(Fig. 5.2);  transamination of OAA to aspartate;  efflux of aspartate, which then 
undergoes a reverse transamination.  
     Williamson et al. (1969c) reported an increase of oxygen uptake, upon separate 
ethanol and oleate addition to alanine in fasted perfused rat liver, of 1.2-fold and 1.5-fold, 
respectively.  The model predicts this enhancement of oxygen uptake by ethanol and 
oleate, but to a somewhat larger extent-- 1.5 fold (Fig. 5.7) and  2.3 fold  (Fig. 5.9), 
respectively.  On the other hand, the addition of ethanol following oleate addition during 
lactate perfusion causes no additional rise in the oxygen consumption rate; instead a 
small decrease was estimated by the model (Fig. 5.5), which correlates well with the 
small decrease observed from Williamson et al. 1969c when ethanol was added to 
alanine+oleate  perfusions (5% reduction).  
     The model demonstrates the inhibitory effect of ethanol on the TCA cycle.  The model 
predicts a 42% inhibition by ethanol addition to lactate (IDH, Fig. 5.3). The oleate 
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addition prior to ethanol causes a further inhibition of the TCA cycle by 60%  (Fig. 5.5, 
AKGDH, IDH). These model estimates seem to match closely with the data from 
Williamson et al. (1969c) of 75% reduction in TCA cycle with alanine perfusion. The 
three enzymes-- CS, IDH, and AKGDH --are generally considered the main regulatory 
points of the TCA cycle, and all thee are inhibited when ethanol is added to lactate plus 
oleate (Fig. 5.5).  However, the model illustrates that ethanol inhibition of the TCA cycle 
occurs primarily at the sites of IDH and AKGDH, since there is no change in the rate of 
CS (Fig.5.3, 7,9), during all other perfusions.  In the presence of oleate, ethanol seems to 
counteract the oleate-induced enhancement of CS,  resulting in reduction in the rate of 
citrate synthase (CS) in addition to significant reduction in the rate of IDH and AKGDH 
(Fig. 5.5).  These flux inhibitions are most likely caused both by reductions in substrate 
concentrations, as observed from experimental decreases in  citrate, alphaKG, and 
succinate during alanine-oleate-ethanol perfusions (Williamson, et al. 1969c), and 
increased mitochondrial NADH, which cause inhibition of these three reactions, as 
represented in the in vitro kinetics (Tables 4.1 and 5.1).  
     The rise in the rate of ketone production by ethanol in both lactate and pyruvate 
perfusion scenarios is attributed mainly to the increase in the mitochondrial redox ratio, 
rather than a surplus of  AcCoA, since CS is not inhibited significantly in most 
circumstances.   The addition of ethanol to lactate causes a 6-fold increase in the rate of 
BHB production, at the expense of AcAc production, which settles at essentially zero 
(Fig.5.3).  Although these experimental measurements are not available for lactate-
ethanol perfusions, these predictions are corroborated by alanine-ethanol perfusion data 
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(Williamson et al. 1969c), of  approximately 11-fold increase in the  BHB flux with the 
addition of ethanol to alanine.  
     Due to the dearth of experimental data with ethanol and pyruvate and lactate in fasted 
rat livers, data from ethanol and alanine perfusions were used to qualitatively validate 
many of the results presented here.  However, alanine metabolism is more complicated 
than lactate and pyruvate metabolism, since the alanine degradation pathway interacts 
with ureagenesis pathway, which was not modeled in detail in this work. Thus some 
differences will be expected between simulations using alanine compared to lactate or 
pyruvate as substrate.  One of the future directions of this study be to include the 
interaction between ureagenesis and gluconeogenesis. 
     This model of ethanol oxidation in the fasted perfused rat liver successfully predicts 
the expected trends as well the actual rates of most metabolic reactions.  This will allow 
us in the future to study disease states of the liver related to alcohol, such as fatty liver 
alcohol syndrome and liver cirrhosis, and to investigate the usefulness of potential 
nutritional and pharmaceutical therapies.  
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
 
6.1 Summary of Results 
 
     The study presented here uses mathematical models to represent the metabolism of a 
fasted liver and to predict the intermediate fluxes and concentrations in response to 
different combinations of nutrients and exercise. Two main modeling approaches were 
explored: modeling the carbohydrate metabolism in human liver using a distributed 
approach, and modeling a detailed regulated gluconoegenic model of the fasted perfused 
rat liver.  
 
6.1.1 Distributed Model  
 
     The distributed model consists of reaction and transport equations to represent 
carbohydrate metabolism, tissue heterogeneity, and axial concentration gradients. The 
model features the metabolic zonation concept by incorporating the spatial variation of 
key enzymatic reactions. This model reliably predicts the rate of gluconeogenesis and 
lactate uptake by the liver, and the effect of high intensity exercise on the various hepatic 
fluxes. 
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     The incorporation of zonation of glycolytic and gluconeogenic enzyme activities 
causes the expected increase in glycolysis and decrease in gluconeogenesis along the 
sinusoid length from periportal to perivenous regions, while fluxes are nearly constant 
along the sinusoid length in the absence of enzyme zonation.   These results confirm that 
transport limitations are not sufficient to account for the observed tissue heterogeneity of 
metabolic fluxes.   Modeling results indicate that changes in arterial substrate 
concentrations and hepatic blood flow rate, which occur in the high-intensity exercise 
state, are not sufficient to shift the liver metabolism enough so as to account for the five-
fold increase in hepatic glucose production measured during exercise.  Changes in 
maximal enzyme activities, whether caused by exercise-induced changes in insulin, 
glucagon, or other hormones, are responsible for observed glucose output.  The 
distributed model was expected to offer the opportunity to examine and test the effect and 
the importance of liver structure hetrogeneity on its metabolic functions. However the  
distributed model could not be conclusively validated, since few experimental data are 
available that are capable of representing the complex structure of the liver and its 
enzyme heterogeneity. 
 
6.1.2 Gluconeogenesis and Lipid Metabolism in the Perfused Liver 
 
     The need for a robust and predictive model led us to develop a lumped model of 
hepatic metabolism that incorporates all the significant metabolic pathways needed to 
represent the variety of substrates (e.g: lactate, pyruvate, alanine, fatty acids) under 
variable concentrations in well-controlled experiments, such as use of perfused livers.  In 
general, the predicted steady state glucose production and substrate uptake rates, and 
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especially the ratio of glucose/substrate, are in good agreement with the experimental 
results.  The simulations predict the same trends, in terms of stimulation of substrate 
uptake by fatty acid addition, as observed experimentally.  The model also predicts the 
dynamic response to lactate and pyruvate perfusions with good accuracy. This model 
represents an encouraging step toward developing a comprehensive model for 
carbohydrate metabolism, especially representing the complex interplay between 
gluconeogenesis and the lipid metabolism. One of the limitations of this model was its 
inability, even after numerous attempts at parameter estimation, to correctly predict the 
NADH/NAD+ ratio. This caused discrepancies in the reactions that involved reducing 
equivalents and indicated the need for consideration of cytosolic-mitochondrial 
compartmentation. 
 
6.1.3 Cytosolic-Mitochondrial Compartmentation in the Pefused Liver 
 
     Developing a computational model of metabolic compartmentation and inter-
compartmental transport between the cytosol and the mitochondria allowed the  
successful prediction of the redox ratio, in both the cytosolic and the mitochondrial 
compartments, and major metabolic fluxes. The model also predicts the directional 
movement of the carbon shuttle across the mitochondrial membrane during lactate, 
pyruvate, and oleate perfusions.  The model represents a tool to generate much needed 
time course data on different metabolites and their relative distribution. All simulation 
results were obtained using a single set of parameters.  Parameter estimations were 
primarily performed for matching redox ratios, confirming the central importance of this 
ratio in regulating metabolism.    
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6.1.4 Ethanol Metabolism in the Perfused Liver 
 
     The effects of ethanol on different metabolic rates, such as gluconoegenesis, 
ketogenesis, and TCA cycle, were simulated by using the model developed in Chapter 
IV.   The ethanol simulations constitute a further validation for the model. In general the 
model predicts that ethanol oxidation alters the level of redox ratio in both the cytoplasm 
and the mitochondrial compartment causing inhibition of the gluconoegenesis and TCA 
cycle rates while increasing the rate of ketogenesis in accordance with experimental data. 
The ethanol model can establish a base for studying disease states such as fatty liver 
disease. 
 
 
6.2 Recommendations for Future Directions 
  
     To achieve the overall goal of developing an in silico liver capable of accurately 
predicting the in vivo state of the fasted rat liver, we developed a model that simulated the 
gluconoegenesis from pyruvate and lactate. We now suggest a plan to include the effect 
of alanine and the urea cycle, therefore integrating the effect of the three main 
gluconeogenic precursors. This model will allow for a complete representation and 
detailed pathways interaction.  
 
 
6.2.1 Oxidative Phosphorylation and the Inner Mitochondrial Membrane Space 
 
     The model of oxidative phosphorylation developed in this work is a simplification that 
lumps different steps of the oxidation process and the ATPase reaction into two simple 
reactions.  The ADP: ATP translocase also plays a role in regulating the transport of ADP 
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from the cytosol to the mitochondria in exchange of ATP synthesized in the 
mitochondria. Moreover the exchange of ATP for  ADP is electrogenic and controlled by 
the high membrane potential of the inner membrane.  The model developed in Chapter IV 
predicts the rate of oxygen consumption well within the expected experimental data; 
however the model fails to predict the asymmetry of the ATP/ADP ratio between the 
cytosol and the mitochondria. 
     One possible solution to these shortcomings is to account for the potential energy of 
the inner membrane in the rate of ADP:ATP translocase and to also model separately the 
rate of oxidative phosphorylation and the rate of ATPase. This approach could also lead 
into the consideration of modeling the matrix separately from the intermembrane space. 
We suggest that the detailed model of the oxidative phosphorylation built by Beard et al. 
be used to try to remediate the discrepancies in cytsolic and mitochondrial ATP/ADP 
ratios. 
 
6.2.2 Alanine Metabolism  
     Gluconeogenesis constitutes the main source for glucose production during periods of 
fasting or starvation. The main precursors for gluconeogenesis are lactate, pyruvate, and 
the amino acids. The amino acids are especially important substrates for hepatic 
gluconeogenesis during fasting compared to lactate and pyruvate. Studies involving 
fasted rat livers which were perfused with normal physiological levels of 
gluconeogenesis precursor have indicated that amino acids contributed to more than 50% 
of glucose production (Exton and Park 1967). The amino acids are obtained from the 
breakdown of protein, mostly from skeletal muscle. However experimental data from 
arteriovenous data from human muscle (Felig and Wahren 1974)  and from isolated rat 
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muscle indicate that alanine and glutamine are released into the blood stream to a greater 
extent compared to other amino acids. Alanine constitutes the principal amino acid for 
liver gluconeogenesis whereas glutamine is considered the main gluconeogenic precursor 
for the kidney.  
     Alanine from the muscle and peripheral tissue passes into the blood and travels to the 
liver. Once inside the cytosol alanine transaminase transfers the amino group from 
alanine to α-ketoglutarate, forming pyruvate and glutamate. Pyruvate is the port of entry 
for alanine into the gluconeogenesis pathway. Glutamate enters the mitochondria and 
releases the ammonia through glutamate dehydrogenase. Ammonia is a very toxic 
component for the human body and its accumulation can cause serious risks such as brain 
damage. The urea cycle provides the liver with a specific mechanism to transform the 
toxic ammonia resulting from the catabolism of the alanine into urea, which is then 
released into the urine. Parallel increases in gluconeogenesis and ureagenesis have been 
observed during prolonged starvation in the rat (Parrilla 1978). Hormonal stimulation was 
found to stimulate  gluconeogenesis rate along with an increase in the rate of urea 
production (Ayuso-Parrilla et al. 1976). Moreover, in pathological conditions it has been 
observed that inhibition of gluconeogenesis was accompanied by hyperammonemia 
(Rosenberg 1982) giving further evidence about the relationship between these two 
pathways. These two pathways are linked through the sharing of many enzymes such as 
aspartate and malate dehydrogenase, and through mitochondrial metabolite transport such 
as: glutamate, aspartate and α-ketoglutarate. Experiments (Kashiwagura et al. 1984; 
Meijer et al. 1978; Ohtake and Clemens 1991) with rat livers perfused with NH4+ or 
isolated hepatocytes demonstrated a close relationship between ureagenesis and 
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gluconeogenesis . It has been suggested that the availability of aspartate in the cytosol 
plays a major role in controlling the flux rate through argininosuccinate synthetase 
(Meijer et al. 1978) which could be considered to be the rate limiting steps for 
ureagenesis from NH4+.  Moreover pyruvate has been found to increase the rate of 
ureagenesis from NH4+  (Meijer et al. 1978).  In addition, ureagenesis is responsible for 
malate production in the cytosol, hence different effects are expected, depending on 
whether lactate or pyruvate is used as gluconeogenic precursor. Interactions between the 
two pathways are highly expected; therefore a model of urea cycle is necessary to 
represent the disposal of ammonia, account for the energy requirement in form of ATP 
needed to fuel the urea cycle, and in regulating the transfer of metabolites responsible for 
maintaining the reducing equivalents balance.   
     The urea cycle is subject to short-term regulation by three essential factors: the 
availability of substrate (NH4+), the intramitochondrial concentration of N-
acetylglutamate (AGA) and the availability of ornithine, which is critical for the process 
of the urea cycle. AGA is synthesized in the mitochondria from AcCoA and glutamate by 
N-acetylglutamate synhase.  Carbamoyl-phospahte synthetase, the slowest step in the 
urea cycle, is regulated by AGA, therefore exerting an important role in the control of the 
urea cycle (Shigesada et al. 1978; Shigesada and Tatibana 1971). The rate expression for 
carbamoyl-phosphate synthetase should incorporate the activation by AGA and inhibition 
by products (carbamoyl phosphate, and ADP) (Elliott and Tipton 1974; Lusty 1978). The 
ornithine carbamoyl transferase, argininosuccinate synthetase, and lyase are reversible 
and they should be represented by Haldane relation. The arginase kinetic expression 
should also incorporate the inhibition effect by ornithine.  
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     The urea cycle is partly located in the cytosol and partly in the mitochondria, making 
the compartmentation model developed in Chapter IV of this dissertation a useful 
platform for this model. Inter-compartmental transport for ornithine and citrulline should 
also be added.   We suggest that the integration of the alanine and urea cycle models with 
the compartmental of Chapter IV to be used to simulate the effects of alanine, fatty acid, 
ethanol, and NH4+, and their various combinations, on the rates of gluconeogenesis, 
uregenesis, TCA cycle, and ketogenesis.   Upon validation with experimental data, this 
model will constitute a good representation of the in vivo fasted state of a rat liver. 
 
6.2.3 Insulin and Glucagon Control 
     The model developed in this work accounts for many allosteric and substrate effectors 
on different enzyme kinetics such as PC, PK, FBPase, and PFK. The role of glucagon is 
of great importance especially in controlling the rate of gluconoegenesis. Glucagon 
stimulates the rate of gluconoegenesis from lactate and pyruvate by raising the 
intracellular level of cAMP, which stimulates FBPase a critical intermediate step for 
glucose production.  
     We suggest that the model be modified to include the effects of glucagon on the 
different pathways and regulatory enzymes. The model could be tested and validated with 
the vast data in the literature on glucagon effects during gluconoegenesis. This hormonal 
signaling pathway modeling can constitute the foundation for a model with future 
physiological application. 
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APPENDIX 
 
 
 
 
Codes for the different models are available in the following directories: 
 
1) Chapter II (Distributed model):  
a. Liver_model/distributed_model/ Dist-model.FOR  (Fortran code). 
b. Also need the following Fortran subroutines: 
i. DLSODE.FOR 
ii. DSS1.FOR 
 
 
2) Chapter III (Gluconeogenesis and lipid metabolism in the perfused liver):  
a. Liver_model/Gluconeogenesis_lipid_model/Estimation6.for  
b. Also need the following Fortran subroutines and text files: 
i. GCOMP6.FOR 
ii. Constraints6.FOR 
iii. Diffeqns6.FOR 
iv. Gcomp6.FOR 
v. Opkdomain.FOR 
vi. Opkda1.FOR 
vii. Opkda2.FOR 
viii. Subint.FOR 
ix. Grg2-1.FOR 
x. Grg2-2.FOR 
xi. Initial condition-n3m.txt 
xii. Initial parameters-n3m.txt 
xiii. Initial parameters orig.txt 
xiv. Initial condition.txt 
 
3) Chapter IV (Cytosolic-mitochondrial compartmentation in the perfused liver):  
a. The simbiology core code model:  
Liver_model/Compartmentation_model/ 
gluc_v18_tca_comp_eapperf(vt163.2.5).sbproj  
b. The simbiology code is only compatible with R2007 
c. Executable codes: 
i. lactate+oleate: 
Liver_model/Compartmentation_model/lac_oleate.m 
ii. pyruvate+oleate: 
Liver_model/Compartmentation_model/pyr_oleate.m 
iii. These are Matlab executable code, compatible with R2007 and 
2008 versions.  
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4) Chapter V (Ethanol oxidation in the perfused liver): 
a. The simbiology core code model:  
Liver_model/Compartmentation_model/ 
gluc_v18_tca_comp_eapperf(vt163.2.5).sbproj  
b. The simbiology code is only compatible with R2007 
c. Executable codes: 
i. Lactate+ethanol: 
Liver_model/Compartmentation_model/lac_etoh.m  
ii. Pyruvate+ethanol: 
Liver_model/Compartmentation_model/pyr_etoh.m 
iii. Lactate+oleate+ethanol:Liver_model/Compartmentation_model/la
c_etoh_ol.m 
iv. Pyruvate+oleate+ethanol:Liver_model/Compartmentation_model/
pyr_etoh_ol.m 
v. These are Matlab executable code, compatible with R2007 and 
2008 versions.  
 
